

1 Egg-derived anti-SARS-CoV-2 immunoglobulin Y (IgY) with broad 2 variant activity as intranasal prophylaxis against COVID-19

3
4 Lyn R. Frumkin^{1†}, Michaela Lucas^{2†}, Curtis L. Scribner³, Nastassja Ortega-Heinly⁴, Jayden Rogers⁵,
5 Gang Yin⁶, Trevor J Hallam⁶, Alice Yam⁶, Kristin Bedard⁶, Rebecca Begley¹, Courtney A. Cohen^{7,8},
6 Catherine V. Badger⁷, Shawn A. Abbasi⁷, John M. Dye⁷, Brian McMillan⁹, Michael Wallach¹⁰,
7 Traci L. Bricker¹¹, Astha Joshi¹¹, Adrianus C.M. Boon¹¹, Suman Pokhrel¹², Benjamin R. Kraemer¹²,
8 Lucia Lee¹², Stephen Kargotich¹³, Mahima Agogiya¹, Tom St. John¹, Daria Mochly-Rosen^{1,12,13*}

9
10 ¹ SPARK at Stanford, Stanford University, School of Medicine, Stanford, CA, United States;

11 ² Faculty of Health and Medical Sciences Internal Medicine, The University of Western Australia,

12 Perth, WA, Australia; ³ Independent Regulatory Consultant, Oakland, CA, United States; ⁴Avian

13 Vaccine Services, Charles River Laboratories, Storrs, CT, United States; ⁵ Linear Clinical Research

14 Ltd, Nedlands, WA, Australia; ⁶ Sutro Biopharma Inc., South San Francisco, CA, United States; ⁷

15 United States Army Medical Research Institute of Infectious Diseases, Virology Division, Frederick,

16 MD, United States; ⁸ The Geneva Foundation, Tacoma, WA, United States; ⁹ Bravado

17 Pharmaceuticals, Lutz, FL, United States; ¹⁰ University of Technology Sydney, Sydney, NSW,

18 Australia and SPARK Sydney, Sydney, NSW, Australia; ¹¹ Department of Medicine, Washington

19 University School of Medicine, St. Louis, MO, United States; ¹² Department of Chemical and

20 Systems Biology, Stanford University, School of Medicine, Stanford, CA, United States; ¹³ SPARK

21 Global, Stanford University, School of Medicine, Stanford, CA, United States

22
23 † These authors have contributed equally to this work and share first authorship.

24 * **Correspondence:** Dr. Daria Mochly-Rosen, mochly@stanford.edu

25
26 **Keywords:** Immunoglobulin Y, IgY, chicken immunoglobulin, infectious diseases, SARS-CoV-2,
27 COVID-19, clinical trial

28
29 **Number of Words:** body, 12,348; figures/tables, 10

30

31

32

33

34

35

36

37

38

39

40 **ABSTRACT**

41 COVID-19 emergency use authorizations and approvals for vaccines were achieved in record
42 time. However, there remains a need to develop additional safe, effective, easy-to-produce, and
43 inexpensive prevention to reduce the risk of acquiring SARS-CoV-2 infection. This need is due to
44 difficulties in vaccine manufacturing and distribution, vaccine hesitancy, and, critically, the increased
45 prevalence of SARS-CoV-2 variants with greater contagiousness or reduced sensitivity to immunity.
46 Antibodies from eggs of hens (immunoglobulin Y; IgY) that were administered receptor-binding
47 domain (RBD) of the SARS-CoV-2 spike protein were developed as nasal drops to capture the virus
48 on the nasal mucosa. Although initially raised against the 2019 novel coronavirus index strain (2019-
49 nCoV), these anti-SARS-CoV-2 RBD IgY surprisingly had indistinguishable enzyme-linked
50 immunosorbent assay binding against variants of concern that have emerged, including Alpha
51 (B.1.1.7), Beta (B.1.351), Delta (B.1.617.2), and Omicron (B.1.1.529). This is distinct for sera from
52 immunized or convalescent patients. Culture neutralization titers against available Alpha, Beta, and
53 Delta were also indistinguishable from the index SARS-CoV-2 strain. Efforts to develop these IgY
54 for clinical use demonstrated that the intranasal anti-SARS-CoV-2 RBD IgY preparation showed no
55 binding (cross-reactivity) to a variety of human tissues and had an excellent safety profile in rats
56 following 28-day intranasal delivery of the formulated IgY. A double-blind, randomized, placebo-
57 controlled phase 1 study evaluating single-ascending and multiple doses of anti-SARS-CoV-2 RBD
58 IgY administered intranasally for 14 days in 48 healthy adults also demonstrated an excellent safety
59 and tolerability profile, and no evidence of systemic absorption. As these antiviral IgY have broad
60 selectivity against many variants of concern, are fast to produce, and are a low-cost product, their use
61 as prophylaxis to reduce SARS-CoV-2 viral transmission warrants further evaluation.
62 (ClinicalTrials.gov: NCT04567810, <https://www.clinicaltrials.gov/ct2/show/NCT04567810>)

63 **1. INTRODUCTION**

64 As of March 15, 2022, over 456 million persons with coronavirus disease 2019 (COVID-19)
65 had been identified in 222 countries and territories with an estimated 6 million deaths (1). It is
66 estimated that only 57% of the world population has been fully vaccinated (2), a figure dramatically
67 lower than the 70%-80% believed needed to reach herd immunity to stop the pandemic (3,4).
68 Furthermore, only 14% of people in low-income countries have received at least one vaccine dose to
69 date (2).

70 The fast emergency regulatory authorizations and approvals of COVID-19 vaccines in various
71 countries were a critical turning point in slowing the spread of the pandemic. However, there remains
72 a global need to develop additional safe, effective, easy-to-produce, and inexpensive prophylaxis to
73 prevent or reduce the risk of acquiring severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
74 2) infection (5,6). This need is due in part to the global shortage of essential components necessary
75 for manufacturing the intramuscular mRNA vaccines and the requirement for cold chain storage for
76 distribution. In addition, novel means of prevention are of heightened importance as variants of
77 SARS-CoV-2 such as Delta (B.1.617.20) and Omicron (B.1.1.529) increase contagiousness and
78 evade immunity produced by existing vaccines and previous infection (7-12) and where COVID-19
79 vaccination is unavailable, especially in resource-poor settings. The emergence of these variants has
80 occurred even in populations with high vaccine uptake and are now the most prevalent COVID-19
81 strains globally (13).

82 The main entry route for SARS-CoV-2 is the nasal mucosa, which has high levels of the
83 human angiotensin-converting enzyme 2 (hACE2) receptor that is used by the virus to gain cellular
84 entry (14). Viral binding to the hACE2 receptor is mediated by the spike (S) protein on the surface of
85 the viral envelope (15) for all SARS-CoV-2 variants identified so far; even the highly mutated
86 Omicron variant, with 15 mutations in the receptor-binding domain (RBD) of the S protein, is still
87 dependent on hACE2 for its infectivity (16). Therefore, the nasal mucosa is an excellent site as a

88 critical barrier to reduce SARS-CoV-2 entry; antibodies against the SARS-CoV-2 RBD can compete
89 with viral binding to the hACE2 receptor. In addition, antibodies on epithelial surfaces can greatly
90 inhibit lateral viral motility, agglutinate viral particles, and anchor the virus to the extracellular
91 matrix (17,18), thus making intranasally administered antibodies a potentially important antiviral
92 strategy. Indeed, intranasal antibody prophylaxis has been an effective means against multiple viral
93 pathogens in humans and veterinary applications, including respiratory tract viruses (18). Thus,
94 covering the nasal mucosa with anti-SARS-CoV-2 antibodies could prevent SARS-CoV-2 infection
95 in naïve individuals and may also reduce viral transmission from an infected individual by reducing
96 levels of active virus.

97 Because the RBD remains essential for SARS-CoV-2 infection, even for variants of concern,
98 we chose recombinant RBD of the S protein (amino acids 328-533) as the immunogen. We next
99 considered the optimal species to raise anti-SARS-CoV-2 polyclonal antibodies and chose to
100 immunize egg-laying hens to enable fast, low-cost, and high-volume production. Antibodies
101 generated in commercial hens (immunoglobulin Y; IgY) are concentrated in their eggs to 50-100
102 mg/egg (thus yielding approximately 35 g of IgY per year) within 2-3 weeks following vaccination
103 (19-21). This yield can be up to five times higher (175 g of IgY in one year) when using specific
104 pathogen-free (SPF) hens.

105 Here, we describe the production of anti-SARS-CoV-2 RBD IgY of the S protein in SPF hens
106 and the characterization of these IgY, including in culture neutralization efficacy against current
107 pathogenic viral variants and a phase 1 study that evaluated the safety, tolerability, and
108 pharmacokinetics of anti-SARS-CoV-2 RBD IgY given by intranasal drops in healthy humans.

109 **2. MATERIALS AND METHODS**

110 **2.1 Study Design**

111 The experiments were conducted in 4 parts: 1) production of immunogen (recombinant
112 RBD), immunization of 12 SPF hens, IgY collection from egg yolks, and in vitro characterization of
113 the IgY anti-SARS CoV-2 RBD, 2) Good Laboratory Practice (GLP) blinded safety studies in rat,
114 treated intranasally twice daily for 28 days with a total of 16 mg/kg IgY or vehicle, 3) a preliminary
115 efficacy study of hamsters treated with IgY or phosphate-buffered saline (PBS) for 4 hours before
116 viral challenge, and 4) a placebo-controlled, double-blind phase 1 safety, tolerability, and
117 pharmacokinetic (PK) study conducted in healthy humans using intranasal IgY or vehicle in single-
118 ascending doses followed by multiple doses (3-times daily every 4 hours) for 14 days. Both the
119 single-ascending and multiple-dose parts were followed by a 7-day nontreatment period to further
120 evaluate safety.

121 **2.2 Recombinant SARS-CoV-2 RBD**

122 SARS-CoV-2 RBD (residues 328-533) of the 2019 novel coronavirus index virus (2019-
123 nCoV) was expressed in cell-free protein synthesis reactions at Sutro Biopharma, Inc. (South San
124 Francisco, CA) using the XpressCFTM platform (22,23) and was constructed as a carboxy-terminal
125 fusion to a small ubiquitin-related modifier (SUMO) sequence to enable the production of a tagless
126 RBD protein post enzymatic cleavage. The his-SUMO tag was constructed as previously described
127 with an N-terminal his6-tag followed by a GGS-linker and the yeast SUMO protein Smt3 for Ulp1-
128 enabled cleavage (22,23).

129 Briefly, cell-free reactions were prepared by the addition of 37.5% v/v iodoacetamide-treated
130 S30 extract, 5 µg/mL plasmid, and a supermix containing amino acids, nano-microspheres, and small
131 molecules for energy generation (23). T7 RNA polymerase was over-expressed in *Escherichia coli*
132 and added to the cell-free reaction as a reagent lysate at <1% v/v. Reactions were carried out in a
133 DASbox stirred tank (Eppendorf) at 250 mL volume with pH, dissolved oxygen, and temperature
134 control. Reactions were run for 16 hours at a temperature of 25°C, pH was controlled at 7.0 using 1
135 M citrate and 1 M potassium hydroxide, and dissolved oxygen was maintained at 20%.

136 The XpressCF reaction of SARS-CoV-2-RBD 328-533 was clarified by centrifugation at
137 10,000 rpm for 20 minutes (Beckman, JLA-10.500 rotor) and filtered through a 0.22- μ m membrane
138 filter. The clarified material was loaded onto a 5-mL his-Trap Excel affinity column equilibrated with
139 binding buffer (15 mM Tris-HCl, 500 mM NaCl, pH 8.0). After 20 column volumes were applied to
140 wash unbound impurities, the bound proteins were eluted with 20 mM Tris-HCl, 300 mM imidazole,
141 pH 8.0. The eluted fractions were then analyzed by 4-12% sodium dodecyl sulfate-polyacrylamide
142 gel electrophoresis (SDS-PAGE) and protein concentrations were determined by measured
143 absorbance at 280 nm by NanoDrop (Thermo Fisher Scientific). The his-SUMO tag was removed by
144 Ulp1 protease digestion for 1 hour at room temperature. The digested reaction was analyzed by 4-
145 12% SDS-PAGE to verify full cleavage of the his-SUMO tag before flow-through mode purification
146 by Capto Q (Cytiva). Twenty mM Tris-HCl, pH 8.0, was used to equilibrate the column, and the
147 flow-through containing the cleaved protein was collected. To further purify the CoV-2-RBD, the
148 Capto Q flow-through fraction was bound to a Capto SP ImpRes cation column equilibrated with 20
149 mM Tris-HCl, pH 8.0. The bound protein was eluted with a 30-column volume linear gradient using
150 elution buffer (20 mM Tris-HCl, 300 mM NaCl, pH 8.0). An Amicon Ultra-15, 3kD centrifugal filter
151 was used to concentrate and buffer exchange the target peak fraction into 6% sucrose in PBS at pH
152 7.2. The final purity of the product was demonstrated by high-performance liquid chromatography
153 (HPLC) analysis.

154 **2.2.1. Characterization of the cell-free expressed recombinant RBD using surface plasmon**
155 **resonance** Binding kinetic of cell-free expressed SARS-CoV-2 RBD construct or mammalian
156 expressed his-tagged RBD control (ACROBiosystems SPD-C52H1) were then measured on a
157 Biacore T200 instrument, using Fc-tagged hACE2 receptor protein (ACROBiosystems AC2-H5257).
158 To this end, an anti-human Fc antibody (Jackson ImmunoResearch Labs) was immobilized on all
159 flow cells of a CM5 chip (GE Healthcare). Fc-tagged human ACE2 receptor protein
160 (ACROBiosystems AC2-H5257) was captured at ~100 replication units (RU). Binding of cell-free
161 expressed SARS-CoV-2 S protein RBD construct or mammalian expressed RBD control
162 (ACROBiosystems SPD-C52H1) was measured at concentrations up to 100 nM. Kinetic experiments
163 were performed at 25°C at a flow rate of 50 μ L/min. RBD samples were diluted in HBS-EP buffer
164 (Teknova) and injected over the chip for 180 seconds followed by a 420-second dissociation. The
165 chip was regenerated with 10 mM glycine pH 1.5 after each injection. Affinities were calculated
166 using Biacore T200 Evaluation Software.

167 **2.3 Hen immunization and IgY purification and characterization**

168 Nine SPF hens were obtained from Charles River Laboratories and housed in a filtered air,
169 positive pressure barrier room (3 more hens from the same lot were added to the study after 5
170 months) at Avian Vaccine Services, Charles River Laboratories (Storrs, CT). Each hen was caged
171 individually with access to feed and water. Upon receipt, hens were immunized with an inoculum
172 containing 50 μ g of recombinant cell-free expressed RBD fragment derived from S1 spike protein
173 and water-in-oil adjuvant. Test bleeds were taken before the first immunization and every 2 weeks
174 after the first immunization throughout the project. Serum samples from each hen were tested using
175 an indirect enzyme-linked immunoassay (ELISA) and Western blot. Hens received a boost 14 days
176 after immunization and every 4 weeks after the previous immunization, unless otherwise indicated.

177 Eggs were collected weekly. Yolks in batches up to 100 eggs/batch were separated and IgY
178 was purified. ELISA titration of IgY binding to full-length S1 (ACROBiosystems, S1N-C5255)
179 expressed in human 293 cells and the cell-free expressed RBD of the SARS-CoV-2 spike protein was
180 performed in 96-well plates. IgY was then purified from yolks. Eggs were collected weekly and egg
181 white was separated from the egg yolk and discarded. Yolks were stored frozen at -20°C. For
182 purification of IgY, yolks were thawed and diluted 1:10 in sterile PBS. The pH was reduced to 5.0
183 and the yolk solution was incubated at 4°C overnight. Yolk solution was then centrifuged for 10

184 minutes at 9000 rpm. Supernatant was removed, pooled, pH was increased to 7.0, and final filtration
185 (0.45 μm) was performed.

186 Hen sera and purified IgY were tested by ELISA and Western blot analysis using both the
187 immunogen (RBD) and full length glycosylated S1 protein (ACROBiosystems, cat# S1N-C5255).
188 Lot Y0120 of purified IgY was derived from 50 yolks, starting 2 weeks after the primary
189 immunization. Lot Y0130 was derived from the next 50 yolks, starting 3 weeks after the primary
190 immunization. Lot Y0140 and above were derived from the next 100 yolks collected over the
191 preceding 2 weeks. Lots of purified IgY were tested by indirect ELISA and Western blot to
192 determine antibody response levels within the yolk after purification as well as affinity to the cell-
193 free expressed RBD fragment of S1 spike protein and the entire glycosylated S1 protein
194 (ACROBiosystems, cat# S1N-C5255). Protein concentration was also measured using the Bradford
195 assay. IgY purity was determined using SDS-PAGE under reducing conditions and stained with
196 Coomassie Blue.

197 ELISA titration of IgY binding to full length and the RBD of the SARS-CoV-2 spike protein
198 was performed as follows: 96-well clear flat bottom polystyrene high-binding ELISA plates
199 (Corning, Cat# 9018) were coated with 100 μl /well of 5 $\mu\text{g}/\text{mL}$ recombinant his-tagged (Sino
200 Biological) RBD protein overnight at 4°C. Plates were then washed twice with PBS and blocked with
201 1% bovine serum albumin (BSA)-PBS. After blocking, 100 μL of serial dilutions of IgY was added
202 to the wells and incubated at room temperature for 2 hours. The plates were then washed twice and
203 incubated with horseradish peroxidase (HRP)-conjugated mouse rat anti-chicken IgY (Sapphire, Cat#
204 LO-IgY-16-P-0.5) 1:2000 diluted in 0.5% BSA and 0.05% Tween-20 in PBS) for 60 minutes. After
205 3 final washes using 0.05% PBS-Tween, the plates were read using chemiluminescent substrate
206 (Pierce TMB Substrate Kit, Thermo Fisher, Cat# 34021). Luminescence was read on a plate reader
207 and analyzed with SoftMaxPro 6.0 (Molecular Devices).

208 Hen sera were diluted with 1% BSA at various dilutions and tested in ELISA. One hundred
209 microliters were added to wells and the plate was incubated at room temperature for 1 hour. Plate
210 wells were then rinsed with 1% Tween 20 wash solution, as indicated above. Anti-chicken HRP
211 conjugate (Invitrogen, cat# SA-19509) diluted 1:5000 was added to each well. The plate was
212 incubated at room temperature for 1 hour, followed by another 1% Tween 20 wash. 3,3',5,5'-
213 tetramethylbenzidine substrate (KPL, cat# 5120-0050) was added to each well and the plate was
214 incubated at room temperature for 15 minutes. Optical density was measured using an ELISA reader
215 (Molecular Devices) at 650 nm.

216 Western blot analysis was performed with the cell-free expressed RBD fragment of the index
217 S1 protein or the entire mammalian-expressed S1 protein (ACROBiosystems). One microgram of
218 denatured protein was added to Mini-PROTEAN TGX 4-20% SDS-PAGE. Gel was run at 200V for
219 45 minutes in Tris-glycine buffer and stained using Simply Blue Safestain (Invitrogen) at room
220 temperature for 1 hour. Gels were destained twice using deionized water.

221 An unstained SDS-PAGE gel was transferred to the polyvinylidene difluoride membrane
222 using Trans-Blot Turbo Transfer System (Bio-Rad Laboratories) and cut into strips. Strips were then
223 stored at -20°C until ready to use. Five percent nonfat dry milk was added to strips and incubated at
224 room temperature for 30-60 minutes. Test bleed sera and IgY were diluted 1:2000 and purified IgY
225 was diluted 1:500 in 0.2 μm -filtered PBS and added to strips. Strips were incubated at room
226 temperature for 2 hours followed by 3 washes in filtered PBS. Rabbit anti-chicken IgY (H+L)
227 secondary antibody, HRP (Invitrogen) diluted 1:3000 was added to each strip and incubated at room
228 temperature for 1-2 hours. Strips were washed once again in filtered PBS. Opti-4CN substrate (Bio-
229 Rad Laboratories) was added to each strip and incubated at room temperature for up to 30 minutes in
230 a rocking incubator. Strips were washed twice in deionized water and images were taken using Bio-
231 Rad EZ Gel Imager.

232 **2.4 Evaluation of IgY**

233 **2.4.1. ELISA evaluation of IgY titer against SARS-CoV-2 variants of concern**

234 ELISA titer of the final IgY preparation used in the clinical studies against the Alpha, Beta,
235 Delta, and Omicron-derived RBD [amino acids 319-537; ACROBiosystems SPD-C52H1(index),
236 SPD-C52Hn (Alpha), SPD-C52Hp (Beta), SPD-C525e (Delta), and SPD-C522e (Omicron))] was
237 carried out as described above.

238 **2.4.2 In culture viral neutralization studies using pseudovirus**

239 The neutralization assays using pseudovirus were performed at RetroVirox (San Diego, CA).
240 The assay used 3 non-replicative vesicular stomatitis virus (VSV) pseudoviruses carrying a firefly
241 luciferase reporter gene and expressing the following S protein of SARS-CoV-2 on the surface: the
242 index SARS-CoV-2 Hu-1 spike, a truncated spike with a C-terminal 19 amino acid deletion; the Beta
243 variant (K417N/ E484K / N501Y / D614G full-length spike); and a D614G spike variant with a full-
244 length sequence of the index spike protein. The IgY preparation or plasma was diluted in Dulbecco's
245 Modified Eagle Medium (DMEM) with 5% fetal bovine serum (FBS) to perform pre-incubation with
246 pseudovirus before addition to target cells. The neutralization assay was performed with HEK 293T-
247 hACE2, a human embryonic kidney cell line overexpressing hACE2. Test item was preincubated for
248 60 minutes at 37°C with a previously titrated inoculum of pseudovirus. The mixture was then added
249 to 293T-hACE2 cells and infection was allowed for 24 hours. Pseudovirus infection was determined
250 by measuring firefly luciferase activity (RLU, relative light unit ratio) 24 hours after infection.
251 Putative neutralizing antibodies (human sera, purified IgY, or vehicle) were present in the cell culture
252 for the entire duration of the experiment. The ability of the test item to neutralize pseudovirus
253 carrying SARS-CoV-2 spike was compared with samples treated with vehicle alone. Nine
254 concentrations of the IgY sample were tested in duplicates with each variant in 5-fold serial dilutions
255 starting at 10,000 µg/mL. The half-maximal inhibitory concentration (IC₅₀) and 50% neutralization
256 titer (NT₅₀) values for the IgY and positive control human serum were determined using GraphPad
257 Prism software (GraphPad Software).

258 Quality controls for the pseudovirus neutralization assays were performed to determine: 1)
259 signal-to-background values; 2) variation of the assay, estimated as the average of the coefficient of
260 variation for data points for which 50% or greater infection (RLUs) was observed compared to cells
261 with pseudovirus in the presence of vehicle alone, and 3) neutralization with plasma from an
262 individual who received 2 doses of the Moderna (mRNA-1273) COVID-19 vaccine. All controls
263 worked as anticipated for each assay.

264 **2.4.3 In culture neutralization studies using live virus**

265 At the United States Army Medical Research Institute of Infectious Diseases (USAMARIID;
266 Frederick, MD), all work with authentic (live) SARS-CoV-2 was completed in Biosafety Level 3
267 laboratories following federal and institutional biosafety standards and regulations. Vero-76 cells
268 were inoculated with SARS-CoV-2/Was1 (MT020880.1) at a multiplicity of infection of 0.01 and
269 incubated at 37°C with 5% CO₂ and 80% humidity. At 50 hours post-infection, cells were frozen at -
270 80°C for 1 hour, allowed to thaw at room temperature, and supernatants were collected and clarified
271 by centrifugation at ~2,500 ×g for 10 minutes. Clarified supernatant was aliquoted and stored at -
272 80°C.

273 Authentic (live) SARS-CoV-2/B.1.617.2 at a multiplicity of infection of 1 was incubated for
274 1 hour at 37°C with serially diluted antibodies. Vero-E6 monolayers were exposed to the antibody-
275 virus mixture at 37°C for 1 hour. Following incubation, viral inoculum was removed and fresh cell
276 culture media was added for an additional 23 hours at 37°C. Cells were washed with PBS, fixed in
277 10% formalin, and permeabilized with 0.2% Triton-X for 10 minutes. Detection of infection was
278 accomplished using an anti-SARS-CoV-2 nucleocapsid protein detection antibody (Sino Biological),
279 and a goat α-rabbit secondary antibody conjugated to AlexaFluor488. Infected cells were identified

280 using the PerkinElmer Operetta high-content imaging instrument and data analysis was performed
281 using the Harmony software (PerkinElmer).

282 At RetroVirox (San Diego, CA), purified IgY (lot Y0180) was tested against three live
283 SARS-CoV-2 clinical isolates: MEX-BC15/2021 (lineage B.1.617.2, Delta), USA/SD-RVX01/2022
284 (lineage B.1.529, Omicron) and MEX-BC2/2020 (lineage B.1, carrying the D614G mutation). A
285 virus-induced cytopathic effect (CPE)-based neutralization assay was performed by infecting Vero
286 E6 cells in the presence or absence of test items. Vero E6 cells were maintained in DMEM with 10%
287 FBS. Twenty-four hours after cell seeding, test samples were submitted to serial dilutions with
288 DMEM with 2% FBS in a different plate. Then, virus diluted in the same media alone was pre-
289 incubated with test items for 1 hour at 37°C in a humidified incubator. Following incubation, media
290 was removed from cells. Cells were then challenged with the SARS-CoV-2/antibody pre-incubated
291 mix. The amount of viral inoculum was previously titrated to result in a linear response inhibited by
292 antivirals with known activity against SARS-CoV-2. Cell culture media with the virus inoculum was
293 not removed after virus adsorption, and antibodies and virus were maintained in the media for the
294 duration of the assay (96 hours). After this period, the extent of cell viability was monitored with the
295 neutral red uptake assay.

296 The virus-induced CPE was monitored under the microscope after 3 days of infection, and
297 cells were stained with neutral red to monitor cell viability the following day. Viable cells
298 incorporate neutral red in their lysosomes. The uptake of neutral red relies on the ability of live cells
299 to maintain the pH inside the lysosomes lower than in the cytoplasm, a process that requires ATP.
300 Inside the lysosome, the dye becomes charged and is retained. After a 3-hour incubation with neutral
301 red (0.017%), the extra dye is washed away, and the neutral red is extracted from lysosomes by
302 incubating cells for 15 minutes with a solution containing 50% ethanol and 1% acetic acid. The
303 amount of neutral red is estimated by measuring absorbance at 540 nm in a plate reader.

304 Antibodies were evaluated in triplicates using five-fold serial dilutions starting at 10.0
305 mg/mL. Controls included uninfected cells and infected cells treated with vehicle alone. Some cells
306 were treated with plasma from an uninfected individual who received two doses of Moderna's
307 mRNA COVID-19 vaccine as a positive control.

308 **2.4.4 CPE-based neutralization assay**

309 The average absorbance at 540 nm (A₅₄₀) observed in infected cells in the presence of vehicle alone
310 was calculated, and then subtracted from all samples to determine the inhibition of the virus-induced
311 CPE. Data points were then normalized to the average A₅₄₀ signal observed in uninfected cells after
312 subtraction of the absorbance signal observed in infected cells. In the neutral red CPE-based
313 neutralization assay, uninfected cells remained viable and uptake the dye at higher levels than non-
314 viable cells. In the absence of test items, the virus-induced CPE kills infected cells and leads to lower
315 A₅₄₀ (this value equals 0% inhibition). In contrast, incubation with neutralizing agents prevents the
316 virus-induced CPE and leads to absorbance levels similar to those observed in uninfected cells. Full
317 recovery of cell viability in infected cells represents 100% neutralization of the virus.

318 **2.5 GMP IgY formulation, analytical studies, and stability**

319 Using Good Manufacturing Practice (GMP), anti-S1 RBD IgY was formulated for use as
320 intranasal drops as 0 (placebo control), 5, 10, and 20 mg/mL anti-S1 RBD IgY preparations in sterile
321 2% microcrystalline cellulose and carboxymethylcellulose sodium at Bravado Pharmaceuticals (Lutz,
322 FL). The suspension was packed in a 1.5-mL dropper bottle and tests for GMP drug product release
323 complied with the relevant standards and methods, including microbiological examination of
324 nonsterile products (USP <1111>, <61> and <62>). All formulated products were 100% stable as
325 measured by physical and analytical properties, including HPLC, when stored for at least 6 months at
326 2-8°C and about 1 month when stored at room temperature. Ten and 20 mg/mL solutions stored at
327 room temperature showed 100% analytical stabilities for 3 months. However, several samples had

328 some physical visual abnormalities (slight discoloration and opacity) that occurred beginning at 1
329 month when stored at room temperature. Therefore, all formulated samples used in the subsequent
330 studies were stored at 2-8°C. For stability determination, formulated IgY (20 mL) was
331 chromatographed on a TSK Gel G3000swxl sizing column (with guard column) on HPLC at 0.4
332 mL/min at room temperature, and eluate was monitored at 214 nm. For the rat toxicity and safety
333 study, and for the human study, we used only 20 mg/mL as the highest dose because it was readily
334 soluble.

335 **2.6 GLP rat toxicity and safety study**

336 Thirty-eight female and 38 male >8-week-old Sprague Dawley rats were used in a GLP study
337 conducted at Charles River Laboratories (Spencerville, OH). Rats were identified using a
338 subcutaneously implanted electronic identification chip and were acclimated to their housing for at
339 least 4 days before the first day of dosing. Animals were randomly assigned to groups; males and
340 females were randomized separately and housed in accordance with the United States Department of
341 Agriculture (USDA) Animal Welfare Act (9 CFR, Parts 1, 2, and 3) and as described in the Guide for
342 the Care and Use of Laboratory Animals.

343 For psychological and environmental enrichment, a hiding device, a chewing object, and
344 edible enrichment treats were offered throughout the study and a cycle of 12 hours light and 12 hours
345 dark was maintained. Water and food were freely available. The experimental protocol is
346 summarized in **Supplementary Tables S1-S3**.

347 Detailed clinical observation was conducted once a week and included body weight and food
348 consumption. Ophthalmic examinations were conducted before treatment and during the last week of
349 dosing by a veterinary ophthalmologist and included a short-acting mydriatic solution treatment to
350 each eye to facilitate the ocular examinations. Clinical laboratory assessments included the presence
351 of circulating IgY (in serum) and standard hematology, coagulation, clinical chemistry, and
352 urinalysis parameters tested at pretreatment and Day 28 (last day of treatment) after 4 hours of
353 fasting.

354 Hematology parameters included red blood cell count, hemoglobin concentration, hematocrit,
355 mean corpuscular volume, red blood cell distribution width, mean corpuscular hemoglobin
356 concentration, mean corpuscular hemoglobin, reticulocyte count (absolute), platelet count, white
357 blood cell count, neutrophil count (absolute), lymphocyte count (absolute), monocyte count
358 (absolute), eosinophil count (absolute), basophil count (absolute), large unstained cells (absolute) and
359 other cells (as appropriate). Clinical chemistry parameters included alanine aminotransferase,
360 aspartate aminotransferase, alkaline phosphatase, gamma-glutamyltransferase, creatine kinase, total
361 bilirubin, urea nitrogen, creatinine, calcium, phosphorus, total protein, albumin, globulin (calculated),
362 albumin/globulin ratio, glucose, cholesterol, triglycerides, sodium, potassium, chloride, and sample
363 quality. Urinalysis included color, appearance/clarity, specific gravity, volume, pH, protein, glucose,
364 bilirubin, ketones, and blood.

365 **2.6.1 Cytokine level measurement and analysis**

366 This non-GLP blinded assay was performed on serum by the Immunoassay Team at the Human
367 Immune Monitoring Center at Stanford University (Stanford, CA). Assay kits
368 (RECYMAG65K27PMX Rat) were purchased from EMD Millipore and used according to the
369 manufacturer's recommendations, with modifications described as follows. Briefly, samples were
370 mixed with antibody-linked magnetic beads on a 96-well plate and incubated overnight at 4°C while
371 shaking. Cold and room temperature incubation steps were performed on an orbital shaker at 500-600
372 rpm. Plates were washed twice with wash buffer in a Biotek ELx405 washer. Following 1-hour
373 incubation at room temperature with a biotinylated detection antibody, streptavidin-PE was added for
374 30 minutes while shaking. Plates were washed as described above and PBS was added to wells for
375 reading in the Luminex FLEXMAP 3D Instrument with a lower bound of 50 beads per sample per

376 cytokine. Each sample was measured in duplicate. Custom Assay Chex control beads were purchased
377 from Radix BioSolutions and added to all wells.

378 Median fluorescence intensity data were corrected for plate and nonspecific binding artifacts
379 (23) and regressed on time point. Regression analysis employed linear mixed models (24) in
380 SAS®/STAT (SAS Institute) with a separate model fit for each treatment and cytokine, and with
381 separate sets of models with and without gender as a covariate, for 108 models in total. Of the 108
382 models, 84% met the assumption of normally distributed residuals and 78% for random effects.

383 **2.6.2 IgY in sera of treated rats**

384 The presence of anti-SARS-CoV-2 IgY in sera of rats was evaluated using GLP standards in a
385 qualified ELISA assay at Charles River Laboratories (Reno, NV). ELISA 96-well plates were coated
386 with goat anti-chicken IgY (Thermo Fisher; A16056). After blocking, the plates were incubated with
387 the samples containing anti-SARS-CoV-2 IgY at various concentrations for 1 hour at room
388 temperature. After washing the microplate, rabbit anti-chicken IgY (Thermo Fisher; A16130) - HRP
389 conjugate was added and incubated for 1 hour at room temperature. The ELISA plate was washed
390 and substrate (3,3',5,5'-tetramethylbenzidine) was added to the wells and incubated for 20 minutes.
391 The color development was stopped by the addition of 2N sulfuric acid and color intensity measured
392 in a microplate reader at 450 nm. A calibration curve from the absorbance values was obtained from
393 the standards using a 4-parameter curve fit with a weighting equation of 1/y². The concentrations of
394 anti-SARS-CoV-2 IgY in the samples were determined from the calibration curve. After 4 analytical
395 method validations, lower and upper limit of detection, intra- and inter-assay precision and accuracy,
396 dilution integrity, and short-term stability, IgY levels in the blood samples of rats before and after 28
397 days of treatment were below the limit of detection.

398 **2.7 Human tissue cross-reactivity study**

399 A GLP study examining human tissue reactivity of the anti-SARS-CoV-2 RBD IgY was conducted at
400 Charles River Laboratories (Frederick, MD) using at least 3 tissues from at least 3 donors
401 (**Supplementary Table S4**). Ten mL of 10 mg/mL or 20 mg/mL IgY control (negative control) and
402 anti-SARS-CoV-2 RBD IgY or an anti-human hypercalcemia of malignancy peptide (amino acid
403 residues 1-34, Sigma-Aldrich; Catalog No. H9148; positive control), each in 1% BSA, were
404 incubated for 1 hour with acetone-fixed human tissues (normal) of at least 3 separate donors after 20
405 minutes incubation with block solution of PBS + 1% BSA, 0.5% casein and 5% normal rabbit serum.
406 After PBS washes, the secondary antibody (peroxidase [HRP]-conjugated rabbit anti-chicken IgY;
407 Testing Facility antibody tracking No. A45764; of 2 µg/mL) was added for 30 minutes. After PBS
408 washes, DAB (3,3'-diaminobenzidine) was applied for 4 minutes as a substrate for the peroxidase
409 reaction. All slides were rinsed with tap water, counterstained, dehydrated, and mounted for
410 visualization. For the β₂-microglobulin antibody (positive control staining) 1 µg/mL of antibodies
411 were incubated with the slides for 1 hour and bound antibodies were detected with biotinylated
412 secondary antibody (goat anti-rabbit IgG; 2 µg/mL) for 30 minutes, as above. The slides were then
413 visualized on light microscopy.

414 **2.8 Virus preparation for the efficacy study in a hamster model of COVID-19 and** 415 **quantitation of viral load in the animals**

416 Syrian hamsters develop mild-to-moderate disease with progressive weight loss that starts several
417 days after SARS-CoV-2 infection by intranasal inoculation (25,26). SARS-CoV-2 (strain 2019-
418 nCoV/USA-WA1/2020) was propagated on Vero-TMPRSS2 cells, and the virus titer was determined
419 by plaque assays on Vero-hACE2 and Vero-hACE2-TMPRSS2 cells. Briefly, cells were seeded in
420 24-well plates, and the next day, virus stocks were serially diluted 10-fold, starting at 1:10, in cell
421 infection medium [Minimum Essential Media (MEM) containing 2% FBS, L-glutamine, penicillin,
422 and streptomycin]. Two hundred and fifty microliters of the diluted virus were added to a single well
423 per dilution per sample. After 1 hour at 37°C, the inoculum was aspirated and a 1% methylcellulose

424 overlay in MEM supplemented with 2% FBS was added. Seventy-two hours after virus inoculation,
425 the cells were fixed with 4% formalin and the monolayer was stained with crystal violet (0.5% w/v in
426 25% methanol in water) for 1 hour at 20°C. The number of plaques was counted and used to
427 calculate the plaque-forming units (PFU)/mL.

428 **2.8.1 Study protocol: hamster infection with SARS-CoV-2**

429 Five- to 6-week-old Syrian golden hamsters (Charles River Laboratories) infected with SARS-CoV-2
430 as previously described (26) were housed at the Washington University (St. Louis, MO) Biosafety
431 Level 3 facility in HEPA-filtered rodent cages. Before challenge with SARS-CoV-2, all animals
432 received 100 µL of a placebo control fluid or fluid-formulated anti-SARS-CoV-2 RBD IgY (1 mg/50
433 mL of the 20 mg/mL solution per nare). The amount of nasal anti-SARS-CoV-2 RBD IgY drops was
434 limited by the volume that could be given per nare. Four hours after the delivery, animals were
435 challenged with 10^4 or 5×10^4 PFU of SARS-CoV-2 (titer determined on Vero-hACE2; see below).
436 The protocol included 18 hamsters in 4 planned groups: Group 1: Control with high 5×10^4 PFU (4
437 animals); Group 2: Control with 1×10^4 PFU (4 animals); Group 3: Anti-SARS-CoV-2 RBD IgY
438 with 5×10^4 PFU (5 animals); and Group 4: Anti-SARS-CoV-2 RBD IgY with 1×10^4 PFU (5
439 animals). Note that the viral titer in Vero-hACE2-hTMPRSS2 cells, which express the essential
440 protease to liberate the RBD from the S protein on the surface of the virus (27), was subsequently
441 found to be almost 100-fold higher for Groups 1 and 3 (4×10^6 PFU) and Groups 2 and 4 (0.8×10^6
442 PFU).

443 Animal weight was recorded daily. Three days after challenge, the animals were sacrificed
444 and lungs were collected. The left lobe was homogenized in 1.0 mL of DMEM and the clarified
445 supernatant was used for viral load analysis by plaque assay and quantitative reverse transcription
446 PCR.

447 **2.8.2 Virus titration assays from hamster samples**

448 Plaque assays were performed on Vero-hACE2 and Vero-hACE2-TMPRSS2 cells in 24-well plates.
449 Lung tissue homogenates were serially diluted 10-fold, starting at 1:10, in cell infection medium
450 (DMEM containing 2% FBS, L-glutamine, penicillin, and streptomycin). Two hundred and fifty
451 microliters of the diluted lung homogenates were added to a single well per dilution per sample.
452 After 1 hour at 37°C, the inoculum was aspirated and a 1% methylcellulose overlay in MEM
453 supplemented with 2% FBS was added. Seventy-two hours after virus inoculation, the cells were
454 fixed with 4% formalin, and the monolayer was stained with crystal violet (0.5% w/v in 25%
455 methanol in water) for 1 hour at 20°C. The number of plaques was counted and used to calculate the
456 PFU/mL. To quantify viral load in lung tissue homogenates, RNA was extracted from 100 µL
457 samples using QIAamp viral RNA mini kit (Qiagen) and eluted with 50 µL of water. RNA (4 µL)
458 was used for real-time quantitative reverse transcription PCR to detect and quantify N gene of SARS-
459 CoV-2 using TaqMan™ Fast Virus 1-Step Master Mix (Applied Biosystems) or using the following
460 primers and probes for the N-gene, forward: GACCCAAAATCAGCGAAAT; reverse:
461 TCTGGTTACTGCCAGTTGAATCTG, probe: ACCCCGCATTACGTTTGGTGGACC, or the 5'-
462 UTR, forward: ACTGTCGTTGACAGGACACG, reverse: AACACGGACGAAACCGTAAG,
463 probe: CGTCTATCTTCTGCAGGCTG. Viral RNA was expressed as gene copy numbers per mg for
464 lung tissue homogenates and per mL for nasal swabs, based on a standard included in the assay that
465 was created by in vitro transcription of a synthetic DNA molecule containing the target region of the
466 N gene or 5'-UTR.

467 **2.9 Statistical Analysis**

468 Data were analyzed with GraphPad Prism 9.0 and statistical significance was assigned when P values
469 were < 0.05. All tests and values are indicated in figure legends.

470 **2.10 Phase 1 safety, tolerability, and pharmacokinetic study in humans**

471 **2.10.1 Study design and dose selection**

472 A single-center, randomized, double-blind, placebo-controlled phase 1 study of anti-SARS-CoV-2
473 RBD IgY given intranasally to 48 healthy adults was conducted at Linear Clinical Research-Harry
474 Perkins Research Institute (Nedlans, WA, Australia) (see **Figure 1**). Written informed consent was
475 obtained from all participants. The study is registered at ClinicalTrials.gov: NCT04567810. The
476 study period was conducted between September 25, 2020 and December 14, 2020. The protocol for
477 this trial is available as supporting information (**Supplementary Methods**).

478 Healthy male and female participants ≥ 18 and ≤ 45 years old with a body weight ≥ 50 kg and
479 a body mass index ≥ 18.0 and ≤ 32.0 kg/m² were eligible for this study. Females of childbearing
480 potential who were pregnant or lactating or planning to become pregnant during the study and
481 participants with a history of alcohol and drug abuse, current smoking, clinically significant
482 laboratory abnormalities, history of nasal surgical procedures, frequent or recurrent nasal conditions,
483 current use of any nasal preparations, evidence of or history of clinically significant conditions, or
484 positive test for hepatitis B, hepatitis C, human immunodeficiency virus, or SARS-CoV-2 nucleic
485 acid or serology were excluded from participation. Full eligibility criteria are summarized in
486 **Supplementary Methods**.

487 The master randomization schedule and the associated code break envelope files were
488 produced by an unblinded statistician using a computer-generated (SAS® v9.4 PLAN procedure)
489 pseudo-random permutation procedure. For Part 1, the first two randomization numbers for each
490 cohort were randomly assigned in a 1:1 ratio (anti-SARS-CoV-2 IgY: Placebo) to allow for sentinel
491 dosing, and the remainder of the numbers for each cohort was generated in a 5:1 (anti-SARS-CoV-2
492 IgY: Placebo) ratio using a permuted blocked randomization with a block size of six. For Part 2, 24
493 numbers were generated in a 1:1:1:1 ratio (6 mg anti-SARS-CoV-2 IgY: 12 mg anti-SARS-CoV-2
494 IgY: 24 mg anti-SARS-CoV-2 IgY: Placebo) using a permuted blocked randomization with a block
495 size of six. The block sizes were kept confidential during the study.

496 The site personnel randomized eligible participants on Day 1 by assigning the next available
497 randomization number for the specific study part to the participant and reporting the randomization
498 number on the case report form. Study drug was prepared by an unblinded pharmacist based on the
499 treatment corresponding to the assigned randomization number on the randomization schedule that
500 was only available to the pharmacist. In the event of an emergency, authorized personnel were able to
501 unblind a participant through the code break envelope associated with the randomization number
502 assigned to the participant.

503 In Part 1, participants were randomly assigned to receive a single dose of anti-SARS-CoV-2
504 RBD IgY antibodies or placebo in a sequential escalating manner. Three groups were sequentially
505 dosed with 8 healthy participants per group (6 active and 2 placebo in each group). Each group in
506 Part 1 included the initial dosing of a sentinel group (1 anti-SARS-CoV-2 RBD IgY and 1 placebo) at
507 least 24 hours before dosing the remaining 6 participants in the cohort (5 anti-SARS-CoV-2 RBD
508 IgY and 1 placebo). The remainder of the cohort were dosed if, in the opinion of the investigator,
509 there were no significant safety concerns identified in the sentinel participants within the first 24
510 hours after administration of the dose (anti-SARS-CoV-2 RBD IgY or placebo). A Safety Monitoring
511 Committee (SMC) reviewed safety data before each dose escalation. The following regimens were
512 administered: 2 mg anti-SARS-CoV-2 RBD IgY preparation or placebo, 4 mg anti-SARS-CoV-2
513 RBD IgY preparation or placebo, and 8 mg anti-SARS-CoV-2 RBD IgY preparation or placebo. In
514 Part 1, 2 drops were applied to each nostril as a single administration. A 7-day nontreatment follow-
515 up period assessed safety after completion of the dosing.

516 In Part 2, participants were randomly assigned to receive multiple daily administrations of
517 anti-SARS-CoV-2 RBD IgY or placebo every 4 hours (3-times daily) for 14 days in a parallel-group
518 manner. Up to 24 healthy participants were randomized to 1 of 4 treatment regimens (6 participants
519 per regimen). The following regimens were administered: 6 mg total daily dose anti-SARS-CoV-2
520 RBD IgY preparation for 14 days, 12 mg total daily dose anti-SARS-CoV-2 RBD IgY preparation

521 for 14 days, 24 mg total daily dose anti-SARS-CoV-2 RBD IgY preparation for 14 days, and 0 mg
522 total daily dose placebo preparation for 14 days. In Part 2, 2 drops were applied to each nostril every
523 4 hours (3-times daily). A 7-day nontreatment follow-up period assessed safety after completion of
524 the dosing.

525 In each part, 3 groups with 8 healthy participants per group (6 active and 2 placebo in each
526 group) were dosed. Safety and tolerability were evaluated using adverse event, physical examination
527 (including vital signs), electrocardiogram, and clinical laboratory data. PK of anti-SARS-CoV-2
528 RBD IgY was evaluated by measuring serum concentrations pretreatment and at Day 14 when given
529 as multiple doses administered intranasally for 14 days.

530 The investigational drug was supplied as a liquid preparation in a nose drop bottle containing
531 1.5 mL anti-SARS-CoV-2 RBD IgY preparation nasal suspension at 5, 10, or 20 mg/mL, or placebo,
532 for intranasal application. Each bottle of nasal drops had enough material for one day of use. The
533 liquid preparation contained anti-SARS-CoV-2 RBD IgY 0.5 mg/100 μ L/drop, 1 mg/100 μ L/drop, or
534 2 mg/100 μ L/drop. The total maximum daily dose of anti-SARS-CoV-2 RBD IgY used in the present
535 study (24 mg) was based in part on solubility considerations and is less than the daily dose of anti-
536 *Pseudomonas aeruginosa* IgY previously given prophylactically as an oral (mouth rinse) treatment to
537 prevent pulmonary infections in 17 patients with cystic fibrosis (28). For the maximum anti-SARS-
538 CoV-2 RBD IgY dose of 4 mg/nare, we calculated a favorable ratio of IgY to viral particles, even
539 when virus covers the nasal pathway.

540 All participants were provided with a Dose Administration Guide and instructed to “Gently
541 blow your nose before using this drug. Then tilt your head back while sitting or lying down. After the
542 study drug is administered, keep your head tilted for a few minutes. Try not to blow your nose for at
543 least 5 minutes after study drug administration.”

544 **2.10.2 Assessments**

545 Safety (and tolerability) were evaluated using adverse event, physical examination (including vital
546 signs), electrocardiogram, and clinical laboratory data that included nonfasted collection of a)
547 hematology (hemoglobin, hematocrit, erythrocyte count, mean cell volume, neutrophils,
548 lymphocytes, monocytes, eosinophils, basophils, platelets, reticulocyte count), b) serum metabolic
549 panel (sodium, potassium, chloride, total bilirubin, alkaline phosphatase, alanine transaminase,
550 aspartate transaminase, blood urea nitrogen, creatinine, uric acid, phosphorous, calcium, plasma
551 glucose, total protein, albumin, cholesterol, creatinine kinase, c) coagulation, d) urinalysis, and e)
552 urine human chorionic gonadotropin values. Pharmacokinetics following intranasal administration of
553 anti-SARS-CoV-2 RBD IgY were evaluated in the multiple-dose part of the study by measuring
554 serum anti-SARS-CoV-2 RBD IgY concentration (lower limit of quantification, 30 ng/mL) at
555 baseline and 2 hours after final dosing on Day 14, as described above (Charles River Laboratories,
556 Reno, NV).

557 Serum cytokine levels for exploratory analyses were evaluated from the sera of 19 multiple-
558 dose participants before and 2 hours after dosing on Days 1 and 2, as described above (Stanford
559 Human Immune Monitoring Center, Stanford CA). An exploratory analysis was conducted of
560 pretreatment serum total IgE and anti-IgE antibody (mainly anti-ovalbumin) levels in the 24
561 participants in the multiple-dose part of the trial.

562 **2.10.3 Changes in the Conduct of the Study**

563 All participants were enrolled, treated, and assessed under Protocol CVR001 version 3.0, dated 29
564 September 2020 (**Supplementary Methods**). The following changes were made to the conduct of the
565 study from what was specified in the protocol:

- 566 • Participants were reconsented to allow for exploratory cytokine analyses on stored blood
567 samples.
- 568 • Per the study protocol, serum anti-SARS-CoV-2 IgY samples were obtained from participants in
569 the multiple-dose part of the study before dosing and at 0.5, 1, 1.5, and 2 hours after dosing on

570 Days 1 and 14, as well as before dosing and 2 hours after dosing on Days 2, 3, and 4. Because
571 anti-SARS-CoV-2 IgY was not measurable at the time of the theoretical maximum serum
572 concentration at 2 hours postdose on Day 14, the remaining postbaseline PK samples were not
573 analyzed.

574 **2.10.4 Interim Analyses**

575 Before dose escalation in the single-ascending dose cohorts, the SMC was to review all available
576 safety and tolerability data for a minimum of 7 participants who completed the planned safety
577 assessments up to 48 hours after dosing. The SMC comprised three physician members (the principal
578 investigator, sponsor medical representative, and independent medical monitor). The data was to be
579 reviewed blinded, unless the SMC considered it necessary to unblind the data for safety concerns.
580 Before breaking the code per standard procedures, the potential decisions and actions were to be
581 determined. SMC decisions on dose escalation were to be taken in consensus between the members
582 of the SMC. The SMC decisions and their rationale were documented.

583 **2.10.5 Analyses**

584 No formal sample size calculations were done. Based on experience for previous similar studies, the
585 target number of participants to be enrolled was appropriate for the assessment of safety, tolerability,
586 and PK. The planned sample size was 48 participants. A total of 48 participants were enrolled and
587 included in the safety analyses. The analysis of safety variables included all participants who
588 received study drug. All variables were summarized by descriptive statistics for each treatment
589 group. The statistics for continuous variables included mean, median, standard deviation, and number
590 of observations. Categorical variables were tabulated using frequencies and percentages. The
591 incidence of all reported treatment-emergent adverse events and treatment-related adverse events was
592 tabulated by treatment group. Adverse events were also classified by system organ class and
593 preferred term using the Medical Dictionary for Regulatory Activities. Adverse events were to be
594 listed and summarized by treatment group, preferred term, severity, seriousness, and relationship to
595 study drug. In the event of multiple occurrences of the same adverse event with the same preferred
596 term in one participant, the adverse event was counted once as the worst occurrence. Summary
597 statistics for actual values and change from baseline were analyzed for laboratory results by treatment
598 group and scheduled visit. Data summarized by treatment included adverse events, vital signs,
599 electrocardiogram parameters, and clinical laboratory evaluations.

600 **2.10.6 Cytokine measurement and analysis**

601 This non-GLP blinded assay was performed on sera of study participants by the Immunoassay Team
602 at the Human Immune Monitoring Center at Stanford University (Stanford, CA), as described for the
603 rat cytokine assay above. The levels of 80 different cytokines were determined.

604 **2.10.7 GLP bioanalytical analysis of IgY in blood samples – toxicokinetic analysis**

605 The presence of anti-SARS-CoV-2 IgY in sera of study participants was evaluated using GLP
606 standards in a qualified ELISA assay at Charles River Laboratories (Reno, NV). ELISA 96-well
607 plates were coated with goat anti-chicken IgY (Thermo Fisher; A16056) and, after blocking, were
608 incubated with the samples containing anti-SARS-CoV-2 IgY at various concentrations for 1 hour at
609 room temperature. After washing the microplate, rabbit anti-chicken IgY (Thermo Fisher; A16130) -
610 HRP conjugate was added and incubated for 1 hour at room temperature. The ELISA plate was
611 washed and substrate (3,3',5,5'-tetramethylbenzidine) was added to the wells and incubated for 20
612 minutes. The color development was stopped by the addition of 2N sulfuric acid and color intensity
613 measured in a microplate reader at 450 nm. A calibration curve from the absorbance values was
614 obtained from the standards using a 4-parameter curve fit with a weighting equation of 1/y². The
615 concentrations of anti-SARS-CoV-2 IgY in the samples were determined from the calibration curve.
616 After 4 analytical method validations, lower and upper limit of detection, intra- and inter-assay
617 precision and accuracy, dilution integrity, and short-term stability, IgY levels in study participants
618 before and after 14 days of treatment were below the limit of detection.

619 **2.11 Good Laboratory Practice**

620 The study was performed at Charles River Laboratories following the U.S. Department of Health and
621 Human Services, Food and Drug Administration (FDA), United States Code of Federal Regulations,
622 Title 21, Part 58: Good Laboratory Practice for Nonclinical Laboratory Studies and as accepted by
623 Regulatory Authorities throughout the European Union (OECD Principles of Good Laboratory
624 Practice), Japan (MHLW), and other countries that are signatories to the OECD Mutual Acceptance
625 of Data Agreement.

626 **2.12 Animal welfare assurance and standards**

627 The protocols and any amendment(s) or procedures involving the care and use of animals (hen
628 immunization and rat tolerability studies) were reviewed and approved by Charles River Laboratories
629 Institutional Animal Care and Use Committee before conduct. The hamster efficacy study was
630 conducted following the recommendations in the Guide for the Care and Use of Laboratory Animals
631 of the National Institutes of Health and the protocol was approved by the Institutional Animal Care
632 and Use Committee at the Washington University School of Medicine (assurance number A3381–
633 01). Stanford Institutional Animal Care and Use Committee did not initially review the animal
634 studies because they were not conducted at Stanford, but were retroactively approved.

635 **2.13 Regulatory and ethics considerations**

636 Ethical review of the clinical trial protocol and any amendments was obtained by Bellberry Human
637 Research Ethics Committee (Australian equivalent to U.S. Institutional Review Board) and the
638 clinical trial was conducted solely at a single investigative site, Linear Clinical Research-Harry
639 Perkins Research Institute (Nedlands, Australia). Stanford Institutional Review Board did not review
640 the research. The study was conducted following the protocol and ethical principles stated in the
641 2013 version of the Declaration of Helsinki and the applicable guidelines on Good Clinical Practice,
642 and all applicable federal, state, and local laws, rules, and regulations.

643 **3. RESULTS**

644 **3.1 Antigen production**

645 The overall scheme describing the production of anti-SARS CoV-2 IgY antibody to be used as
646 intranasal prophylaxis in humans is shown in **Figure 2A**. We produced a recombinant protein to
647 immunize hens. A tagless RBD of SARS-CoV-2 (**Figure 2B**; index SARS-CoV-2 variant), amino
648 acids 328-533, was produced in a cell-free protein synthesis reaction using *E.coli* extract (19,20,26).
649 Analysis of the purified CoV-2 RBD protein yielded a single protein band with an apparent molecular
650 weight of 23 kDa (**Figure 2C**). The purified SARS-CoV-2 RBD was eluted as a single peak by
651 analytical size-exclusion chromatography with >95% monomer content (**Figure 2C**). Bacterial
652 endotoxin contamination was determined to be <0.1 EU/mg by Charles River Endosafe LAL
653 cartridge system.

654 Integrity of the cell-free (non-glycosylated) SARS-CoV-2 RBD was then verified by kinetic
655 binding to the hACE2 receptor. Binding kinetics and affinity were similar to a mammalian expressed
656 and glycosylated S1 fragment (**Figure 2D**) and were consistent with previously described binding
657 affinities, suggesting the RBD expressed cell-free was properly folded and bioactive.

658 **3.2 Hen immunization with SARS-CoV-2 RBD and IgY characterization in vitro**

659 Cell-free expressed RBD (**Figure 2B**; 50 µg in simple oil emulsion) was injected into 9 SPF hens
660 (46-weeks old) and IgY was extracted from egg yolks using a water-based method 2 weeks after the
661 second immunization and thereafter. The IgY preparation was subjected to protein and Western blot
662 analyses (**Figure 3A**). The IgY preparations were >95% pure; a quantitative Western blot analysis
663 demonstrated that this preparation contained less than 2% ovalbumin by weight (**Figure 3A**).
664 Chromatography of the IgY preparations on size-exclusion HPLC identified 5 peaks (**Figure 3B**);
665 SDS-PAGE and Western blot analysis of the peaks collected between 17 and 30 minutes confirmed

666 that these peaks all contain IgY. The anti-SARS-CoV-2 RBD IgY antibodies recognized both the
667 immunogen, cell-free expressed RBD, and the mammalian-expressed full-length and glycosylated S1
668 protein (**Figure 3C**). One egg yolk of the SPF hens provided about 500 mg of purified IgY and each
669 of >10 independent batches of IgY, purified from 100 eggs, each yielded an average of 47 ± 13 g
670 (SD) of purified IgY (see **Figure 3D** for select examples). There was limited variability in the affinity
671 of the various IgY batches for the S glycosylated protein as judged by ELISA (**Figure 3D**; average
672 titer against full-length S1 was 1:18,000). Furthermore, there was almost no difference in titer of
673 individual hens towards the full-length glycosylated S protein, suggesting minimal variability
674 between hens (**Figures 3E, F**). Over 11 months, IgY was collected in batches of 100 eggs per
675 preparation with a similar yield of IgY per preparation and a similar response; interruption of
676 immunization for 3 months did not result in a drop in titer (**Figure 3F**, right panel).

677 **3.3 Neutralization of SARS-CoV-2 index strain and variants of interest and** 678 **concern with anti-SARS-CoV-2 RBD IgY**

679 Pseudoviruses are synthetic chimeras that consist of a surrogate viral core derived from a parent virus
680 and an envelope glycoprotein derived from a heterologous virus (29). Viral neutralization assays in
681 culture (RetroVirox) used non-replicative VSV pseudoviruses carrying a firefly luciferase reporter
682 gene and expressing S of SARS-CoV-2 on the surface of the virion (VSV-S). The neutralization
683 assay was performed with HEK 293T-hACE2, a human embryonic kidney cell line overexpressing
684 hACE2, the receptor of the SARS-CoV-2 virus. First, 5 batches of RBD IgY preparations were tested.
685 The neutralization activity of the purified IgY, defined as the concentration inhibiting 50% of the
686 viruses (IC_{50}) was ~ 170 $\mu\text{g/mL}$ (**Figure 3G**). Importantly, ~ 10 -fold higher neutralization activity
687 towards the index SARS-CoV-2 virus was observed when using a live index virus (**Figure 3H**).
688 Approximately 30 $\mu\text{g/mL}$ IgY provided 50% neutralization of the index virus in culture (**Figure 3H**).

689 Because at least 13 common variants of SARS-CoV-2 with amino acid mutations in the RBD
690 had emerged since December 2020 (30-32) (**Figure 4A**), we tested the activity of the anti-SARS-
691 CoV-2 IgY against several variants (including Beta, Delta, and Omicron; **Figures 4A, B**) and D614G,
692 an amino acid substitution outside the RBD that is now found in most variants. Beta, Delta, and
693 Omicron were classified as variants of concern, associated with increased transmissibility or
694 detrimental change in COVID-19 epidemiology, or an increase in virulence or change in clinical
695 disease presentation.

696 First, IgY antibody ELISA titer against Beta RBD was compared with the RBD of the index
697 SARS-CoV-2 virus as well as the most common Alpha variant. ELISA with recombinant full-length
698 S protein or the RBD of the 3 mutants as well as the immunizing RBD fragment of the index virus
699 yielded a virtually identical titer (**Figure 4C**). Although the Omicron variant still uses the hACE2
700 receptor to infect human cells (10,33), the RBD contains a total of 15 mutations compared to the
701 index virus, 11 of which were not found in the previous variants (**Figure 4A, B**). Yet, the ELISA titer
702 of IgY against the Omicron RBD was also equivalent or slightly better than that towards the RBD of
703 the index virus (**Figure 4H**).

704 Next, we tested the neutralization titer of anti-SARS-CoV-2 RBD IgY (lot Y0180) against the
705 RBD of the index, Alpha, and Beta variants, thus including all the amino acid substitutions within the
706 RBD also found in the RBD of Gamma, Zeta, Eta, Theta, Iota, and Mu variants and 1 of the 2
707 substitutions in the Kappa variant (**Figure 4A**). The IC_{50} of the VSV-S pseudovirions for the index
708 strain and Beta variant were virtually identical: 668 $\mu\text{g/mL}$ for the index strain, 568 $\mu\text{g/mL}$ for Beta
709 (**Figure 4D**), and 2-fold lower for Alpha ($IC_{50} = 302$ $\mu\text{g/mL}$; **Figure 4D**). RetroVirox also provided
710 data using plasma from a single Moderna-vaccinated individual for a titer comparison of
711 neutralization with anti-SARS-CoV-2 RBD IgY, tested with 3 of the variants. In a side-by-side study,
712 the IC_{50} generated with the human plasma from a recipient of the mRNA Moderna vaccine (2 doses;

713 index SARS-CoV-2) showed the highest titer against the index virus, followed by a 2.8-fold drop in
714 titer towards Alpha and a 6.7-fold lower titer for Beta (**Figure 4F**).

715 The anti-SARS-CoV-2 IgY preparation was similarly effective against the Delta variant
716 compared with the index strain (**Figure 4E**). The assays show that Y0180 displays similar
717 neutralizing activity against both isolates, with slightly reduced neutralizing activity against Omicron
718 (**Figures 4E, I**); IC_{50} values generated were 635 $\mu\text{g/mL}$ (Delta) and 739 $\mu\text{g/mL}$ (index virus). The
719 neutralization assay against Omicron generated IC_{50} values of 143 $\mu\text{g/mL}$ (index) and 785 $\mu\text{g/mL}$
720 (Omicron) (**Figure 4I**). Plasma from a Moderna-vaccinated individual was also tested in parallel with
721 both isolates. NT_{50} values generated with this plasma against the variants were 1:1274 (Delta
722 pseudovirus) and 1:1091 (index pseudovirus). The neutralization activities of the antibody and control
723 plasma against both variants were also confirmed by microscopy evaluating the virus-induced CPE in
724 infected cell monolayers (**Figure 4G**). The human serum had a similar degree of neutralization against
725 the index pseudovirus and Delta (**Figure 4G**) when tested at a dose that is three times higher than that
726 required for 50% neutralization (1:640 in **Figure 4H**, middle panels, vs. 1:2,000 in **Figure 4F**). In
727 contrast, anti-SARS-CoV-2 IgY tested at 400 $\mu\text{g/mL}$ (**Figure 4G**, right panels), a dose below that
728 required for 50% neutralization (~ 650 $\mu\text{g/mL}$; **Figure 4E**), was equally effective against both
729 variants. Together, these data indicate that the spectrum of the polyclonal anti-SARS-CoV-2 RBD
730 IgY displays sufficient diversity so that none of the common point mutations in the RBD associated
731 with a greater transmission rate of the virus affected the neutralization efficacy of these most common
732 SARS-CoV-2 variants of concern.

733 **3.4 Efficacy study in a hamster model of COVID-19**

734 We did not find in vivo efficacy of anti-SARS-CoV-2 RBD IgY in the Syrian golden hamster
735 COVID-19 model against a challenge with a titer of 0.8 or 4×10^6 of SARS-CoV-2 virus, likely
736 because the amount of virus we employed was too high. Lung viral load after 3 days was comparable
737 between the control treatment group and the anti-SARS-CoV-2 RBD IgY treatment group, but body
738 weight loss was more severe in control animals (**Supplementary Figure S2**).

739 **3.5 Rat toxicity and safety study**

740 All 8-week-old Sprague Dawley rats (10 males and 10 females) in the 28-day GLP safety study
741 survived to scheduled euthanasia with no mortality, test article-related organ weight changes, or gross
742 or microscopic findings (see **Figure 5B**). There were also no differences between female and male
743 groups in each treatment arm. The GLP-qualified assay detected no anti-SARS-CoV-2 RBD IgY in
744 the sera of animals after 28 days of daily treatment with 4 mg anti-SARS-CoV-2 RBD IgY (lower
745 limit of detection of 30 ng/mL).

746 There was no evidence of significant systemic immune activation in the rats (20/group)
747 treated as above by measuring changes in levels of 27 proinflammatory serum cytokines after anti-
748 SARS-CoV-2 RBD IgY administration (**Figure 5C**). When comparing posttreatment (Day 1 at 4
749 hours and Day 28 at 24 hours after twice-daily treatments) to pretreatment serum levels (Day 1, time
750 0; D1 H0), there were no changes for most of the cytokines (22 of the 27 tested) in both placebo- and
751 IgY-treated groups at any time. Compared with D1 H0, we detected a transient, slight increase in
752 interleukin-1 (IL-1) beta and monocyte chemoattractant protein-1 (MCP1) on Day 1, 4 hours after
753 anti-SARS-CoV-2 RBD IgY administration. A similar trend that did not reach significance was also
754 observed in the placebo group at the same time; increases in IL-1 beta and MCP1 were not seen at
755 any other time. There was a significant increase in interferon-inducible protein 10 (IP10) on Day 1, 4
756 hours after the first treatment compared to D1 H0, observed in both treatment and placebo group. A
757 significant decrease in D1 H24 in the placebo arm was observed only for RANTES. Nonetheless,
758 none of these changes in cytokines were observed in the rats at other time points. Together, our data
759 show that long-term twice-daily administration of 4 mg/mL IgY (or 16 mg/kg) up to 28 days in rats
760 has excellent safety and tolerability with no evidence of systemic immune activation.

761 **3.6 Human tissue cross-reactivity study**

762 We determined potential cross-reactivity of the anti-SARS-CoV-2 RBD IgY protein to a full panel of
763 human tissues (at least 3 donors per tissue; see **Supplementary Table S4** for a list of human tissues
764 tested for reactivity). Anti-SARS-CoV-2 RBD IgY reactivity at two concentrations (20 and 10
765 µg/mL) was compared with control polyclonal chicken IgY antibodies (negative control), and with
766 anti-human macroglobulin (positive control for staining). No specific binding was observed with the
767 anti-SARS-CoV-2 RBD IgY to any of the human tissue panels examined, including human nasal
768 cavity and lung (see **Figure 6**).

769 **3.7 Phase 1 Clinical Trial Results**

770 Forty-seven of 48 enrolled participants completed the study drug treatment period and planned study
771 visits (**Supplementary Figure S1, CONSORT flow diagram**). One participant in the multiple-dose
772 part was withdrawn from the study after receiving 3 doses (Day 1) of placebo due to a concurrent
773 upper respiratory tract infection, judged to be unrelated to study drug by the investigator.

774 **3.7.1 Baseline Demographics**

775 Study participants ranged in age from 20 to 43 years (median, 25.5) in the single-dose part of the
776 study and 18 to 40 years (median, 23.0) in the multiple-dose part (**Tables 1, 2**). Female participants
777 comprised 75% of the population in the single-dose study segment and 46% in the multiple-dose
778 study segment. Demographics are summarized in **Tables 1 and 2**.

779 **3.7.2 Safety and tolerability**

780 The overall incidence of treatment-emergent adverse events was 29% (7 of 24 participants; **Table 3**)
781 in the single-dose part of the study and 58% (14 of 24 participants; **Table 4**) in the multiple-dose part
782 of the study, with similar incidence rates between anti-SARS-CoV-2 RBD IgY (42%) and placebo
783 (50%) groups. The most frequent treatment-emergent adverse event was headache, with similar rates
784 between placebo (17%) and anti-SARS-CoV-2 RBD IgY (14%) (**Tables 3 and 4**).

785 All adverse events were mild (grade 1) in severity. No serious adverse event or lab-related
786 adverse event was reported, and there was no dose dependency of adverse events observed.

787 Furthermore, no participant receiving anti-SARS-CoV-2 RBD IgY had an adverse event of nasal
788 irritation or nasal congestion. There were no clinically significant observations or trends noted in
789 laboratory assessments, vital signs, physical exam findings, or electrocardiograms during the study.

790 **3.7.3 Pharmacokinetics**

791 PK analyses indicated no evidence of serum anti-SARS-CoV-2 RBD IgY above the lowest detection
792 levels of 30 ng/mL (using a GLP study at Charles River Laboratories) in the 18 participants who
793 received anti-SARS-CoV-2 RBD IgY in the multiple-dose part of the study.

794 **3.7.4 Serum cytokines**

795 Levels of 80 different cytokines in sera of 19 participants of the multiple-dose part were
796 tested before treatment (D1 pre-dose), 2 hours after dosing on day 1 (D1 H2); day 2, before treatment
797 (D2 pre-dose), and 2 hours after the first dosing on day 2 (D2 H2; **Supplementary Figure S3**). There
798 were slight but statistically significant decreases (red histograms) in 10 of the 80 cytokines
799 (**Supplementary Figure S3**). These slight declines in CCL27, CXCL9, IL23, IL27, LIF, MIP5,
800 RESISTIN, TNF α , TNF α , and TNFRSF6 were noted only in the 12 mg/day group compared to the
801 pretreatment levels. These declines also occurred only 2 hours after the first dose (D1 H2) and were
802 not sustained, except for MIP5. There was also a small decrease in IL3, 2 hours after the first dose of
803 6 mg/day group anti-SARS-CoV-2 RBD IgY, but there were no changes in this cytokine at any other
804 times or doses. These slight changes, which were also not sustained or dose dependent, were judged
805 to be artifactual. Overall, there were no clinically relevant increases in serum cytokines at any time
806 for any of the treatment groups (6, 12, or 24 mg total daily dose of anti-SARS CoV-2 RBD IgY for
807 14 days).

808 **3.7.5 IgE and anti-IgE**

809 The anti-SARS-CoV-2 IgY preparation contains ovalbumin. Although participants with egg allergies
810 were excluded from the trial, an exploratory analysis was conducted of pretreatment serum total IgE
811 and anti-IgE antibody (mainly anti-ovalbumin) levels in the 24 participants in the multiple-dose part
812 of the trial. No participant had detectable serum egg-white specific IgE antibodies (all <0.35 kU/L).

813 **4. DISCUSSION**

814 Despite recent successes in generating highly effective COVID-19 vaccines, there is an ongoing need
815 for widely available and safe antiviral strategies that reduce infection and transmission worldwide.
816 Limitations to current vaccines include global vaccine availability and affordability, vaccine
817 hesitancy, and rapidly emerging highly infective viral strains that escape vaccine-induced immunity.
818 This has been particularly apparent following the emergence of Delta and Omicron. The latter variant
819 was first detected in specimens collected on November 8, 2021 (35), within a few weeks became the
820 dominant SARS-CoV-2 variant in the United States (36), and is now the most common strain
821 globally (13). Both convalescent sera from early strain-infected patients and fully vaccinated
822 individuals exhibited a low neutralization capacity against Omicron (9-12); a reduction of 30 to 40-
823 fold in neutralization titers was reported. Furthermore, of eight currently authorized or approved
824 monoclonal antibodies, seven did not neutralize the Omicron variant and one had a 3-fold reduction
825 in neutralization titer (11). These data highlight the need for alternative and complementary
826 approaches to curb COVID-19.

827 Here, we describe the production of the first chicken egg yolk-derived anti-index SARS-CoV-
828 2 RBD IgY polyclonal antibodies as an intranasal drop product for humans with equal *in vitro*
829 activity against all variants of concern. These IgY were raised in SPF hens and showed an excellent
830 safety profile when given intranasally by drops to rats for 28 days (4 mg/day). No toxicity, innate
831 inflammatory response, or systemic exposure to IgY were noted in this GLP study. In 48 healthy
832 adult participants, anti-SARS-CoV-2 RBD IgY given intranasally at single-ascending doses of 2, 4,
833 and 8 mg and as total daily doses of 6, 12, and 24 mg for 14 days also had a highly favorable safety
834 and tolerability profile. Importantly, no participant receiving intranasal anti-SARS-CoV-2 IgY in the
835 multiple-dose phase had measurable levels of anti-SARS-CoV-2 RBD IgY in their sera, reflecting the
836 absence of systemic absorption of topically administered IgY following intranasal application. We
837 also found no evidence of a systemic inflammatory immune response triggered by the topical
838 treatment with anti-SARS-CoV-2 RBD IgY in humans, and no detectable increase in 80 sera
839 cytokines.

840 Hen-derived IgY antibodies have several advantages for topical use in humans; these
841 antibodies do not bind the Fc receptor or rheumatoid factor or activate the human complement
842 cascade (37), thus greatly reducing the risk of severe immune responses. These features support the
843 clinical applications of IgY for nasal treatment in a wide range of persons, including the elderly,
844 immunocompromised, and children. IgY have been beneficial with favorable safety and tolerability
845 when given prophylactically in both animal models and clinical settings of viral diseases, including
846 respiratory infections [reviewed in (38)]. Overall, available data to date suggest that IgY given by
847 nonparenteral administration do not have unwanted off-target proinflammatory effects and are
848 nontoxic to humans, thus permitting potential clinical applications in diverse populations and
849 diseases.

850 The potential use of IgY from hens immunized with inactivated virus (39), full-length
851 recombinant S protein (40-43), or N protein (44) has been explored with studies evaluating
852 neutralization of the virus in cells, with IC₅₀ values of 10 mg/mL (39), 1 mg/mL (40), 16.8 mg/mL
853 (41), and 0.27 mg/mL (42). However, the ability of these egg-derived antibodies to neutralize other
854 common SARS-CoV-2 variants has not been evaluated and their safety profile in animals or humans
855 has not been assessed.

856 Intranasally administered proteins are removed from the mucosal surface through ciliary
857 movement (40, 45), which was the basis for using a 3-times daily (every 4 hours) regimen in our
858 phase 1 study. The anti-SARS-CoV-2 RBD IgY was designed to capture and immobilize SARS-
859 CoV-2 on the nasal mucosa, preventing the virus from binding to and spreading across the nasal
860 mucosa, and also preventing the transmission of the virus to other individuals. Intranasal delivery of
861 mammalian immunoglobulins as antiviral agents has been extensively evaluated in humans (46-51).
862 Human immunoglobulins G (IgG) and A given intranasally are well tolerated (46-51), including in
863 pediatric populations. Our decision to protect from viral entry at the nasal mucosa stems from the
864 observation that levels of lung hACE2 are much lower than in the nose; infection of lung tissue is >5
865 orders of magnitude lower compared with nasal mucosa (52,53). Therefore, inhibition of viral entry
866 at the nose is likely the correct target site for optimal efficacy.

867 Our product is egg-derived immunoglobulins, which could contain potentially antigenic
868 residual chicken proteins. However, it is not indicated for those who are allergic to egg yolks. Note
869 also that most humans are exposed to egg-derived antigens through their diet and are not allergic.
870 Furthermore, anaphylaxis for those who consume eggs regularly is rare. However, the safety and
871 tolerability of hen-derived IgY as intranasal treatment in humans have not been described despite
872 their extensive use in a variety of routes in animals and aquaculture (38,54).

873 Several other studies have examined anti-COVID-19 intranasal prophylaxis, mostly in animal
874 models (55-61). These prophylaxes include polymer barriers, active vaccines, existing antiviral
875 drugs, inhibitors of protease-induced activation of the virus, antiseptics, antimicrobial agents, and
876 antibodies. Most relevant for comparison with our study is the use of neutralizing antibodies. In one
877 study, intranasal treatment with a monoclonal human antibody (500 µg in 100 µL/nare) 12 hours
878 after infection in hamsters inoculated with 5×10^4 median tissue culture infective dose (TCID₅₀) of
879 SARS-CoV-2 decreased clinical disease signs and improved recovery during 9 days of infection
880 compared with control antibody-treated hamsters (61). However, in contrast to our study, there was a
881 substantial systemic exposure to the human antibody 24 hours after a single intranasal treatment with
882 2.5 mg; serum levels of the treated antibodies in that study were 210 ng/mL vs. below detection
883 levels (30 ng/mL) in our study following administration of 4 mg IgY antibodies intranasally daily for
884 up to 28 days. Therefore, the benefit of the treatment in their study (61) could have been due to
885 neutralization of the virus that had entered the body rather than blocking entry of the virus at the
886 nasal mucosa. Similarly, a single intranasal monoclonal immunoglobulin M (IgM) antibody
887 administration in a mouse model of COVID-19 was highly efficacious when mice were infected with
888 10^4 PFU (59). Human IgM systemic exposure was also noted in mice treated with human IgM
889 monoclonal antibody anti-SARS-CoV-2, although the study attributed the protection to the persistent
890 presence of the antibody at the nasal cavity for over 48 hours based on fluorescent tag measurement
891 (59). Such long persistence of levels of IgM in the nasal cavity is at odds with other studies,
892 including when using ^{99m}Tc-labeled albumin particles or fluorescently labeled IgY antibodies that
893 showed residence time of 2-4 hours (40). If the long persistence is not an artifact of the method, it
894 may suggest a unique benefit of IgM treatment as COVID-19 prophylaxis. Note, however, that with
895 one exception (59), none of these studies assessed the cross-reactivity of antibodies against the
896 variants.

897 Our work shows that, although the IgY was raised against the ancestral (index) strain RBD,
898 the repertoire of the antibodies raised in hens was diverse and polyclonal so that binding affinities
899 measured by ELISA for the single (Alpha), double (Delta), and triple amino acid (Beta) substitutions,
900 or the Omicron variant with 15 amino acid substitutions in the RBD were similar to the affinity for
901 the index RBD or full-length S protein (**Figure 4C, H**). We then confirmed that there was no
902 difference between Alpha, Beta, and Delta variants, and the index strain in a neutralization assay in
903 culture using a VSV-S pseudovirus or live virus (**Figure 4D, E, I**), whereas a reduced neutralization
904 activity of human serum was observed in side-by-side experiments (**Figure 4F, G**). The viral

905 neutralization studies reported here were conducted by a commercial provider (RetroVirox) and by
906 an established laboratory at the USAMRIID, both comparing the results with either convalescent sera
907 or an immunized human, for relative titer evaluation.

908 The culture neutralization titer of anti-SARS-CoV-2 RBD IgY is lower than the human anti-
909 SARS-CoV-2 sera (e.g., **Figures 4F vs. 4D**). However, this may reflect the need for protease-induced
910 RBD exposure in the full-length S protein for binding by IgY, which might not occur effectively in
911 the culture model. A comparison of titer values between our product and sera from an immunized
912 person can also be calculated based on values of IgG levels in human sera (~15 mg/mL); a titer of
913 1:2,000 (**Figure 4F**; dashed line) is equivalent to ~7 ug/mL or 100-fold higher IgG titer than our IgY
914 (**Figure 4D**; ~600 ug/mL). However, as the dose of the IgY anti-SARS-CoV-2 preparation in humans
915 is planned to be 4 mg/dose, more important is the equal potency of the IgY towards the various
916 variants when used even at ~1/10 of the intended IgY dose (**Figure 4E, I**).

917 Another potentially important difference between our findings and the previously published
918 study is the antigen used to raise the antibodies. When expressed in mammalian cells, the full-length
919 S1 protein has at least 22 glycosylation sites per S monomer (62). As glycosylated amino acids are
920 more immunogenic, the affinity of the human antisera may reflect binding to the glycosylated
921 determinants of the protein. However, as glycosylation sites in the S1 protein are heavily mutated and
922 new sites may be formed in many of the variants (31), immune reactivity that is biased towards
923 glycosylated sites may lead to loss of activity as the virus mutates. This will not occur when the non-
924 glycosylated RBD is used as the immunogen, as we have done in our study using cell-free expressed
925 RBD (23,24). Supporting the negative impact of glycosylated antigen, increased immunogenicity of
926 protein antigens after removal of glycosylation sites has been previously shown for hepatitis C virus
927 envelope antigen-based vaccines (63). Furthermore, the apparent higher titer in the neutralization
928 assay may be biased if the tested virus has the same glycosylation sites as that used as an immunogen
929 in vaccinated individuals; many studies use the original viral isolates rather than the common current
930 variants.

931 An important feature of our product is the ease of developing prophylaxis that can be quickly
932 and inexpensively produced. We found that 24 mg total daily dose (divided into three equal doses) of
933 intranasal anti-SARS-CoV-2 IgY for 14 days had an excellent safety profile in humans; this daily
934 dose represents ~1/20 of one egg of immunized SPF hen and ~1/5 of an egg of commercial hen,
935 underscoring that such an IgY dose is feasible for both production cost and effort.

936 There are some limitations to our studies. Our phase 1 clinical trial in healthy volunteers was
937 to assess initial safety, tolerability, and PK of anti-SARS-CoV-2 IgY and was not designed to
938 evaluate efficacy. In addition, we were unable to obtain in vivo data showing viral neutralization
939 (**Supplementary Figure S2**). This may reflect using too much virus in this animal model of COVID-
940 19; our study used 8×10^5 or 4×10^6 , vs. 1 or 5×10^4 TCID₅₀ (58,60). In addition, our intranasal
941 formulated IgY preparation was viscous to obtain better delivery in humans. As hamsters are
942 obligatory nose-breathers, they may have blown out the formulated IgY. Finally, the virus that was
943 delivered in 50 μ L of liquid directly into each nare may have washed out some antibodies. Another
944 limitation in our study is that the neutralization studies comparing the hen IgY vs. human sera were
945 not comprehensive and included only 1 or 2 human samples. Nevertheless, our study is the first to
946 demonstrate that anti-SARS-CoV-2 IgY against all the current variants of concern had a favorable
947 safety profile when used chronically as intranasal drops in rats and humans.

948 There are also several advantages for the use of IgY as prophylaxis against other pathogens
949 besides SARS-CoV-2 that cause disease in humans. As we noted above, IgY generation is
950 inexpensive and fast; one egg of an SPF hen produces 20-80 daily doses (at 6 mg/dose) within 3
951 weeks from the first injection (1 week after the first boost). We found a limited variability between
952 individual immunized hens as determined by ELISA and Western blot analyses and a batch-to-batch
953 consistency (**Figure 3A-F**). IgY is also easy to distribute; besides the known long-term stability of

954 purified IgY (64), we also found excellent stability of the formulated material at 2-8°C for at least 6
955 months (maximum time point measured so far) and greater than 2 weeks when stored at room
956 temperature. This is in contrast to vaccines, some of which require cold-chain storage at -80°C that
957 complicates the coordination of global distribution and to resource-poor regions, in particular.

958 Another important advantage of IgY-based prophylaxis is the ease of local production,
959 including in low- and middle-income countries. As hen immunization is a standard procedure around
960 the world, IgY purification and formulation do not require expensive equipment and are simple to
961 conduct. In a separate study, we developed a step-by-step protocol for IgY purification for two
962 settings in low- and middle-income countries where electricity is available using inexpensive, readily
963 available materials in place of costly specialized laboratory equipment and chemicals (65). Therefore,
964 anti-SARS-CoV-2 IgY can be readily made available worldwide as an additional means of reducing
965 SARS-CoV-2 infection. Each day, one immunized hen can produce the daily dose required for
966 prophylaxis of a family. In addition, by reducing viral mobility and anchoring the virus to the nasal
967 mucus, transmission of the virus from infected to healthy individuals may be reduced.

968 **5. Conclusion**

969 The current COVID-19 pandemic illustrates the need for prophylactics that can be produced
970 rapidly at low cost, are technically accessible anywhere in the world, and complement traditional
971 vaccine development. The safety and benefit of IgY and the ease to produce it at low cost are well
972 described for animal farms. In contrast, the clinical adaptation of IgY for human use has been slow,
973 likely hampered by a lack of economic benefit that has hindered commercial development by
974 industry. For that reason, we undertook the effort of establishing the ability of anti-SARS-CoV-2 IgY
975 to neutralize variants of concern and the initial safety of the IgY preparation using industry GLP and
976 GMP standards. We suggest that until vaccination that is highly effective against prevalent variants
977 becomes available worldwide or herd immunity is achieved, intranasal delivery of anti-SARS-CoV-2
978 IgY may provide passive immunization, including for use as an add-on to personal protective
979 equipment and other preventive measures for the general population. This IgY may also provide
980 short-term protection in addition to vaccines in less well-ventilated environments, such as trains,
981 airplanes, and lecture halls. We also suggest that this approach has the potential to provide a means to
982 curb new threats of epidemics by airborne infectious agents; by providing the relevant immunogen
983 for hen immunization at the geographical site where the threat was detected, an effective passive
984 immunity can be initiated locally to stop the spread of the airborne infectious agent before it becomes
985 an epidemic. We hope that this study will trigger further work to evaluate the safety and efficacy of
986 anti-SARS-CoV-2 IgY in those at risk of SARS-CoV-2 infection.

987 **Conflict of Interest**

988 None of the authors declare competing interests.

989 **Author Contributions**

990 Contributions were made by MW, DM, and LF to project conceptualization; LF, ML, CS, NO, AY,
991 TH, AY, KB, CC, JD, BM, AB, and TS to methodology; ML, NO, GY, CC, CB, SA, TB, AJ, SP,
992 BK, and LL to the investigations; LL and DM to visualization; DM and SK to funding acquisition;
993 MA, RB, LL, JR to project administration; JR, JD, BM, TH, AB, SK, and DM to supervision; DM
994 and LF to writing the original draft; and DM, LF, BK, and TS to editing. All authors reviewed and
995 approved the submitted version.

996 **Funding**

997 This project was supported by funds from SPARK at Stanford, SPARK GLOBAL, and grants from
998 the Booz-Allen Foundation and ChEM-H (Stanford University). We are also grateful for the financial
999 support from the Moonchu Foundation, the Human Immune Monitoring Center (HIMC) at Stanford
1000 University, and the generous monetary donations of many others. The funders had no role in study
1001 design, data collection and analysis, decision to publish, or preparation of the manuscript.

1002 **Acknowledgments**

1003 We thank our many SPARK at Stanford advisors for their support, both financially and through their
1004 invaluable advice. We also thank Miao Wen, Nina A. Carlos, Lawrence Huang, Cuong Tran,
1005 Stephanie Armstrong, and Daniel Calarese of Sutro Biopharma for their help in the production of the
1006 cell-free expressed RBD, Roxanne Lopardo at Avian Vaccine Services, Charles River Laboratories
1007 for her work in IgY testing, and David Goodkin for helpful advice and critical review. We also thank
1008 the study staff at Linear Clinical Research Ltd and Resolutum Global for their outstanding conduct
1009 and analysis of the phase 1 clinical study and Yael Rosenberg-Hasson, Tyson H Holmes, Prof. Mark
1010 Davis, and other members of the Immunoassay Team at the Human Immune Monitoring Center
1011 (Stanford University) for cytokine analyses and statistical consultation. Linda MacKeen provided
1012 invaluable editing support. This manuscript has previously appeared online as a preprint (66).

1013 **Data and materials availability**

1014 The original contributions presented in the study are included in the article/supplementary material.
1015 Further inquiries can be directed to the corresponding author.

1016 **Disclaimer**

1017 Opinions, conclusions, interpretations, and recommendations are those of the authors and are not
1018 necessarily endorsed by the U.S. Army. The mention of trade names or commercial products does not
1019 constitute endorsement or recommendation for use by the Department of the Army or the Department
1020 of Defense.

1021 **Abbreviations**

1022 BSA, bovine serum albumin; COVID-19, coronavirus disease 2019; CPE, cytopathic effect; DMEM,
1023 Dulbecco's Modified Eagle Medium; ELISA, enzyme-linked immunosorbent assay; FBS, fetal
1024 bovine serum; GLP, Good Laboratory Practice; GMP, Good Manufacturing Practice; hACE2, human
1025 angiotensin-converting enzyme 2; HPLC, high-performance liquid chromatography; HRP,
1026 horseradish peroxidase; IC₅₀, half-maximal inhibitory concentration; IgA, immunoglobulin A; IgE,
1027 immunoglobulin E; IgG, immunoglobulin G; IgM, immunoglobulin M; IgY, immunoglobulin Y;
1028 MEM, Minimum Essential Media; NT₅₀, 50% neutralization titer; PBS, phosphate-buffered solution;
1029 PFU, plaque-forming units; PK, pharmacokinetic; RBD, receptor-binding domain; RLU, relative
1030 light unit ratio; RU, replication units; S, spike; SARS-CoV-2, severe acute respiratory syndrome
1031 coronavirus 2; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; SPF, specific
1032 pathogen-free; SMC, Safety Monitoring Committee; SUMO, small ubiquitin-related modifier;
1033 TCID₅₀, tissue culture infective dose; USAMRIID, United States Army Medical Research Institute
1034 of Infectious Diseases; VSV, vesicular stomatitis virus; VSV-S, VSV expressing spike protein on its
1035 surface

1036 **Figure Captions**

1037 **Fig. 1. Design of phase 1 human single-ascending and multiple-dose study**

1038 **Fig. 2. RBD and IgY preparation.** (A) Workflow of the study. IgY preparation for intranasal drops
1039 as antiviral prophylaxis. (B) Cell-free expressed RBD derived from the Spike protein on the viral
1040 envelope of SARS-CoV-2. (C) Characterization of the recombinant protein RBD by ELISA and
1041 HPLC. (D) Determination of the affinity of the cell-free expressed RBD (amino acids 328-533) and
1042 mammalian-expressed full-length S1 to the hACE2 using Biacore.

1043 **Fig. 3. IgY purification and characterization.** (A) Western blot analysis of the IgY preparation. (B)
1044 HPLC profile of the IgY preparation. (C) Western blot analysis of anti-SARS-CoV-2 IgY against
1045 RBD fragment and full S1 recombinant protein. (D) IgY yield for various batches derived from 100
1046 eggs each. (E) Western blot data of different lots of anti-SARS-CoV-2 RBD IgY (Y0120-Y0199).
1047 Pools of 100 eggs laid by 9 hens over 2 weeks were used for each pool of IgY preparation between
1048 May 2020 and March 2021. IgY lot samples were diluted 1:500 followed by a 1:3000 dilution of
1049 rabbit anti-IgY HRP conjugate. First left lane shows the Coomassie stain of the same gels. (F) Time-
1050 dependent ELISA titers of sera from 3 individual hens following continual immunization (left);

1051 arrows indicate immunization timing. Time-dependent ELISA titer of 3 hens after immunization was
1052 stopped for up to 12 weeks (right). **(G)** Neutralization of pseudovirus SARS-CoV-2 by various lots of
1053 anti-SARS-CoV-2 RBD IgY (conducted at RetroVirox). **(H)** Neutralization of live index SARS-CoV-
1054 2 virus by anti-SARS-CoV-2 RBD IgY (Y0180, conducted at USAMRIID).

1055 **Fig. 4. Common SARS-CoV-2 variants and anti-SARS-CoV-2 IgY interaction with them** **(A)** A
1056 scheme depicting locations of mutated amino acids in Alpha through Mu variants of SARS-CoV-2,
1057 focusing on the RBD domain only. Each color bar indicates the amino acid in the index virus that was
1058 mutated in the variant. **(B)** Spike protein of SARS-CoV-2 Alpha, Beta, Delta, and Omicron are shown
1059 from left to right. Molecular Operating Environment was used to create the figure (34). The location
1060 of mutations in the structure of the S protein trimer of SARS-CoV-2 (PDB ID: 7A98) for 4 of the
1061 common variants are indicated in red and glycosylation sites are indicated in pink throughout the S
1062 protein. Blue ribbon indicates RBD (amino acids 328-533) and the orange ribbon indicates receptor
1063 binding motif (amino acids 437-508). **(C)** Binding of anti-SARS-CoV-2 RBD IgY to recombinant S1
1064 full length (FL) of the index virus, the RBD of the Alpha and Beta variants, and the immunizing RBD
1065 of the index virus by ELISA. **(D)** Neutralization of pseudovirus (VSV-S) SARS-CoV-2 carrying S
1066 protein of index virus, Alpha, or Beta variants by anti-RBD IgY. **(E)** Neutralization of live index or
1067 Delta viruses by anti-SARS-CoV-2 IgY against the RBD. **(F)** Neutralization of pseudoviruses listed
1068 in (D) by human serum of immunized individuals. **(G)** Neutralization of live D614G vs. Delta
1069 variants by human serum of immunized individual or by anti-SARS CoV-2 IgY. Microscopic
1070 evaluation of monolayers of Vero E6 cells after 96 hours infection with the indicated authentic (live)
1071 SARS-CoV-2 variant. Images from infected cells are shown after 4 days of infection with SARS-
1072 CoV-2 variants in the absence or presence of test items. Top three panels: Infection in the presence of
1073 MEX-BC2/2020 and bottom three panels: infection with the Delta variant each in the presence of
1074 vehicle alone, serum of a person immunized twice with the Moderna (mRNA-1273) vaccine or anti-
1075 SARS CoV-2 RBD IgY, as indicated, all at the indicated concentration (neutralization experiments in
1076 panels D-H & I were conducted by RetroVirox using pseudovirus or live virus, as indicated). **(H)**
1077 Binding of anti-SARS-CoV-2 RBD IgY to the index virus and Omicron variant (B.1.1.529) RBD
1078 domain using ELISA. **(I)** Neutralization of live index or Omicron variant of SARS-CoV-2 by anti-
1079 SARS-CoV-2 RBD IgY. Except when indicated, the studies were done over several months;
1080 therefore, the absolute titers in the ELISA and neutralization studies were not identical. However,
1081 each experiment included the same positive control; index RBD for ELISA and index virus for
1082 neutralization assays.

1083 **Fig. 5. Preclinical toxicity of 28-day treatment with anti-SARS-CoV-2 RBD IgY in rats.** **(A)**
1084 Study design. **(B)** Summary of findings. **(C)** Serum levels of 27 cytokines over time in rats treated
1085 with IgY (Tx) or vehicle/placebo (PL). Data are provided for Day 1 before treatment (D1H0); Day 1,
1086 4 hours after the treatment (D1H4); 24 hours after the two treatments, 6 hours apart, at 24 hours after
1087 the first treatment (D1H24); 28 days of twice-daily treatments and 4 hours of the treatment of that day
1088 (D28H4); and 28 days of twice-daily treatments and 24 hours of the treatment of that day (D28H24).
1089 Red indicates a statistical difference with a false discovery rate (FDR) significant p-value ($p < 0.05$)

1090 **Fig. 6. Lack of cross-reactivity of anti-SARS-CoV-2 RBD IgY with human tissues.**

1091 Immunohistochemical testing of anti-SARS-CoV-2 RBD IgY (top row), control IgY (middle row;
1092 negative control), and anti-human macroglobulin antibodies (bottom row; positive control) with
1093 human nasal mucosa (left two panels) and human lungs (right two panels). Bars provide a
1094 magnification scale.

1095 REFERENCES

- 1096 1. World Health Organization. WHO Coronavirus (COVID-19) Dashboard (2022).
1097 <https://covid19.who.int/> [Accessed March 15, 2022].
- 1098 2. University of Oxford. Vaccination by location (2022). [https://ourworldindata.org/covid-](https://ourworldindata.org/covid-vaccinations?country=OWID_WRL)
1099 [vaccinations?country=OWID_WRL](https://ourworldindata.org/covid-vaccinations?country=OWID_WRL) [Accessed March 15, 2022].

- 1100 3. Irwin A. What it will take to vaccinate the world against COVID-19. *Nature* (2021) 592: 176-8.
- 1101 4. Lopman BA, Shioda K, Nguyen Q, Beckett SJ, Siegler AJ, Sullivan PS, et al. A framework for
- 1102 monitoring population immunity to SARS-CoV-2. *Ann Epidemiol* (2021) 63: 75-8.
- 1103 5. Koff WC, Schenkelberg T, Williams T, Baric RS, McDermott A, Cameron CM, et al.
- 1104 Development and deployment of COVID-19 vaccines for those most vulnerable. *Sci Transl*
- 1105 *Med* (2021) 13: eabd1525.
- 1106 6. Pardi N, Weissman D. Development of vaccines and antivirals for combating viral pandemics.
- 1107 *Nat Biomed Eng* (2020) 4: 1128-33.
- 1108 7. Mlcochova P, Kemp S, Dhar MS, Papa G, Meng B, Ferreira IATM, et al. SARS-CoV-2
- 1109 B.1.617.2 Delta variant replication and immune evasion. *Nature* (2021) 599: 114-9.
- 1110 8. Liu C, Ginn HM, Dejnirattisai W, Supasa P, Wang B, Tuekprakhon A, et al. Reduced
- 1111 neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. *Cell* (2021) 184:
- 1112 4220-6.
- 1113 9. National Institutes of Health, National Center for Advancing Translational Sciences. OpenData
- 1114 Portal. SARS-CoV-2 Variants & Therapeutics. <https://opendata.ncats.nih.gov/variant/summary>
- 1115 [Accessed March 10, 2022].
- 1116 10. Zhang Z, Wu S, Wu B, Yang Q, Chen A, Li Y, et al. SARS-CoV-2 Omicron strain exhibits
- 1117 potent capabilities for immune evasion and viral entrance. *Sig Transduct Target Ther* (2021) 6:
- 1118 430.
- 1119 11. Cameroni E, Bowen JE, Rosen LE, Saliba C, Zepada SK, Culp K, et al. Broadly neutralizing
- 1120 antibodies overcome SARS-CoV-2 Omicron antigenic shift. *Nature* (2022) 602: 664-70.
- 1121 12. Liu L, Iketani S, Guo Y, Chan J F-W, Wang M, Liu L, et al. Striking Antibody Evasion
- 1122 Manifested by the Omicron Variant of SARS-CoV-2. *Nature* (2022) 602: 676-81.
- 1123 13. University of Oxford. SARS-CoV-2 variants in analyzed sequences (by country).
- 1124 <https://ourworldindata.org/grapher/covid-variants-area?country=~USA> [Accessed March 10,
- 1125 2022].
- 1126 14. Hu B, Guo H, Zhou P, Shi Z-L. Characteristics of SARS-CoV-2 and COVID-19. *Nat Rev*
- 1127 *Microbiol* (2021) 19: 141-54.
- 1128 15. Walls AC, Park Y-J, Tortorici MA, Wall A, McGuire AT, Velesler D. Structure, function, and
- 1129 antigenicity of the SARS-CoV-2 spike glycoprotein. *Cell* (2020) 181: 281-92.
- 1130 16. Zhang Z, Wu S, Wu B, Yang Q, Chen A, Li Y, et al. SARS-CoV-2 Omicron strain exhibits
- 1131 potent capabilities for immune evasion and viral entrance. *Sig Transduct Target Ther*
- 1132 (2021) 6: 430.
- 1133 17. Murin CD, Wilson IA, Ward AB. Antibody responses to viral infections: a structural
- 1134 perspective across three different enveloped viruses. *Nat Microbiol* (2019) 4:734–47.
- 1135 18. Weltzin R, Monath TP. Intranasal antibody prophylaxis for protection against viral disease.
- 1136 *Clin Microbiol Rev* (1999) 12: 383-93.
- 1137 19. Xu Y, Li X, Jin L, Zhen Y, Lu Y, Li S, et al. Application of chicken egg yolk immunoglobulins
- 1138 in the control of terrestrial and aquatic animal diseases: a review. *Biotechnol Adv* (2011) 29:
- 1139 860-8.
- 1140 20. Michael A, Meenatchisundaram S, Parameswari G, Subbraj T, Selvakumaran R, Ramalingam
- 1141 S. Chicken egg yolk antibodies (IgY) as an alternative to mammalian antibodies. *Indian J Sci*
- 1142 *Technol* (2010) 3:468-74.
- 1143 21. Pauly D, Chacana PA, Calzado EG, Brembs B, Schade R. IgY technology: extraction of
- 1144 chicken antibodies from egg yolk by polyethylene glycol (PEG) precipitation. *J Vis Exp*
- 1145 (2011) 51:3084
- 1146 22. Cai Q, Hanson JA, Steiner AR, Tran C, Masikat MR, Chen R, et al. A simplified and robust
- 1147 protocol for immunoglobulin expression in *Escherichia coli* cell-free protein synthesis systems.
- 1148 *Biotechnol Prog* (2015) 31: 823-31.

- 1149 23. Zawada JF, Yin G, Steiner AR, Yang J, Naresh A, Roy SM, et al. Microscale to manufacturing
1150 scale-up of cell-free cytokine production - a new approach for shortening protein production
1151 development timelines. *Biotechnol Bioeng* (2011) 108:1570-8.
- 1152 24. SAS Institute Inc. 2015. SAS/IML® 14.1 User's Guide. Cary, NC: SAS Institute, Inc.
- 1153 25. Chan J F-W, Zhang AJ, Yuan S, Poon V K-M, Chan C C-S, Lee A C-Y, et al. Simulation of
1154 the clinical and pathological manifestations of coronavirus disease 2019 (COVID-19) in a
1155 Golden Syrian hamster model: implications for disease pathogenesis and transmissibility. *Clin*
1156 *Infect Dis* (2020) 71:2428-46.
- 1157 26. Bricker TL, Darling TL, Hassan AO, Harastani HH, Soung A, Jiang X, et al. A single
1158 intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2
1159 vaccine protects against pneumonia in hamsters. *Cell Rep* (2021) 20; 36:109400.
- 1160 27. Neerukonda SN, Vassell R, Herrup R, Liu S, Wang T, Takeda K, et al. Establishment of a well-
1161 characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with
1162 stable expression of ACE2 and TMPRSS2. *PLoS One* (2021) 16: e0248348.
- 1163 28. Kollberg H, Carlander D, Olesen H, Wejåker PE, Johannesson M, Larsson A. Oral
1164 administration of specific yolk antibodies (IgY) may prevent *Pseudomonas aeruginosa*
1165 infections in patients with cystic fibrosis: a phase I feasibility study. *Pediatr Pulmonol* (2003)
1166 35:433-40.
- 1167 29. Lee C-D, Sun H-C, Hu S-M, Chiu C-F, Homhuan A, Liang S-M, et al. An improved SUMO
1168 fusion protein system for effective production of native proteins. *Protein Sci* (2008) 17: 1241-8.
- 1169 30. Pokhrel S, Kraemer BR, Lee L, Samardzic K, Mochly-Rosen D. Increased elastase sensitivity
1170 and decreased intramolecular interactions in the more transmissible 501Y.V1 and 501Y.V2
1171 SARS-CoV-2 variants' spike protein-an in silico analysis. *PLoS One* (2021) 16: e0251426.
- 1172 31. Pokhrel S, Kraemer BR, Burkholz S, Mochly-Rosen D. Natural variants in SARS-CoV-2 Spike
1173 protein pinpoint structural and functional hotspots with implications for prophylaxis and
1174 therapeutic strategies. *Sci Rep* (2021) 11: 13120.
- 1175 32. World Health Organization. Tracking SARS-CoV-2 variants.
1176 <https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/> [Accessed March 10, 2022].
- 1177 33. Dejnirattisai W, Shaw RH, Supasa P, Liu C, Stuart AS, Pollard AJ, et al. Reduced
1178 neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum. *Lancet*.
1179 (2021) S0140-6736:02844-0.
- 1180 34. Chemical Computing Group. Molecular Operating Environment (MOE). Montreal, Canada.
1181 2021.
- 1182 35. Centers for Disease Control and Prevention. Science Brief: Omicron (B.1.1.529) variant
1183 (December 2, 2021). [https://www.cdc.gov/coronavirus/2019-ncov/science/science-](https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/scientific-brief-omicron-variant.html)
1184 [briefs/scientific-brief-omicron-variant.html](https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/scientific-brief-omicron-variant.html) [Accessed March 10, 2022].
- 1185 36. Centers for Disease Control and Prevention. Potential Rapid Increase of Omicron Variant
1186 Infections in the United States (December 20, 2021). [https://www.cdc.gov/coronavirus/2019-](https://www.cdc.gov/coronavirus/2019-ncov/science/forecasting/mathematical-modeling-outbreak.html)
1187 [ncov/science/forecasting/mathematical-modeling-outbreak.html](https://www.cdc.gov/coronavirus/2019-ncov/science/forecasting/mathematical-modeling-outbreak.html) [Accessed March 10, 2022].
- 1188 37. Carlander D, Ståhlberg J, Larsson A. Chicken antibodies: a clinical chemistry perspective. *Ups J*
1189 *Med Sci* (1999) 104:179-89.
- 1190 38. Lee L, Samardzic K, Wallach M, Frumkin LR, Mochly-Rosen D. Immunoglobulin Y for
1191 potential diagnostic and therapeutic applications in infectious diseases. *Front Immunol*
1192 (2021)12:696003.
- 1193 39. Artman C, Brumfield KD, Khanna S, Goepf J. Avian antibodies (IgY) targeting spike
1194 glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) inhibit
1195 receptor binding and viral replication. *PLoS One* (2021)16:e0252399.

- 1196 40. Shen H, Cai Y, Zhang H, Wu J, Ye L, Yang P, et al. Anti-SARS-CoV-2 IgY isolated from egg
1197 yolks of hens immunized with inactivated SARS-CoV-2 for immunoprophylaxis of COVID-
1198 19. *Virologica Sinica* (2021) 36:1080-2.
- 1199 41. Bao L, Zhang C, Lyu J, Yi P, Shen X, Tang B, et al. Egg yolk immunoglobulin (IgY) targeting
1200 SARS-CoV-2 S1 as potential virus entry blocker. *J Appl Microbiol* (2022) 132: 2421-30.
- 1201 42. Wei S, Duan S, Liu X, Wang H, Ding S, Chen Y, et al. Chicken egg yolk antibodies (IgYs)
1202 block the binding of multiple SARS-CoV-2 spike protein variants to human ACE2. *Int*
1203 *Immunopharmacol* (2021) 90:107172.
- 1204 43. Lu Y, Wang Y, Zhang Z, Huang J, Yao M, Huang G, et al. Generation of chicken IgY against
1205 SARS-COV-2 spike protein and epitope mapping. *J Immunol Res* (2020) 2020:9465398.
- 1206 44. Lyu J, Bao L, Shen X, Yan C, Zhang C, Wei W, et al. The preparation of N-IgY targeting
1207 SARS-CoV-2 and its immunomodulation to IFN- γ production in vitro. *Int Immunopharmacol*
1208 (2021) 96:107797.
- 1209 45. Marttin E, Schipper GM, Verhoef JC, Merkus WHM. Nasal mucociliary clearance as a factor
1210 in nasal drug delivery. *Adv Drug Deliv Rev* (1998) 29: 13-38.
- 1211 46. Keller MA, Stiehm ER. Passive immunity in prevention and treatment of infectious diseases.
1212 *Clin Microbiol Rev* (2000) 13: 602-14.
- 1213 47. Hemmingsson P, Hammarström L. Nasal administration of immunoglobulin as effective
1214 prophylaxis against infections in elite cross-country skiers. *Scand J Infect Dis* (1993) 25: 783-
1215 5.
- 1216 48. Lindberg K, Berglund B. Effect of treatment with nasal IgA on the incidence of infectious
1217 disease in world-class canoeists. *Int J Sports Med* (1996) 17: 235-8.
- 1218 49. Giraudi V, Riganti C, Torales MR, Sédola H, Gaddi E. Upper respiratory infections in children:
1219 Response to endonasal administration of IGA. *Int J Pediatr Otorhinolaryngol* (1997) 39: 103-
1220 10.
- 1221 50. Heikkinen TA, Ruohola A, Ruuskanen O, Waris M, Uhari M, Hammarström L. Intranasally
1222 administered immunoglobulin for the prevention of rhinitis in children. *Pediatr Infect Dis J*
1223 (1998) 17: 367-72.
- 1224 51. Gleich GJ, Yunginger JW. Ragweed hay fever: treatment by local passive administration of
1225 IgG antibody. *Clin Allergy* (1975) 5:79-87.
- 1226 52. Hou YJ, Okuda K, Edwards CE, Martinez DR, Asakura T, Dinnon KH 3rd, et al. SARS-CoV-2
1227 Reverse genetics reveals a variable infection gradient in the respiratory tract. *Cell* (2020) 182:
1228 429-446.e14.
- 1229 53. Mason RJ. Pathogenesis of COVID-19 from a cell biology perspective. *Eur Resp J* (2020) 55:
1230 2000607.
- 1231 54. Kovacs-Nolan J, Mine Y. Egg yolk antibodies for passive immunity. *Ann Rev Food Sci*
1232 *Technol* (2012) 3: 163-182.
- 1233 55. Kim Y-II, Kim D, Yu K-M, Seo HD, Lee S-A, Casel MAB, et al. Development of Spike
1234 receptor-binding domain nanoparticles as a vaccine candidate against SARS-CoV-2 infection
1235 in ferrets. *mBio* (2021) 12: e00230-21.
- 1236 56. Palit P, Chattopadhyay D, Thomas SS, Kundu A, Kim HS, Rezaeif N. Phytopharmaceuticals
1237 mediated Furin and TMPRSS2 receptor blocking: can it be a potential therapeutic option for
1238 Covid-19? *Phytomedicine* (2021) 85: 153396.
- 1239 57. Burton MJ, Clarkson JE, Goulao B, Glennly A-M, McBain AJ, Schilder AG, et al. Worthington,
1240 Use of antimicrobial mouthwashes (gargling) and nasal sprays by healthcare workers to protect
1241 them when treating patients with suspected or confirmed COVID-19 infection. *Cochrane*
1242 *Database Syst Rev* (2021) 9: CD013626.

anti-SARS-CoV-2 IgY intranasal prophylaxis

1243 58. Higgins TS, Wu AW, Illing EA, Sokoloski KJ, Weaver BA, Anthony BP, et al. Intranasal
 1244 antiviral drug delivery and coronavirus disease 2019 (COVID-19): A state of the art review.
 1245 *Otolaryngol Head Neck Surg* (2021) 163:682-94.
 1246 59. Ku Z, Xie X, Hinton PR, Liu X, Ye X, Muruato AE, et al. Nasal delivery of an IgM offers
 1247 broad protection from SARS-CoV-2 variants. *Nature* (2021) 595: 718-23.
 1248 60. Nambulli S, Xiang Y, Tilston-Lunel NL, Rennick LJ, Sang Z, Klimstra WB, et al. Inhalable
 1249 nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low
 1250 doses. *Sci Adv* (2021) 7: eabh0319.
 1251 61. Fu Y, Maruyama J, Singh A, Lim R, Ledesma A, Lee D, et al. Protective effects of sti-2020
 1252 antibody delivered post-infection by the intranasal or intravenous route in a Syrian Golden
 1253 Hamster COVID-19 model. *bioRxiv [Preprint]* (2022) Available at:
 1254 <https://www.biorxiv.org/content/10.1101/2020.10.28.359836v1> (Accessed February 26, 2022).
 1255 62. Watanabe Y, Berndsen ZT, Raghwani J, Seabright GE, Allen JD, Pybus OG, et al.
 1256 Vulnerabilities in coronavirus glycan shields despite extensive glycosylation. *Nat Commun*
 1257 (2020) 11: 2688.
 1258 63. Fournillier A, Wychowski C, Boucreux D, Baumert TF, Meunier JC, Jacobs D, et al. Induction
 1259 of hepatitis C virus E1 envelope protein-specific immune response can be enhanced by
 1260 mutation of N-glycosylation sites. *J Virol* (2001) 75:12088-97.
 1261 64. Schade R, Gutierrez Calzado E, Sarmiento R, Chacana PA, Porankiewicz-Asplund J, Terzolo
 1262 HR. Chicken egg yolk antibodies (IgY-technology): a review of progress in production and use
 1263 in research and human and veterinary medicine. *Altern Lab Anim* (2005) 33:129-54.
 1264 65. Chen CJ, Hudson AF, Jia AS, et al. Affordable IgY-based antiviral prophylaxis for resource-
 1265 limited settings to address epidemic and pandemic risks. *J Glob Health* (2022) 12:05009.
 1266 66. Frumkin LR, Lucas L, Scribner CL, Ortega-Heinly N, Rogers J, Yin G, et al. Egg-derived anti-
 1267 SARS-CoV-2 immunoglobulin Y (IgY) with broad variant activity as intranasal prophylaxis
 1268 against COVID-19. *medRxiv [Preprint]* (2022) Available at:
 1269 <https://doi.org/10.1101/2022.01.07.22268914> (Accessed February 26, 2022).

Table 1. Demographics of participants in single-ascending dose group (Part 1).

Anti-SARS-CoV-2 IgY	2 mg	4 mg	8 mg	Placebo	All Participants
	N=6	N=6	N=6	N=6	N=24
Age, years					
Mean (SD)	28.8 (7.99)	27.3 (4.76)	27.7 (5.65)	22.7 (2.34)	26.6 (5.72)
Median (range)	26.5 (20-43)	28.0 (21-33)	27.5 (20-37)	22.0 (20-27)	25.5 (20-43)
Gender, n (%)					
Female	4 (66.7)	4 (66.7)	4 (66.7)	6 (100)	18 (75.0)
Male	2 (33.3)	2 (33.3)	2 (33.3)	0	6 (25.0)
Ethnicity, n (%)					
Hispanic or Latino	1 (16.7)	0	0	0	1 (4.2)
Not Hispanic or Latino	5 (83.3)	6 (100)	6 (100)	6 (100)	23 (95.8)
Race, n (%)					
Asian	2 (33.3)	1 (16.7)	0	0	3 (12.5)

anti-SARS-CoV-2 IgY intranasal prophylaxis

Native Hawaiian or Other Pacific Islander	0	0	0	1 (16.7%)	1 (4.2%)
White	4 (66.7)	5 (83.3)	6 (100)	5 (83.3)	20 (83.3)

1274

1275 **Table 2: Demographics of participants in the multiple-dose group (Part 2).**

Anti-SARS-CoV-2 IgY	Anti-SARS-CoV-2 IgY				All Participants N=24
	2 mg TID N=6	4 mg TID N=6	8 mg TID N=6	Placebo TID N=6	
Age, years					
Mean (SD)	26.0 (8.37)	21.8 (2.14)	27.5 (6.92)	25.3 (6.41)	25.2 (6.33)
Median (range)	23.0 (18-40)	22.0 (19-25)	25.0 (21-37)	25.0 (18-36)	23.0 (18-40)
Gender, n (%)					
Female	1 (16.7)	4 (66.7)	2 (33.3)	4 (66.7)	11 (45.8)
Male	5 (83.3)	2 (33.3)	4 (66.7)	2 (33.3)	13 (54.2)
Ethnicity, n (%)					
Hispanic or Latino	0	0	1 (16.7)	1 (16.7)	2 (8.3)
Not Hispanic or Latino	6 (100)	6 (100)	5 (83.3)	5 (83.3)	22 (91.7)
Race, n (%)					
Asian	1 (16.7)	2 (33.3)	2 (33.3)	2 (33.3)	7 (29.2)
Black or African American	0	0	0	1 (16.7)	1 (4.2)
White	5 (83.3)	4 (66.7)	4 (66.7)	3 (50.0)	16 (66.7)

1276 tid = 3-times daily

1277

1278 **Table 3. Adverse events by preferred term- single ascending-dose study (Part 1).**

	Anti-SARS-CoV-2 IgY					All Participants (N=24)
	2 mg (N=6)	4 mg (N=6)	8 mg (N=6)	Placebo (N=6)		
	n (%) E	n (%) E	n (%) E	n (%) E	n (%) E	
Participants with ≥ 1 TEAE	1 (16.7%)	1	2 (33.3%)	2	2 (33.3%)	7 (29.2%)
MedDRA Preferred Term						
Fatigue	0	0	1 (16.7%)	1	1 (16.7%)	2 (8.3%)
Erythema	0	0	1 (16.7%)	1	0	1 (4.2%)
Headache	0	1 (16.7%)	1	0	0	1 (4.2%)
Sneezing	0	1 (16.7%)	1	0	0	1 (4.2%)
Tension headache	1 (16.7%)	1	0	0	0	1 (4.2%)
Thermal burn	0	0	0	1 (16.7%)	1	1 (4.2%)

1279 E = number of events; n = number of participants; TEAE = treatment-emergent adverse event

1280

1281


1282





1283 **Table 4. Adverse events by preferred term- multiple-dose study (Part 2).**

	Anti-SARS-CoV-2 IgY				
	2 mg TID	4 mg TID	8 mg TID	Placebo TID	All Participants
	(N=6) n (%) E	(N=6) n (%) E	(N=6) n (%) E	(N=6) n (%) E	(N=24) n (%) E
Participants with ≥ 1 TEAE	4 (66.7%) 7	2 (33.3%) 3	4 (66.7%) 5	4 (66.7%) 5	14 (58.3%) 20
MedDRA Preferred Term					
Headache	0	0	3 (50.0%) 3	2 (33.3%) 2	5 (20.8%) 5
Upper respiratory tract infect	0	0	1 (16.7%) 1	1 (16.7%) 1	2 (8.3%) 2
Contusion	0	0	0	1 (16.7%) 1	1 (4.2%) 1
Dental discomfort	1 (16.7%) 1	0	0	0	1 (4.2%) 1
Dizziness	1 (16.7%) 1	0	0	0	1 (4.2%) 1
Ear pain	1 (16.7%) 1	0	0	0	1 (4.2%) 1
Epistaxis	1 (16.7%) 1	0	0	0	1 (4.2%) 1
Eyelid irritation	0	0	1 (16.7%) 1	0	1 (4.2%) 1
Injection site haematoma	1 (16.7%) 1	0	0	0	1 (4.2%) 1
Nasal congestion	0	0	0	1 (16.7%) 1	1 (4.2%) 1
Parosmia	0	1 (16.7%) 1	0	0	1 (4.2%) 1
Presyncope	1 (16.7%) 1	0	0	0	1 (4.2%) 1
Rhinorrhoea	0	1 (16.7%) 1	0	0	1 (4.2%) 1
Skin abrasion	0	1 (16.7%) 1	0	0	1 (4.2%) 1
Tenderness	1 (16.7%) 1	0	0	0	1 (4.2%) 1




1284 E = number of events; n = number of participants; TEAE = treatment-emergent adverse event

1285










Sample	k_a (1/Ms)	k_d (1/s)	K_D (M)	Chi ² /Rmax
Glycosylated RBD	5E+05	9E-03	2E-08	4.38
Aglycosylated RBD	7E+05	1E-02	2E-08	0.271


A IgY Profile - Western**B IgY Profile - HPLC****C IgY anti-RBD and -S1****D IgY anti-RBD and anti-S1**

Batch	Yield (g)	Anti-S1
Y0140	54.2	1:8000
Y0150	52.0	1:16,000
Y0160	54.0	1:32,000
Y0170	60.3	1:16,000
Y0180	49.8	1:16,000

B**F****G Neutralization of SARS-CoV-2 using SVS-S pseudovirus****H In culture neutralization; live virus using index SARS-CoV-2 virus**



A Twice daily treatment @ 4 mg or vehicle
(0 or 1mg/nare/dose)




B


TEST	FINDINGS
CLINICAL OBSERVATIONS	No drug-related clinical observations.
CLINICAL PATHOLOGY	No differences in hematology, coagulation, or clinical chemistry parameters.
FOOD CONSUMPTION	No notable differences in food consumption.
BODY WEIGHT	No notable differences in mean body weights.
OPHTHALMIC	No drug-related ocular findings.
NECROPSY OBSERVATIONS	No drug-related macroscopic and microscopic findings, including nasal histology.

C


D1H0 is Common Comparator Timepoint within a Treatment
Red Denotes FDR Significant p-value ($p < 0.05$).




Anti-SARS-CoV-2 IgY




IgY Control




Anti-Macroglobulin




Anti-SARS-CoV-2 IgY



IgY Control



Anti-Macroglobulin



Supplementary Material

Table of Contents

Supplementary Table S1 Experimental protocol of the rat toxicity study.

Supplementary Table S2 Bioanalytical sample collection from the rat toxicity study.

Supplementary Table S3 Cytokine sample collection for the rat toxicity study.

Supplementary Table S4 Human tissue cross-reactivity; list of tissues examined.

Supplementary Figure S1 CONSORT flow diagram of phase 1 single-ascending and multiple-dose study.

Supplementary Figure S2 Hamster efficacy study.

Supplementary Figure S3 Serum cytokines for human participants in the phase 1 study

Supplementary Methods Protocol for “Phase 1 Study in Healthy Participants to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single-Ascending and Multiple Doses of an Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Chicken Egg Antibody (IgY)”

Supplementary Table S1. Experimental protocol of the rat toxicity study

Group No.	Test Material	Dose Volume (µL dose)	Dose Concentration (mg/mL)	No. of Animals			
				Main Study		Toxicokinetic Study	
				Males	Females	Males	Females
1	Control Article	100	0	10	10	3	3
2	IgY SARS-CoV-2 RBD	100	20	10	10	6	6
3	Control Article	100	0	3 ^a	3 ^a	-	-
4	IgY SARS-CoV-2 RBD	100	20	3 ^a	3 ^a	-	-

^a = These animals were for cytokine analysis only.

Supplementary Material

Supplementary Table S2. Bioanalytical sample collection from the rat toxicity study

Group No.	Subgroup	No. of Animals (M/F)	(Time Post the first daily dose) on Day 1		
			15 min	6 ^a hr	24 hr
1	A	3/3	X	-	X
2	A	3/3	X	-	X
	B	3/3	-	X	-

Method/Comments:	Venipuncture of the jugular vein (under isoflurane anesthesia). The tail vein may be used if blood cannot be obtained via the jugular vein.
Target Volume (mL):	0.3
Anticoagulant:	K ₂ EDTA
Special requirements:	Tubes will be chilled after blood collection.
Processing:	Plasma

X = Sample to be collected; M = Male; F = Female; - = Not applicable

^a Sample to be collected before the second daily dose.

S3 Table. Cytokine sample collection for the rat toxicity study

Group No.	No. of Animals (M/F)	(Time Post the first daily dose) on Day 28		
		0 ^a hr	4 hr	24 hr
3	3/3	X	X	X
4	3/3	X	X	X

Method/Comments:	Venipuncture of the jugular vein (under isoflurane anesthesia). The tail vein may be used if blood cannot be obtained via the jugular vein.
Target Volume (mL):	0.3
Anticoagulant:	K ₂ EDTA
Special requirements:	Tubes will be chilled on wet ice after blood collection.
Processing:	Plasma

X = Sample to be collected; M = Male; F = Female; - = Not applicable

^a Sample to be collected before dosing.

Supplementary Material

Supplementary Table S4. Human tissue cross-reactivity; list of tissues examined.

Binding of anti-SARS-CoV-2 RBD IgY was determined using the following normal human tissue from 3 separate donors.

Adrenal	Liver	Spinal Cord
Bladder (urinary)	Lung	Spleen
Blood Cells ^a	Lymph Node	Striated Muscle (skeletal)
Blood Vessels (endothelium) ^b	Ovary	Testis
Bone Marrow	Nasal Mucosa	Thymus
Brain - cerebellum	Pancreas	Thyroid
Brain - cerebral cortex	Parathyroid	Tongue
Breast (mammary gland)	Peripheral Nerve	Tonsil
Eye	Pituitary	Trachea
Fallopian Tube (oviduct)	Placenta	Ureter
Gastrointestinal (GI) Tract ^c	Prostate	Uterus - cervix
Heart	Salivary Gland	Uterus- endometrium
Kidney (glomerulus, tubule)	Skin	

^a Evaluated from peripheral blood smears.


^b Evaluated from all tissues where present.

^c Included esophagus, large intestine/colon, small intestine, and stomach (including underlying smooth muscle).


Supplementary Figure 1: CONSORT flow diagram of phase I single-ascending and multiple-dose study.

CONSORT 2010 Flow Diagram


Part I: Single-Ascending Dose (Cohorts A-C consecutively enrolled)



Part II: Multiple Dose (Concurrent enrollment)



Supplementary Figure 2. Hamster efficacy study




Placebo control and IgY-treated Syrian hamsters were challenged with a high (4×10^6) or 'low' (8×10^5) dose of SARS-CoV-2. Infectious virus titers were measured in the lungs 3 days post-infection by plaque assay. Each symbol is a single animal. One animal in the placebo group challenged with a low dose of the virus did not have any detectable virus in the lung homogenate. This was ruled an outlier based on the viral RNA levels in other assays. Viral RNA levels were quantified RT-PCR in lung homogenates of nasal swabs using 2 different primer-probe sets. Each symbol is a single animal and the bars represent the geometric mean with geometric standard deviation.

Supplementary Figure S3 (next page). Serum cytokines for human participants in the phase 1 study. Blood cytokine levels before treatment (D1 pre-dose), 2 hours after the first treatment (D1H2), 24 hours after 3-times daily intranasal (D2 pre-dose), and 2 hours after the first dose on the second day (D2H2) of anti-SARS-CoV-2 RBD IgY (0, 2, 4 and 8 mg/dose or 0, 6, 12, and 24 mg/day). D1 pre-dose is common comparator within a treatment. Red denotes false discovery rate (FDR) significant p-value ($p < 0.05$).

D1 Pre Dose is Common Comparator within a Treatment
 Red Denotes FDR Significant p-value ($p < 0.05$).

□ D1 Pre Dose □ D1 H2 ■ D2 Pre Dose ■ D2 H2



medRxiv preprint doi: <https://doi.org/10.1101/2022.01.07.22268914>; this version posted March 21, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Supplementary Material

Supplementary Methods. Protocol for “Phase 1 Study in Healthy Participants to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single-Ascending and Multiple Doses of an Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Chicken Egg Antibody (IgY)”



Protocol Number: CVR001

A Phase 1 Study in Healthy Participants to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single-Ascending and Multiple Doses of an Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Chicken Egg Antibody (IgY)

Investigational Drug: Anti-SARS-CoV-2 IgY

Sponsor:
SPARK at Stanford

Sponsor Contact:
Daria Mochly-Rosen, PhD
Professor, Dept. of Chemical and Systems Biology
George D. Smith Professor of Translational Medicine
CCSR Room 3145a, 269 Campus Drive
Stanford University School of Medicine
Stanford, California 94305-5174
Tel: (650) 725-7720 (mobile)
E-mail: mochly@stanford.edu

Version 3.0, dated 29 September 2020

The information contained in this protocol is confidential and intended for the use of the study staff. The information in this document is the property of the sponsor and may not be disclosed unless federal or state law or regulations require such disclosure. Subject to the foregoing, this information may be disclosed only to those persons involved in the study who need to know, with the obligation not to further disseminate this information.

PROTOCOL SYNOPSIS

Protocol Number: CVR001

Title: A Phase 1 Study in Healthy Participants to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single -Ascending and Multiple Doses of an Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Chicken Egg Antibody (IgY)

Objectives:

Part 1: Single Ascending Dose

The primary objective of Part 1 is to assess the safety and tolerability of anti-SARS-CoV-2 IgY when given as single ascending doses administered intranasally to healthy participants.

Part 2: Multiple Dose

The primary objective of Part 2 is to assess the safety and tolerability of anti-SARS-CoV-2 IgY when given as multiple doses administered intranasally in healthy participants. A secondary objective is to assess the pharmacokinetics of anti-SARS-CoV-2 IgY when given as multiple doses administered intranasally to healthy participants.

Study Design:

This is a single-center, randomized, double-blind, placebo-controlled phase 1 study of anti-SARS-CoV-2 IgY given intranasally to healthy participants.

Part 1: Participants will be randomly assigned to receive a single dose of anti-SARS-CoV-2 IgY antibodies or placebo in a sequential escalating manner. It is planned that up to 3 groups will be dosed with 8 healthy participants per group (6 active and 2 placebo in each group). Each group in Part 1 will include the initial dosing of a sentinel group (1 anti-SARS-CoV-2 IgY and 1 placebo) at least 24 hours prior to dosing the remaining 6 subjects in the cohort (5 anti-SARS-CoV-2 IgY and 1 placebo). The remainder of the cohort will only be dosed if, in the opinion of the investigator, there are no significant safety concerns identified in the sentinel subjects within the first 24 hours after administration of the dose (anti-SARS-CoV-2 IgY or placebo). The following regimens are planned:

- Regimen A: 2 mg anti-SARS-CoV-2 IgY preparation (2 drops of 0.5 mg/100 µL/drop to each nostril) or placebo.
- Regimen B: 4 mg anti-SARS-CoV-2 IgY preparation (2 drops of 1 mg/100 µL/drop to each nostril) or placebo.
- Regimen C: 8 mg anti-SARS-CoV-2 IgY preparation (2 drops of 2 mg/100 µL/drop to each nostril) or placebo.

Part 2: Participants will be randomly assigned to receive multiple daily administrations of anti-SARS-CoV-2 IgY or placebo every 4 hours (3-times daily) for 14 days in a parallel-group manner. It is planned that up to 24 healthy participants will be randomised to 1 of 4 treatment regimens (6 participants per regimen). The following regimens are planned:

- Regimen A: 6 mg total daily dose anti-SARS-CoV-2 IgY preparation (2 drops of 0.5 mg/100 μ L/drop to each nostril 3-times daily) for 14 days
- Regimen B: 12 mg total daily dose anti-SARS-CoV-2 IgY preparation (2 drops of 1 mg/100 μ L/drop to each nostril 3-times daily) for 14 days.
- Regimen C: 24 mg total daily dose anti-SARS-CoV-2 IgY preparation (2 drops of 2 mg/100 μ L/drop to each nostril) for 14 days.
- Regimen D: 0 mg total daily dose placebo preparation (2 drops of 0 mg/100 μ L/drop to each nostril) for 14 days.

Summary of Participant Eligibility Criteria:

Inclusion Criteria:

- Healthy males or non-pregnant, non-lactating females aged 18 to 45 years.
- Body weight of at least 50 kg.
- Body mass index ≥ 18.0 and ≤ 32.0 kg/m². If outside this range, eligible if not considered clinically significant.
- Good state of health (mentally and physically) in the opinion of the investigator as indicated by a comprehensive clinical assessment (detailed medical history and a complete physical examination), electrocardiogram (ECG), and laboratory investigations (hematology, clinical chemistry, coagulation, and urinalysis).
- Female participants are eligible to participate if they are not pregnant, not breastfeeding, and at least 1 of the following conditions applies:
 - Not of childbearing potential, defined as surgically sterile (hysterectomy, bilateral salpingectomy, tubal ligation or bilateral oophorectomy - verbal confirmation through medical history review acceptable) or postmenopausal (no menses for 12 months and confirmed by FSH level ≥ 40 mIU/mL);
 - Of childbearing potential and agrees to practice true abstinence or agrees to use a highly effective method of contraception consistently from 30 days prior to Day 1 until at least 30 days after dosing. Highly effective contraception includes hormonal contraception (oral, injected, implanted or transdermal) plus use of a condom, placement of an intrauterine device or intrauterine system plus use of a condom, or a vasectomized male partner (performed at least 6 months prior) who has been documented to no longer produce sperm - verbal confirmation through medical history review acceptable. Contraception requirements do not apply for participants in an exclusively same-sex relationship

- Male participants must agree to practice true abstinence; be surgically sterilized (performed at least 6 months prior and documented to no longer produce sperm - verbal confirmation through medical history review acceptable); or agree to use a condom plus effective contraception (i.e. established use of hormonal contraception - started at least 30 days prior to Day 1; or placement of an intrauterine device or intrauterine system) for their female partner, if of childbearing potential, from screening and for at least 90 days after dosing and refrain from donating sperm during this period. Contraception requirements do not apply for participants in an exclusively same-sex relationship
- Must provide written informed consent before any study procedure is performed

Exclusion Criteria:

- Participants who have received any investigational drug in a clinical research study within the previous 30 days prior to screening or 5 half-lives, whichever is longer.
- Participants who are study site employees, or immediate family members of a study site or sponsor employee.
- History of any drug or alcohol abuse in the past 2 years defined as >21 units of alcohol per week for males and >14 units of alcohol per week for females. Where 1 unit = 360 mL of beer, 150 mL wine, or 45 mL of spirits.
- Current smokers or users of e-cigarettes and nicotine replacement products and those who have used more than 3 of these products per month within the last 6 months.
- Females of childbearing potential who are pregnant or lactating or planning to become pregnant during the study (female participants of childbearing potential must have a negative pregnancy test at screening and Day 1). A woman is considered of childbearing potential unless she is permanently sterile (hysterectomy, bilateral salpingectomy and bilateral oophorectomy - verbal confirmation through medical history review acceptable) or is postmenopausal (had no menses for 12 months without an alternative medical cause and a serum follicle-stimulating hormone [FSH] concentration ≥ 40 IU/L).
- Participants who do not have suitable veins for multiple venipunctures/cannulation as assessed by the investigator at screening.
- Clinically significant abnormal biochemistry, hematology, coagulation, or urinalysis as judged by the investigator.
- Positive drugs of abuse test result.
- Evidence of renal impairment at screening, as indicated by an estimated creatinine clearance of <80 mL/min using the Cockcroft-Gault equation.

- Abnormal liver function tests as indicated by alanine aminotransferase (ALT) > 1.5 x upper limit of normal (ULN), aspartate aminotransferase (AST) > 1.5 x ULN or total bilirubin >1.5 x ULN. Note: may be repeated once at the discretion of the investigator. Participants with Gilbert's Syndrome may be enrolled at the discretion of the investigator.
- Positive test result for hepatitis B, hepatitis C or Human Immunodeficiency Virus (HIV) at Screening
- Positive test result for SARS-CoV-2 by RT-PCR or positive SARS-CoV-2 serology result at Screening.
- Evidence or history of clinically significant allergic (except for untreated, asymptomatic, seasonal allergies at time of dosing), hematological, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, renal, psychiatric, or neurological disease.
- Participants with a history of egg allergy.
- History of nasal surgical procedures (e.g., turbinectomy, rhinoplasty, etc).
- Frequent or recurrent nasal conditions, as determined by the investigator, or any nasal conditions within the 7 days prior to Day 1 (e.g., rhinitis, hay fever).
- Current use of any nasal preparations (e.g. decongestants, steroids, etc).
- Acute illness (gastrointestinal, infection [e.g., influenza] or known inflammatory process) at screening or Day 1.
- Abnormal screening ECG, including QT intervals corrected with Fridericia's formula >450 msec for males or >470 msec for females, or subject has any cardiac rhythm other than sinus rhythm that is interpreted by the investigator to be clinically significant.
- Supine resting bradycardia (pulse heart rate [HR] <40 bpm) or a supine resting tachycardia (HR >100 bpm) at screening or Day 1.
- Hypertension, defined as a supine resting systolic blood pressure >140 mm Hg or a supine resting diastolic blood pressure >90 mm Hg at screening or Day 1.
- Hypotension, defined as a supine resting systolic blood pressure <90 mm Hg or a supine resting diastolic blood pressure <40 mm Hg at screening or Day 1.
- Known personal or family history of congenital long QT syndrome or known family history of sudden death.
- Any condition possibly affecting drug absorption or elimination, such as previous surgery on the nose.
- Donation or loss of greater than 400 mL of blood within the previous 3 months from screening.

- Taking, or have taken, any prescribed or over-the-counter drug (other than acetaminophen, or hormone replacement therapy and hormonal contraception) or herbal remedies in the 14 days before screening. Exceptions may apply on a case-by-case basis, if considered not to interfere with the objectives of the study, as agreed by the principal investigator and sponsor's medical monitor.
- Failure to satisfy the investigator of fitness to participate for any other reason.

Investigational Drug:

anti-SARS-CoV-2 IgY

Study Drug Doses and Route of Administration:

- Anti-SARS-CoV-2 IgY or placebo given intranasally. Study drug will be provided as drops from a bottle. Part 1 will include single ascending doses of anti-SARS-CoV-2 IgY preparation 2 mg, 4 mg, and 8 mg. Part 2 will include multiple doses of anti-SARS-CoV-2 IgY preparation 2 mg, 4 mg, and 8 mg every 4 hours while awake (3-times daily) for 14 days.

Safety Assessments:

- Clinical chemistry, hematology, coagulation, and urinalysis.
- Vital signs (blood pressure, heart rate, oral temperature, respiratory rate).
- Electrocardiogram.
- Physical examination.
- Adverse events.

Pharmacokinetic Assessment:

- Serum anti-SARS-CoV-2 IgY concentration.

Criteria for Dose Escalation:

- Progression to the next dose group in Parts 1 will be permitted after review of safety data suggests that it is safe to do so. For dose escalation to proceed, data must be available from a minimum of 7 participants who have completed the planned safety assessments up to 48 h after dosing to ensure that at least 5 participants in Part 1 received active study drug.
- The following data are required for interim study decisions: adverse events (mandatory), vital signs, safety laboratory values, ECG, and physical examinations.
- Dose escalation will not occur with any of the following:
 - a serious adverse reaction (i.e., a serious adverse event considered at least possibly related to the active drug) in one subject.
 - severe non-serious adverse reactions (i.e., severe non-serious adverse event considered at least possibly related to the active drug administration) in two participants in the same cohort, independent of within or not within the same system organ class.

Sample Size, Power, and Number of Sites:

- No formal sample size calculation was done. Based on experience from previous similar studies, the target number of participants to be enrolled is appropriate for the assessment of safety and tolerability.
- In Part 1, 24 healthy participants will be enrolled into 3 groups, each of 8 participants. In Part 2, 24 healthy participants will be enrolled into 4 parallel treatment arms of 6 participants each.
- In both Parts 1 and 2, up to 2 replacement participants may be enrolled per group. Participants withdrawn due to an adverse event related to the anti-SARS-CoV-2 IgY will be considered evaluable and will not be replaced.
- Planned number of sites: one (Australia).

Removal of Participants from Study Drug or Assessment:

A participant must prematurely discontinue study drug under any of the following circumstances:

- The participant wishes to discontinue study drug.
- The investigator wishes the participant to discontinue study drug, especially but not limited to the investigator concluding that further treatment puts the participant at unacceptable risk.
- The participant develops a condition or begins a therapy that would have excluded entry into the study.
- The participant becomes pregnant during the study period. In this circumstance, the pregnancy must be immediately reported by telephone to the sponsor.
- The participant develops an adverse event with the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events that is grade 3 or greater toxicity and related to study drug in the judgment of the investigator.

A participant who discontinues study drug should complete all scheduled study visits *provided that written consent to do so has not been withdrawn.*

A participant must be withdrawn from the study (and discontinue any study drug) under the following circumstances:

- The participant requests discontinuation from the study.

Statistical Analysis:

Safety will be assessed on an intent-to-treat basis for all participants who have received study drug. Data will be summarized using descriptive statistics (number of participants, mean, median, standard deviation, minimum, and maximum) for continuous variables and frequency and percentages for categorical variables. Where confidence intervals are presented, they will be two-sided 95% confidence intervals.

Sponsor: SPARK at Stanford

TABLE OF CONTENTS

1.	LIST OF ABBREVIATIONS.....	10
2.	INTRODUCTION	11
2.1	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.....	11
2.2	Immunoglobulin Y	11
2.3	Use of anti-SARS-CoV-2 IgY for Prevention of SARS-CoV-2 Infection.....	12
3.	OBJECTIVES	14
4.	INVESTIGATIONAL PLAN.....	15
4.1	Summary of Study Design.....	15
4.2	Outline of Visit Schedule.....	16
4.2.1	Screening Evaluations.....	16
4.2.1.1	Part 1: Single-Ascending Dose Schedule of Events	17
4.2.1.2	Part 2: Multiple Dose Schedule of Events	19
5	DISCUSSION OF DESIGN	22
6	STUDY POPULATION	23
6.1	Inclusion & Exclusion Criteria.....	23
6.2	Removal of Participants from Study Drug or Assessment.....	26
6.2.1	Early Discontinuation of Study Drug	26
6.2.2	Participant Withdrawal from the Study	26
7	TREATMENTS	27
7.1	Participant Assignment	27
7.2	Method of Assignment to Treatment	27
7.3	Materials and Supplies	27
7.3.1	Formulation, Packaging and Labeling	27
7.3.2	Storage and Handling.....	29
7.3.3	Final Disposition of Clinical Supplies	29
7.4	Dosage Administration.....	29
7.5	Blinding.....	30
7.6	Concomitant Therapy.....	30
7.7	Dosing Diary	30
8	ADVERSE EVENT REPORTING.....	31
8.1	Definition of Adverse Event	31

8.1.1	Reporting Procedures for All Adverse Events.....	31
8.1.2	Adverse Event Severity.....	32
8.1.3	Adverse Event Relationship to Study Drug.....	32
8.1.4	Serious Adverse Event Definition and Reporting Procedures.....	33
8.1.5	Laboratory Tests.....	34
8.1.6	Safety Monitoring.....	34
9	QUALITY CONTROL AND QUALITY ASSURANCE.....	35
10	DATA ANALYSIS METHODS.....	36
10.1	Determination of Sample Size.....	36
10.2	Safety Variables.....	36
10.3	Pharmacokinetic Variable.....	36
10.4	Immunoglobulin E.....	36
10.5	Statistical and Analytical Plans.....	36
10.5.1	General Considerations.....	36
10.5.2	Handling of Missing Data.....	37
10.5.3	Participant Disposition.....	37
10.5.4	Participant Characteristics.....	37
10.5.5	Treatment Compliance.....	37
10.5.6	Safety Analyses.....	37
10.5.7	Pharmacokinetic Analysis.....	38
10.5.8	Interim Analyses.....	38
11	ADMINISTRATIVE, ETHICAL, AND REGULATORY CONSIDERATIONS.....	39
11.1	Ethical Review.....	39
11.2	Regulatory Considerations.....	39
11.2.1	Investigator Information.....	39
11.2.2	Protocol Amendments and Study Termination.....	40
11.2.3	Study Documentation, Privacy, and Records Retention.....	40
11.3	Study Finances.....	40
11.4	Publications.....	40
12	REFERENCES.....	41
	APPENDIX A: Sponsor Protocol Approval.....	46

1. LIST OF ABBREVIATIONS

ABBREVIATION	DEFINITION
ACE2	angiotensin-converting enzyme 2
AE	adverse event
ALT	alanine transaminase
AST	aspartate transaminase
BUN	blood urea nitrogen
CLIA	Clinical Laboratory Improvement Amendments
COVID-19	coronavirus disease 2019
CRF	case report form
DAIDS	Division of AIDS
EC	Ethics Committee
FSH	follicle-stimulating hormone
hCG	human chorionic gonadotropin
HIPAA	Health Insurance Portability and Accountability Act
HIV	human immunodeficiency virus
IgG	immunoglobulin G
IgM	immunoglobulin M
IgY	immunoglobulin Y
INR	international normalized ratio
ITT	intent-to-treat
MedDRA	Medical Dictionary for Regulatory Activities
mg	milligram
mL	milliliter
µL	microliter
PT	prothrombin time
aPTT	activated partial thromboplastin time
rt-PCR	reverse transcription-polymerase chain reaction
SAE	serious adverse event
SARS-CoV-2	severe acute respiratory syndrome coronavirus 2
SDS-PAGE	sodium dodecyl sulfate-polyacrylamide gel electrophoresis
SMC	Safety Monitoring Committee
WHO	World Health Organization

2. INTRODUCTION

2.1 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection

Coronaviruses are a large family of single-stranded RNA viruses that infect mammals and birds, causing respiratory infection. In December 2019, a novel coronavirus was identified as the cause of a cluster of pneumonia cases in Wuhan, China. Its rapid spread resulted in an epidemic throughout China that was followed by a dramatically increased number of cases worldwide. In February 2020, the World Health Organization (WHO) designated COVID-19 (coronavirus disease 2019) to be caused by a novel coronavirus termed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (World Health Organization 2020). As of August 3, 2020, over 18 million persons with COVID-19 had been identified in 215 countries with an estimated 692,000 deaths (World Health Organization 2020). The progression from isolated cases in China in late 2019 to the current worldwide pandemic is underscored by asymptomatic (Chan et al., 2020; Li et al., 2020; Mizumoto and Chowell, 2020) and presymptomatic (Arons et al., 2020; He et al., 2020; Kimball et al., 2020) infection and transmission, in addition to potential transmission through environmental contamination (Ong et al., 2020). Viral entry is most prominent through the nasal passage, where binding of the viral spike protein to the human angiotensin-converting enzyme 2 (ACE2) receptor facilitates cell entry (Sungank et al., 2020; Zhou et al., 2020). The ACE2 receptor is localized on mucosal epithelial cells (Hamming et al., 2004; Jia et al., 2006). There is currently no drug or vaccine that prevents or reduces the risk of acquiring SARS-CoV-2 infection.

2.2 Immunoglobulin Y

Antibody-based passive immunization with immunoglobulin G (IgG) has a long history of effectiveness in both preventing and treating human infectious diseases (Keller and Stiehm, 2000). The possibility of protective immunity following infection with SARS-CoV-2 has led to uncontrolled studies in a small number of critically ill hospitalized patients with COVID-19 that suggest potential benefit from the effect of convalescent plasma containing neutralizing antibodies (Duan et al., 2020; Salazar et al., 2020; Shen et al., 2020). As such, the potential of passive immunization with egg yolk antibodies against SARS-CoV-2 infection has also been raised (Constantin et al., 2020; Somasundaram et al., 2020).

Egg yolk antibodies, termed immunoglobulin Y (IgY), are present in birds, reptiles, and amphibians, and considered the evolutionary precursor of immunoglobulins such as IgG present only in mammals (Kovas-Nolan and Mine, 2012). Immunoglobulin Y does not cross-react with mammalian antibodies or other unintentional targets or activate the mammalian complement system or Fc receptors (Warr et al., 1995; Zhang et al., 2017).

Immunoglobulin Y has been beneficial with favorable safety and tolerability when given prophylactically in both animal models and clinical settings of viral diseases, including respiratory infections (Kovas-Nolan and Mine, 2012). For example, animal studies have

shown that the prophylactic treatment of calf and newborn piglets with orally administered IgY was highly effective and well tolerated against coronaviruses and rotavirus (Ikemori et al., 1997; Vega et al., 2011). Intranasal administration of IgY was beneficial and well tolerated in mouse models of influenza infection (Nguyen et al., 2010; Wallach et al., 2011; Yang et al., 2014) and *P. aeruginosa* acute pneumonia (Ranjbar et al., 2019), and a guinea pig model of allergic rhinitis (Guo-Zhu et al., 2015; Wei-Xu et al., 2016). Inhaled anti-*Pseudomonas* IgY were protective and well tolerated in a ventilated piglet model of *P. aeruginosa* infection (Otterbeck et al., 2019).

In humans, continuous prophylactic treatment by daily mouth rinse with specific IgY against *P. aeruginosa* in 17 patients with cystic fibrosis for up to 12 years (114 patient-years) significantly reduced pulmonary *P. aeruginosa* infections compared with 23 cystic fibrosis control patients, with no adverse events (Kollberg et al., 2003; Nilsson et al., 2008). A randomized, double-blind, placebo-controlled phase 3 trial of 164 patients with cystic fibrosis conducted at 47 European sites from 2011 to 2015 evaluated nightly treatment with a gargling solution of anti-*P. aeruginosa* IgY (Schuster et al., 2019). No clinically meaningful differences in adverse events were reported between the treatment arms. Additional clinical studies evaluating IgY given orally include (a) treatment with a gel containing anti-*Candida* IgY, which improved tongue coating and the number of *Candida* colonies (Takeuchi et al., 2016), (b) treatment with lozenges containing anti-*P. gingivalis* IgY, which improved gum pocket depth, gingival bleeding, and bacterial levels (Yokoyama et al., 2007; Nguyen et al., 2018), (c) ingestion of anti-rotavirus IgY, which reduced stool frequencies, viral excretion, and lowered hydration needs in children with rotavirus diarrhea (Sarker et al., 2001; Rahman et al., 2012), and (d) suppression of *H. pylori* after ingestion of yogurt containing anti-*H.pylori* IgY (Horie et al., 2004).

Overall, available data to date suggest that IgY given systemically do not have off-target inflammatory effects and are nontoxic to humans, thus permitting clinical applications in a wide range of vulnerable populations including the elderly, immunocompromised, and young children (Rahman et al., 2013).

2.3 Use of anti-SARS-CoV-2 IgY for Prevention of SARS-CoV-2 Infection

There are no published studies that have evaluated the use of anti-SARS-CoV-2 IgY to prevent human SARS-CoV-2 infection. Active vaccination requires the induction of an immune response that takes time to develop and varies depending on the vaccine and recipient. In contrast, passive antibody administration may provide immediate immunity to susceptible persons.

Passive immunization with sera from recovered patients infected with SARS-CoV-2 is currently under investigation and requires the availability of a population of donors who have recovered from the disease and can donate convalescent serum, blood banking facilities to

process the serum donations, availability of assays to detect SARS-CoV-2 in serum, virologic assays to measure viral neutralization, virology laboratory support to perform these assays, and clinical protocols that are well designed and comply with country-specific and local regulatory approval (Casadevall and Pirofski, 2020). Passive immunization with anti-SARS-CoV-2 IgY may offer advantages in the known safety profile of IgY, applicability to a wide array of individuals, high yield per egg, and rapid mass production at a low cost given the large production of eggs for human consumption (Constantin et al., 2020; Somasundaram et al., 2020). In addition, anti-SARS-CoV-2 IgY would not be expected to elicit antibody-dependent enhancement of infection due to an inability to bind to human IgG Fc receptors on immune cells.

Intranasal antibody prophylaxis is an especially effective means against multiple viral pathogens (Hemmingsson and Hammarström, 1993; Giraudi et al., 1997; Heikkinen et al., 1998; Weltzin and Monath, 1999). Further, key characteristics of the mechanism of action of anti-SARS-CoV-2 IgY may be ideal for effective immunization: a) anti-SARS-CoV-2 IgY may bind to the spike protein on the surface of the virus, competing with the binding of the viral spike protein to the human ACE2 receptor to prevent cell entry and infection, b) anti-SARS-CoV-2 IgY may also agglutinate SARS-CoV-2 on the surface of the mucosa, thus preventing viral entry across the mucosa, and c) intranasal administration can deliver anti-SARS-CoV-2 IgY to the nasal passage and throat mucosa (through mucociliary clearance), the main routes of viral entry and replication.

In the absence of an active vaccine, this approach may be especially valuable for immediate and short-lived protection when used with personal protective equipment and other preventative measures to provide added protection for frontline health care personnel or other service workers at increased risk of infection.

Neutralization test results showed that SARS-CoV-2 IgY was effective in neutralizing SARS-CoV-2 (SPARK at Stanford, data on file). More detailed information about nonclinical and preclinical studies can be found in the Investigator's Brochure.

3. OBJECTIVES

Part 1: Single Ascending Dose

The primary objective of Part 1 is to assess the safety and tolerability of anti-SARS-CoV-2 IgY when given as single-ascending doses administered intranasally to healthy participants.

Part 2: Multiple Dose

The primary objective of Part 2 is to assess the safety and tolerability of anti-SARS-CoV-2 IgY when given as multiple doses administered intranasally to healthy participants. A secondary objective is to assess the pharmacokinetics of anti-SARS-CoV-2 IgY when given as multiple doses administered intranasally to healthy participants.

Safety will be evaluated using adverse event (AE), physical examination (including vital signs), electrocardiogram, and clinical laboratory data. Pharmacokinetics will be evaluated by serum anti-SARS-CoV-2 IgY concentration.

4. INVESTIGATIONAL PLAN

4.1 Summary of Study Design

This is a single-center, randomized, double-blind, placebo-controlled phase 1 study of anti-SARS-CoV-2 IgY given intranasally to healthy participants at a single site in Australia. Participants will be recruited from the Linear Clinical Research Ltd panel or by direct advertising to the public.

Part 1: Participants will be randomly assigned to receive a single dose of anti-SARS CoV-2 IgY or placebo in a sequential escalating manner. It is planned that up to 3 groups will be dosed with 8 healthy participants per group (6 active and 2 placebo in each group). Each group in Part 1 will include the initial dosing of a sentinel group (1 anti-SARS-CoV-2 IgY and 1 placebo) at least 24 hours prior to dosing the remaining 6 subjects in the cohort (5 anti-SARS-CoV-2 IgY and 1 placebo). The remainder of the cohort will only be dosed if, in the opinion of the investigator, there are no significant safety concerns identified in the sentinel subjects within the first 24 hours after administration of the dose (anti-SARS-CoV-2 IgY or placebo). The following regimens are planned:

- Regimen A: 2 mg anti-SARS-CoV-2 IgY preparation (2 drops of 0.5 mg/100 µL/drop to each nostril) or placebo.
- Regimen B: 4 mg anti-SARS-CoV-2 IgY preparation (2 drops of 1 mg/100 µL/drop to each nostril) or placebo.
- Regimen C: 8 mg anti-SARS-CoV-2 IgY preparation (2 drops of 2 mg/100 µL/drop to each nostril) or placebo.

Part 2: Participants will be randomly assigned to receive multiple daily administrations of anti-SARS-CoV-2 IgY or placebo every 4 hours (3-times daily) for 14 days in a parallel-group manner. It is planned that up to 24 healthy participants will be randomised to 1 of 4 treatment regimens (6 participants per regimen). The following regimens are planned:

- Regimen A: 6 mg total daily dose anti-SARS-CoV-2 IgY preparation (2 drops of 0.5 mg/100 µL/drop to each nostril 3-times daily) for 14 days.
- Regimen B: 12 mg total daily dose anti-SARS-CoV-2 IgY preparation (2 drops of 1 mg/100 µL/drop to each nostril 3-times daily) for 14 days.
- Regimen C: 24 mg total daily dose anti-SARS-CoV-2 IgY preparation (2 drops of 2 mg/100 µL/drop to each nostril) for 14 days.
- Regimen D: 0 mg total daily dose placebo preparation (2 drops of 0 mg/100 µL/drop to each nostril) for 14 days

4.2 Outline of Visit Schedule

4.2.1 Screening Evaluations

Screening assessments must be done to determine participant eligibility. Written consent must be obtained before conducting any study procedures.

4.2.1.1 Part 1: Single-Ascending Dose Schedule of Events

Part 1: Single-Ascending Dose Schedule of Events										
Study Assessment	Screening	Treatment Period						Phone Visit	Phone Visit	EOS Visit
Assessment	Day -28 to -1	Day 1						Day 2 ¹¹	Day 3	Day 8
		Pre-dose	0 hrs	30 min	1 hr	1.5 hrs	2 hrs	24 hrs	N/A	N/A
Visit Windows	NA	-2 hrs	NA	(± 10 min)	(± 15 min)	(± 15 min)	(± 15 min)		(+ 1 day)	(+ 1 day)
Visit to study site ¹	X	X								X
Informed consent ²	X									
Inclusion/exclusion criteria	X	X ³								
Demographic data	X									
Medical history	X	X								
Prior medication history	X	X								
Vein assessment	X									
Physical examination ⁴	X						X (abbrev)			X (abbrev)
Height	X									
Weight	X	X								
Vital signs ⁵	X	X		X	X	X	X			X
12-lead electrocardiogram ⁶	X	X					X			
Randomization		X								
Investigational Product			X							
Adverse event reporting				X (continuous reporting)				X	X	X
Concomitant medications				X (continuous reporting)				X	X	X
Alcohol breath test	X	X								
Drugs of abuse screen	X	X								
Pregnancy screen ⁷	X	X								
FSH ⁸	X									

Part 1: Single-Ascending Dose Schedule of Events										
Study Assessment	Screening	Treatment Period						Phone Visit	Phone Visit	EOS Visit
Assessment	Day -28 to -1	Day 1						Day 2 ¹¹	Day 3	Day 8
		Pre-dose	0 hrs	30 min	1 hr	1.5 hrs	2 hrs	24 hrs	N/A	N/A
Visit Windows	NA	-2 hrs	NA	(± 10 min)	(± 15 min)	(± 15 min)	(± 15 min)		(+ 1 day)	(+ 1 day)
Serology ⁹	X									
Clinical Safety Labs ¹⁰	X						X			X
SARS-CoV-2 Test	X									
IgE Test ¹²	X									

Footnotes

- 1 Participants will be required to attend the study site on the morning of Day 1 and will be confined to the study site until after collection of the 2-hour post-dose assessments;
- 2 Informed consent will be obtained prior to any study procedures being performed;
- 3 Pre-dose on Day 1 continued eligibility following the screening visit will be confirmed prior to dosing;
- 4 Physical examination will include examination of: general appearance, head, ears, eyes, nose, throat, neck (including thyroid), skin, cardiovascular system, respiratory system, gastrointestinal system, musculoskeletal system, lymph nodes and nervous system. Abbreviated exam will include at a minimum assessment of general appearance, head, nose, throat, respiratory system and cardiovascular system.
- 5 Vital signs include blood pressure, heart rate, respiratory rate and oral temperature and will be collected following a minimum 5 minutes rest in a seated or supine position;
- 6 ECGs will be collected following a minimum 5 minutes rest in a supine position;
- 7 Females of childbearing potential will be screened for pregnancy. The screening pregnancy test will be by blood sample to detect the presence of β -HCG (collected as part of clinical chemistry sample). Pre-dose on Day 1, pregnancy will be determined by urine dipstick.
- 8 Only for women of postmenopausal status.
- 9 Serology screening will include tests for tests hepatitis B surface antigen, hepatitis C virus and human immunodeficiency virus;
- 10 Clinical safety labs will be collected non-fasted and include:
 - Haematology: hemoglobin, hematocrit, erythrocyte count (RBC), mean cell volume (MCV), neutrophils, lymphocytes, monocytes, eosinophils, basophils, platelets, reticulocyte count;
 - Clinical chemistry: Serum concentrations of sodium, potassium, chloride, total bilirubin, indirect bilirubin (screening only), direct bilirubin (screening only), alkaline phosphatase, alanine transaminase (ALT/SGPT), aspartate transaminase (AST/SGOT), blood urea nitrogen (BUN), creatinine, uric acid, phosphorous, calcium, plasma glucose, total protein, albumin, cholesterol, creatinine kinase (CK), creatinine clearance (screening only);
 - Coagulation: prothrombin time (PT), activated partial thromboplastin time (aPTT), international normalized ratio (INR); and
 - Urinalysis: specific gravity, pH, protein, glucose, blood, nitrites, leukocyte esterase. Microscopy will be performed if abnormalities noted for protein, blood or leukocytes, or if clinically indicated.
- 11 Follow-up phone call 24 hours post-dose for sentinel participants only, to confirm dosing in rest of cohort.
- 12 IgE sample is not required as an entry criterion and may be collected any time prior to dosing on Day 1.

4.2.1.2 Multiple Dose Schedule of Events

Part 2: Multiple Dose Schedule of Events																						
Study Assessment	Screening			Treatment Period																	F/U Visit	EOS Visit
Assessment	Day -28 to -1	Day 1						Day 2-4			Day 5-6	Day 7 (+1 day) ¹⁴		Day 8-13	Day 14						Day 16	Day 21
		Pre-dose	0 hrs	30 min	1 hr	1.5 hrs	2 hrs	Pre-dose	0 hrs	2 hrs		Pre-dose	0 hrs		Pre-dose	0 hrs	30 min	1 hr	1.5 hrs	2 hrs	N/A	N/A
Visit Windows	NA	-2 hrs	NA	± 10 min	± 15 min	± 15 min	± 15 min	-2 hrs	NA	± 15 min		-2 hrs	NA		-2 hrs	NA	± 10 min	± 15 min	± 15 min	± 15 min	+ 1 day	+ 1 day
Visit to study site ¹	X	X						X				X			X						X	X
Informed consent ²	X																					
Inclusion/exclusion criteria	X	X ³																				
Demographic data	X																					
Medical history	X	X																				
Prior medication history	X	X																				
Vein assessment	X																					
Physical examination ⁴	X						X (abb)			X (abb)										X (abb)		X (abb)
Height	X																					
Weight	X	X						X				X			X							
Vital signs ⁵	X	X		X	X	X	X	X		X		X			X		X	X	X	X	X	X
12-lead electrocardiogram ⁶	X	X					X	X ⁷							X					X		
Randomization		X																				
Administer Study Drug			X						X		X		X	X		X						

Part 2: Multiple Dose Schedule of Events

Study Assessment	Screening		Treatment Period																		F/U Visit	EOS Visit
Assessment	Day -28 to -1	Day 1						Day 2-4			Day 5-6	Day 7 (+1 day) ¹⁴		Day 8-13	Day 14						Day 16	Day 21
		Pre-dose	0 hrs	30 min	1 hr	1.5 hrs	2 hrs	Pre-dose	0 hrs	2 hrs		Pre-dose	0 hrs		Pre-dose	0 hrs	30 min	1 hr	1.5 hrs	2 hrs	N/A	N/A
Visit Windows	NA	-2 hrs	NA	± 10 min	± 15 min	± 15 min	± 15 min	-2 hrs	NA	± 15 min		-2 hrs	NA		-2 hrs	NA	± 10 min	± 15 min	± 15 min	± 15 min	+ 1 day	+ 1 day
Dispense Study Drug							X			X			X									
Dosing Diary Review								X				X			X							
Adverse event reporting			X (continuous reporting)																		X	X
Concomitant medications			X (continuous reporting)																		X	X
Alcohol breath test	X	X																				
Drugs of abuse screen	X	X																				
Pregnancy screen ⁸	X	X												X								
FSH ⁹	X																					
Serology ¹⁰	X																					
Clinical Safety Labs ¹¹	X						X			X ¹²										X		X
SARS-CoV-2 Test	X																					
IgE Test ¹³	X																					
Serum anti-SARS-CoV-2 IgY concentration		X		X	X	X	X	X		X				X		X	X	X	X	X		

Footnotes

- 1 Participants will be required to attend the study site on the morning of Day 1-4, Day 7 and Day 14, and will be confined to the study site until after collection of the 2-hour post-dose assessments on Days 1-4 and 14. On Day 7, participants can be discharged following dosing;
- 2 Informed consent will be obtained prior to any study procedures being performed;
- 3 Pre-dose on Day 1 continued eligibility following the screening visit will be confirmed prior to dosing;
- 4 Physical examination will include examination of: general appearance, head, ears, eyes, nose, throat, neck (including thyroid), skin, cardiovascular system, respiratory system, gastrointestinal system, musculoskeletal system, lymph nodes and nervous system. Abbreviated exam will include at a minimum assessment of general appearance, head, nose, throat, respiratory system and cardiovascular system.
- 5 Vital signs include blood pressure, heart rate, respiratory rate, and oral temperature and will be collected following a minimum 5 minutes rest in a seated or supine position;
- 6 ECGs will be collected following a minimum 5 minutes rest in a supine position;
- 7 Day 4 only
- 8 Females of childbearing potential will be screened for pregnancy. The screening pregnancy test will be by blood sample to detect the presence of β -HCG (collected as part of clinical chemistry sample). Pre-dose on Day 1, pregnancy will be determined by urine dipstick.
- 9 Only for women of postmenopausal status.
- 10 Serology screening will include tests for tests hepatitis B surface antigen, hepatitis C virus and human immunodeficiency virus;
- 11 Clinical safety labs will be collected non-fasted and include:
 - Haematology: hemoglobin, hematocrit, erythrocyte count (RBC), mean cell volume (MCV), neutrophils, lymphocytes, monocytes, eosinophils, basophils, platelets, reticulocyte count;
 - Clinical chemistry: Serum concentrations of sodium, potassium, chloride, total bilirubin, indirect bilirubin (screening only), direct bilirubin (screening only), alkaline phosphatase, alanine transaminase (ALT/SGPT), aspartate transaminase (AST/SGOT), blood urea nitrogen (BUN), creatinine, uric acid, phosphorous, calcium, plasma glucose, total protein, albumin, cholesterol, creatinine kinase (CK), creatinine clearance (screening only);
 - Coagulation: prothrombin time (PT), activated partial thromboplastin time (aPTT), international normalized ratio (INR); and
 - Urinalysis: specific gravity, pH, protein, glucose, blood, nitrites, leukocyte esterase. Microscopy will be performed if abnormalities noted for protein, blood or leukocytes, or if clinically indicated.
- 12 Haematology, clinical chemistry and coagulation samples collected on Days 2 -4. Urinalysis only collected on Day 4
- 13 IgE sample is not required as an entry criterion and may be collected any time prior to dosing on Day 1.
- 14 Participants will attend the study site on the morning of Day 7 (or Day 8 if the +1 day window is utilized). On the day they do not attend the study site, all doses for that day will be administered at home.

5 DISCUSSION OF DESIGN

This is a single-center, randomized, double-blind, placebo-controlled phase 1 study of anti-SARS-CoV-2 IgY given intranasally to healthy participants.

Part 1: Participants will be randomly assigned to receive a single dose of anti-SARS-CoV-2 IgY or placebo in a sequential escalating manner. It is planned that up to 3 groups will be dosed with 8 healthy participants per group (6 active and 2 placebo in each group).

Part 2: Participants will be randomly assigned to receive multiple daily administrations of anti-SARS-CoV-2 IgY antibodies or placebo every 4 hours (3-times daily) for 14 days in a parallel-group manner. It is planned that up to 24 healthy participants will be randomised to 1 of 4 treatment regimens (6 participants per regimen).

Dose: The maximum feasible solubility of IgY is approximately 20 mg/mL. The total maximum daily dose of anti-SARS-CoV-2 IgY to be used in the present study (24 mg daily) is based in part on solubility considerations and is less than the daily dose of anti- *P. aeruginosa* IgY given prophylactically as continuous oral treatment for up to 12 years (114 patient-years) to prevent pulmonary infections in 17 patients with cystic fibrosis (Nilsson et al., 2008). This study showed a significant reduction in *P. aeruginosa* compared with 23 control patients with cystic fibrosis, with no adverse events (Nilsson et al., 2008). Further, an equivalent of ½ egg/treatment was used/dose, which translates to about 50 mg IgY/dose given once daily (Dr. Anders Larsson, Uppsala University, Sweden, personal communication). As a result, the maximum daily dose in the planned Phase 1 study of 24 mg given intranasally to healthy volunteers for 14 days is significantly less than the oral daily dose given continuously to patients with cystic fibrosis over long periods. For the maximum anti-SARS-CoV-2 IgY dose of 4 mg/nare, we calculate a favorable ratio of IgY to viral particles, even when viral amount covers 100% of the nasal pathway and 100% of the mucosa thickness.

Entry Criteria: Participants will be healthy adults and receive standard assessments to determine eligibility.

Safety Endpoints: The safety assessments of physical examination, vital signs, clinical laboratories, electrocardiogram, and adverse event collection used in this trial are standard assessments for phase 1 studies evaluating the safety of single and repeated dosing.

Pharmacokinetic Endpoint: Serum levels of anti-SARS-CoV-2 IgY will be measured by enzyme-linked immunosorbent assay to determine the presence of systemic exposure.

6 STUDY POPULATION

The investigators participating in this study have expertise in the conduct of phase 1 studies. The participants will comprise healthy adults between the ages of 18 and 45.

Participation in this study is voluntary. The nature of the study will be fully explained to each participant during the informed consent. The participants will have the opportunity to ask questions. An informed consent document will then be signed by the participant and the person performing the consent discussion and retained by the investigator according to Good Clinical Practice. A copy of the signed informed consent document will be given to the participant.

Eligibility for enrollment will be based on the results of screening for the following inclusion and exclusion criteria.

6.1 Inclusion & Exclusion Criteria

Inclusion Criteria

- 1) Healthy males or non-pregnant, non-lactating females aged 18 to 45 years.
- 2) Body weight of at least 50 kg.
- 3) Body mass index between ≥ 18.0 and ≤ 32.0 kg/m². If outside this range, eligible if not considered clinically significant.
- 4) Good state of health (mentally and physically) in the opinion of the investigator as indicated by a comprehensive clinical assessment (detailed medical history and a complete physical examination), electrocardiogram (ECG), and laboratory investigations (hematology, clinical chemistry, coagulation, and urinalysis).
- 5) Female participants are eligible to participate if they are not pregnant, not breastfeeding, and at least 1 of the following conditions applies:
 - Not of childbearing potential, defined as surgically sterile (hysterectomy, bilateral salpingectomy, tubal ligation or bilateral oophorectomy - verbal confirmation through medical history review acceptable) or postmenopausal (no menses for 12 months and confirmed by follicle-stimulating hormone (FSH) level ≥ 40 mIU/mL);
 - Of childbearing potential and agrees to practice true abstinence or agrees to use a highly effective method of contraception consistently from 30 days prior to Day 1 until at least 30 days after dosing. Highly effective contraception includes hormonal contraception (oral, injected, implanted or transdermal) plus use of a condom, placement of an intrauterine device or intrauterine system plus use of a condom, or a vasectomised male partner (performed at least 6 months prior) who has been documented to no longer produce sperm - verbal confirmation through medical history review acceptable. Contraception requirements do not apply for participants in an exclusively same-sex relationship

- 6) Male participants must agree to practice true abstinence; be surgically sterilised (performed at least 6 months prior and documented to no longer produce sperm - verbal confirmation through medical history review acceptable); or agree to use a condom plus effective contraception (i.e. established use of hormonal contraception - started at least 30 days prior to Day 1; or placement of an intrauterine device or intrauterine system) for their female partner, if of childbearing potential, from screening and for at least 90 days after dosing and refrain from donating sperm during this period. Contraception requirements do not apply for participants in an exclusively same-sex relationship
- 7) Must provide written informed consent before any study procedure is performed.

Exclusion Criteria:

- 1) Participants who have received any investigational drug in a clinical research study within the previous 30 days prior to screening or 5 half-lives, whichever is longer.
- 2) Participants who are study site employees, or immediate family members of a study site or sponsor employee.
- 3) History of any drug or alcohol abuse in the past 2 years defined as >21 units of alcohol per week for males and >14 units of alcohol per week for females. Where 1 unit = 360 mL of beer, 150 mL wine, or 45 mL of spirits.
- 4) Current smokers or users of e-cigarettes and nicotine replacement products and those who have used more than 3 of these products per month within the last 6 months.
- 5) Females of childbearing potential who are pregnant or lactating or planning to become pregnant during the study (female participants of childbearing potential must have a negative pregnancy test at screening and Day 1). A woman is considered of childbearing potential unless she is permanently sterile (hysterectomy, bilateral salpingectomy, and bilateral oophorectomy) or is postmenopausal (had no menses for 12 months without an alternative medical cause and a serum follicle-stimulating hormone [FSH] concentration ≥ 40 IU/L).
- 6) Participants who do not have suitable veins for multiple venipunctures/cannulation as assessed by the investigator at screening.
- 7) Clinically significant abnormal biochemistry, hematology, coagulation or urinalysis as judged by the investigator.
- 8) Positive drugs of abuse test result.
- 9) Evidence of renal impairment at screening, as indicated by an estimated creatinine clearance of <80 mL/min using the Cockcroft-Gault equation.

- 10) Abnormal liver function tests as indicated by alanine aminotransferase (ALT) > 1.5 x upper limit of normal (ULN), aspartate aminotransferase (AST) > 1.5 x ULN or total bilirubin >1.5 x ULN. Note: may be repeated once at the discretion of the investigator. Participants with Gilbert's Syndrome may be enrolled at the discretion of the investigator.
- 11) Positive test result for hepatitis B, hepatitis C or human immunodeficiency virus (HIV) at Screening
- 12) Positive test result for SARS-CoV-2 by RT-PCR or positive SARS-CoV-2 serology result at Screening.
- 13) Evidence or history of clinically significant allergic (except for untreated, asymptomatic, seasonal allergies at time of dosing), hematological, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, renal, psychiatric, or neurological disease.
- 14) Participants with a history of egg allergy.
- 15) History of nasal surgical procedures (e.g., turbinectomy, rhinoplasty, etc).
- 16) Frequent or recurrent nasal conditions, as determined by the investigator, or any nasal conditions within the 7 days prior to Day 1 (e.g., rhinitis, hay fever).
- 17) Current use of any nasal preparations (e.g. decongestants, steroids, etc).
- 18) Acute illness (gastrointestinal, infection [e.g., influenza] or known inflammatory process) at screening or Day 1.
- 19) Abnormal screening ECG, including QT intervals corrected with Fridericia's formula >450 msec for males or >470 msec for females, or subject has any cardiac rhythm other than sinus rhythm that is interpreted by the investigator to be clinically significant.
- 20) Supine resting bradycardia (pulse heart rate [HR] <40 bpm) or a supine resting tachycardia (HR >100 bpm) at screening or Day 1.
- 21) Hypertension, defined as a supine resting systolic blood pressure >140 mm Hg or a supine resting diastolic blood pressure >90 mm Hg at screening or Day 1.
- 22) Hypotension, defined as a supine resting systolic blood pressure <90 mm Hg or a supine resting diastolic blood pressure <40 mm Hg at screening or Day 1
- 23) Known personal or family history of congenital long QT syndrome or known family history of sudden death.
- 24) Any condition possibly affecting drug absorption or elimination, such as previous surgery on the nose.
- 25) Donation or loss of greater than 400 mL of blood within the previous 3 months from screening.
- 26) Taking, or have taken, any prescribed or over-the-counter drug (other than acetaminophen, or hormone replacement therapy and hormonal contraception) or herbal remedies in the 14 days before screening. Exceptions may apply on a case-by-case basis, if considered not to interfere with the objectives of the study as agreed by the principal investigator and sponsor's medical monitor.
- 27) Failure to satisfy the investigator of fitness to participate for any other reason.

6.2 Removal of Participants from Study Drug or Assessment

6.2.1 Early Discontinuation of Study Drug

A participant must prematurely discontinue study drug under any of the following circumstances:

- The participant wishes to discontinue study drug.
- The investigator wishes the participant to discontinue study drug, especially but not limited to the investigator concluding that further treatment puts the participant at unacceptable risk.
- The participant develops a condition or begins a therapy that would have excluded entry into the study.
- The participant becomes pregnant during the study period. In this circumstance, the pregnancy must be immediately reported by telephone to the sponsor.
- The participant develops an adverse event with the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events that is grade 3 or greater toxicity and related to study drug in the judgment of the investigator.

6.2.2 Participant Withdrawal from the Study

A participant must be withdrawn from the study (and discontinue any study drug) if:

- the participant requests such study discontinuation.

The reason for study withdrawal must be recorded in the participant's case report form (CRF).

7 TREATMENTS

7.1 Participant Assignment

After signing the informed consent documents, participants who meet all eligibility criteria will be assigned to study drug assignment.

7.2 Method of Assignment to Treatment

Participants who have met all the inclusion criteria for enrollment and none of the exclusion criteria will be randomized to receive either anti-SARS-CoV-2 IgY or placebo, with dosage determined based on cohort assignment. Computer-generated random numbers will be used by the study statistician to generate the randomization allocation sequence. The randomization number assigned to the participant, which will be used to link the participant to the unique medication number for the bottle of study drug to be administered to the participant.

After signing the informed consent form, each participant will be given a screening number according to the screening order. On Day 1, following confirmation of eligibility, participants will be randomized to receive anti-SARS-CoV-2 IgY or placebo.

At the time of randomization, the participant will be assigned a unique randomization number, which will be allocated sequentially based on the pre-determined randomization schedule, and according to their chronological order of inclusion in the study. Confirmation of the treatment number allocated will be documented in the drug accountability records and recorded in the electronic case report form (eCRF).

Both the screening and randomization numbers will be used to identify the participant throughout the study period and on all study-related documentation.

7.3 Materials and Supplies

7.3.1 Formulation, Packaging and Labeling

Study drug (anti-SARS-CoV-2 IgY or placebo) will be administered to the participant in a (personal use) bottle with a dropper (Bravado Pharma, Inc, Lutz, FL) through the site pharmacy. The isolation of IgY from individual eggs was performed using the protocols similar to the one described by Akita and Nakai (1993) and Fu et al (2012). Briefly, egg white was separated from the egg yolk and discarded. The yolk was mixed vigorously with sterilized water and left standing overnight at 4 °C after a slight acidification step. The mixture was then centrifuged at 1200×g for 30 minutes at 4 °C, and the supernatant was lyophilized. The protein concentration in harvested eluate was determined according to Bradford protein assay. Each egg yolk produced ~35-40 mg of IgY-enriched preparation.

The IgY preparation was subjected to analysis by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blot. The isolated IgY had a high purity as

confirmed by SDS-PAGE and purified IgY had good biological activity as confirmed by Western blot. The activity of IgY in yolks diluted at up to 1:128,000 in phosphate buffer saline was assessed using an indirect enzyme-linked immunosorbent assay as described previously (Huang et al., 2005). After immunization of specific-pathogen-free chickens with SARS coronavirus antigen, there were no detectable antibodies against SARS coronavirus in the yolks of eggs laid in the first 3 weeks after the first immunization. The production of anti-SARS antibody in yolks was found to commence 2 weeks after the IgY was produced in serum.

Drug substance (IgY preparation) is formulated with an inactive excipient (2% Carboxymethylcellulose Sodium), at neutral pH at ~300mosm. Each bottle of drug product (anti-SARS-CoV-2 IgY preparation) and matched placebo will have liquid identical in appearance and smell.

Table 7.1 Study Drug Treatment and Packaging (Part 1, Single-Ascending Dose)

Treatment	Study Drug	Frequency	Packaging
anti-SARS-CoV-2 IgY	anti-SARS-CoV-2 IgY preparation in liquid (0.5 mg/100 µL/drop, 1 mg/100 µL/drop, and 2 mg/100 µL/drop)	2 drops to each nostril as a single administration	Nose drop bottle
Placebo	liquid (100 µL/drop)	2 drops to each nostril 3-times daily while awake (every 4 hours)	Nose drop bottle

Table 7.2 Study Drug Treatment and Packaging (Part 2, Multiple Dose)

Treatment	Study Drug	Frequency	Packaging
anti-SARS-CoV-2 IgY	anti-SARS-CoV-2 IgY preparation in liquid (0.5 mg/100 µL/drop, 1 mg/100 µL/drop, and 2 mg/100 µL/drop)	2 drops to each nostril every 4 hours (3-times daily) for 14 days	Nose drop bottle
Placebo	liquid (100 µL/drop)	2 drops to each nostril every 4 hours (3-times daily) for 14 days	Nose drop bottle

Study drug bottle will contain the following information:

- Protocol number (CVR001).
- Dose: Each vial contains 1.5 mL anti-SARS-CoV-2 IgY Preparation Nasal Suspension, 5, 10, or 20 mg/mL, or Placebo, for Intranasal application.
- Lot number (BP0001).

- Retest Date.
- Storage: 2 °C - 8 °C (36 °F - 46 °F).
- A precautionary statement that drug is limited to clinical trial use only.
- Keep out of reach of children.
- Company name (SPARK).
- Manufacturer: Bravado Pharmaceuticals, LLC, 44212 Cypress Gulch Drive, Lutz, FL 33559.

7.3.2 Storage and Handling

The study drug will be in bottles. The study drug will be stored at 2 °C - 8 °C (36 °F - 46 °F). No other special handling is required.

7.3.3 Final Disposition of Clinical Supplies

At the end of the study, study drug supply and accountability records will be reconciled as to drug shipped, drug consumed, and drug remaining. Any discrepancies noted will be documented. Final drug accountability reconciliation will be performed at the visit occurring at the end of treatment or early discontinuation. Unused study drug will be destroyed.

7.4 Dosage Administration

The investigator (or designee) will administer a single dose of study drug in Part 1 and the morning dose on Days 1-4, Day 7 and Day 14 in Part 2. All other doses in Part 2 will be self-administered by the participant. Participants will be instructed with the following language:

“Gently blow your nose before using this drug. Then tilt your head back while sitting or lying down. After the study drug is administered, keep your head tilted for a few minutes. Try not to blow your nose for at least 5 minutes after study drug administration”

In Part 2, participants will be dispensed study drug in a dropper bottle to complete the subsequent doses at home, 4 hours apart for a total of 3 doses per day. They will retain the empty bottles to return to the site at the following visit for accountability. Doses performed at home will be recorded in a dosing diary. On Day 14 there will only be a single morning dose.

The investigator (or designee) is responsible for the correct use of the study drug to the participants, confirming that instructions are followed properly, maintaining accurate records of study drug dispensing, and collection of all unused study drug, including empty drug packaging.

Participants will be instructed to contact the investigator as soon as possible if he or she has a complaint or problem with the study drug or drug delivery system so that the situation can be assessed.

7.5 Blinding

This is a randomized, double-blind, placebo-controlled study. Neither the participants nor the study personnel with direct contact with the participant will know which study drug (anti-SARS-CoV-2 IgY vs. placebo) is being administered during the treatment period. Placebo and active drug liquid for intranasal administration will be similar in appearance and smell, and the amount of study drug will be the same for each treatment group.

Emergency unblinding for AEs will be performed through the code break envelopes. Emergency unblinding for AEs may be used only if a participant's medical care requires knowledge of the participant's treatment assignment. The investigator should make every effort to contact the sponsor before unblinding a participant's treatment assignment. If a participant's treatment assignment is unblinded, the sponsor must be immediately notified by telephone.

7.6 Concomitant Therapy

Nasal treatments that may interfere with administration of study drug in the judgment of the investigator are prohibited during the study.

7.7 Dosing Diary

Participants will be issued a dosing diary to record dosing times for treatment compliance. Participants will be instructed to bring their diary with them during all visits to the clinic.

8 ADVERSE EVENT REPORTING

8.1 Definition of Adverse Event

For purposes of this trial, an AE will be defined as **any** new unfavorable or unintended sign, symptom, or disease or change of an existing condition, which occurs during or after treatment, whether or not considered treatment-related. If clinically significant laboratory values lead to or are associated with clinical symptoms(s), the diagnosis should be reported as an adverse event. Lack of drug effect is not an adverse event in clinical trials because the purpose of the clinical trial is to establish drug effect.

Before enrollment, study site personnel will note the occurrence and nature of each participant's medical condition(s) in the appropriate section of the CRF. During the remainder of the study, site personnel will again note any change in the condition(s) and the occurrence and nature of any adverse events.

If the study drug is discontinued for a participant, study site personnel must report and clearly document the circumstances and data leading to any such discontinuation, using designated case report forms. For adverse events, the participant should be followed until the event resolves or stabilizes, with frequency of follow-up at the discretion of the investigator.

In cases where the investigator notices an unanticipated benefit to the participant, study site personnel should enter “unexpected benefit” with the actual event term (for example, the complete actual term would be “unexpected benefit—sleeping longer”).

Cases of pregnancy that occur during maternal or paternal exposures to study drug should be reported for tracking purposes. Data on fetal outcome and breastfeeding are collected for regulatory reporting and drug safety evaluation.

8.1.1 Reporting Procedures for All Adverse Events

Investigators are responsible for monitoring the safety of participants who have entered this study and noting any event that seems unusual, even if this event may be considered an unanticipated benefit to the participant. The investigator is responsible for appropriate medical care of participants during the study.

The investigator remains responsible for following, through an appropriate health care option, adverse events that are serious or that caused the participant to discontinue the study. The participant should be followed until the event is resolved or explained. Frequency of follow-up is left to the discretion of the investigator.

Adverse event information will be collected through Day 8 (Part 1) and Day 21 (Part 2). Participants who discontinue study drug at any time will have adverse events collected through an additional 1 week, *provided consent to continue in the study has not been withdrawn*.

The investigator is responsible for assessing and recording all adverse experiences. Each AE will be recorded and classified for intensity, seriousness, and causality. All AEs either observed by the investigator or reported by the participant will be recorded regardless of causality. The investigator will follow the participant until an AE resolves or stabilizes.

8.1.2 Adverse Event Severity

The Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events version 2.1 (July 2017) will be used to assess and grade AE severity, including laboratory abnormalities judged to be clinically significant. If the experience is not covered in the DAIDS criteria, the following guidelines should be used to grade severity:

- Mild (grade 1): Mild symptoms causing no or minimal interference with usual social and functional activities with intervention not indicated.
- Moderate (grade 2): Moderate symptoms causing greater than minimal interference with usual social and functional activities with intervention indicate.
- Severe (grade 3): Severe symptoms causing inability to perform usual social and functional activities with intervention or hospitalization indicated.
- Life-threatening (grade 4): Potentially life-threatening symptoms causing inability to perform basic self-care functions with intervention indicated to prevent permanent impairment, persistent disability, or death.

The term “severe” is a measure of intensity and a severe AE is not necessarily serious.

8.1.3 Adverse Event Relationship to Study Drug

The relationship of an AE to the study drug should be based on the judgment of the investigator and assessed using the following guidelines:

- Definitely: Previously known toxicity of agent; or an event that follows a reasonable temporal sequence from administration of the drug; that follows a known or expected response pattern to the suspected drug; that is confirmed by stopping or reducing the dosage of the drug; and that is not explained by any other reasonable hypothesis.
- Probably: An event that follows a reasonable temporal sequence from administration of the drug; that follows a known or expected response pattern to the suspected drug; that is confirmed by stopping or reducing the dosage of the drug; and that is unlikely to be explained by the known characteristics of the participant’s clinical state or by other interventions.
- Possibly: An event that follows a reasonable temporal sequence from administration of the drug; that follows a known or expected response pattern to that suspected drug; but that could readily have been produced by a number of other factors.

- Unrelated: An event that can be determined with certainty to have no relationship to the study drug.

8.1.4 Serious Adverse Event Definition and Reporting Procedures

Any AE that meets the definition of serious noted below and occurs in a participant during the course of the study must be reported to the sponsor by telephone within 24 hours of the investigator becoming aware of the event. In addition, a serious adverse event form (SAE) must be completed by the investigator and faxed to the study sponsor within 24 hours of the investigator becoming aware of the event. In addition, the site investigator must report SAEs to their local Ethics Committee (EC) in accordance with the EC's standard operating procedures and policies.

An SAE is defined as an adverse event that suggests a significant hazard or side effect, regardless of the relationship to study drug. An SAE includes, but may not be limited to, any event that:

- Results in death.
- Is life-threatening. This definition implies that the participant, in the view of the investigator, is at immediate risk of death from the event. It does not include an event that, had it occurred in a more serious form, might have caused death.
- Requires inpatient hospitalization or prolongs existing hospitalization.
- Results in persistent or significant disability/incapacity.
- Results in a congenital anomaly or birth defect. This serious criterion applies if a participant exposed to an investigational product gives birth to a child with a congenital anomaly or birth defect.

Medical and scientific judgment will be exercised in deciding whether classification of an AE as serious is appropriate in other situations, such as important medical events that may not be immediately life-threatening or result in death or hospitalization, but may jeopardize the participant or require intervention to prevent one of the outcomes listed in the definition above. These should also usually be considered serious. Examples of such events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospitalization, or the development of drug dependence or abuse.

Serious adverse events occurring after a participant is discontinued from the study will only be reported if the investigator believes that the event may have been caused by the study drug or a protocol procedure.

For the purpose of expedited reporting to regulatory agencies, an investigator will be responsible for identifying any adverse event that is serious, unexpected, and believed to be related to study drug. An adverse event or suspected adverse reaction is considered

“unexpected” if it is not consistent with the risk information described in the general investigational plan or elsewhere in the current investigational new drug application. For example, under this definition, hepatic necrosis would be unexpected (by virtue of greater severity) if the investigator brochure or investigational drug application referred only to elevated hepatic enzymes or hepatitis. Similarly, cerebral thromboembolism and cerebral vasculitis would be unexpected (by virtue of greater specificity) if the investigator brochure or investigational drug application listed only “cerebral vascular accidents.

8.1.5 Laboratory Tests

Clinical laboratory tests will be performed at the times specified in the Study Schedule (see Section 4.2). All clinical laboratory assessments will be analyzed at the participating site’s local laboratory. Investigators must document their review of each laboratory report by signing or initialing and dating each report.

8.1.6 Safety Monitoring

The sponsor or designee will monitor blinded safety data throughout the study. The sponsor (or designee) will review SAEs within time frames mandated by regulatory requirements and will review trends and adverse events at periodic intervals.

Prior to dose escalation in the SAD cohorts, the Safety Monitoring Committee (SMC) will review all available safety and tolerability data for a minimum of 7 participants who have completed the planned safety assessments up to 48 hours after dosing. The SMC will be composed of the independent medical monitor, principal investigator, and Sponsor’s medical representative. Other members of the investigational team may join the SMC as deemed appropriate.

The data will be reviewed blinded, unless the SMC considers it necessary to unblind the data for safety concerns. Before breaking the code per standard procedures, the potential decisions and actions will be determined.

SMC decisions on dose escalation will be taken in consensus between the members of the Safety Monitoring Committee. If consensus cannot be reached, the investigator, who has the ultimate responsibility for the safety of participants, will make the final decision on whether to continue or stop the study. The SMC’s decisions and their rationale will be documented.

9 QUALITY CONTROL AND QUALITY ASSURANCE

The investigator agrees to be responsible for implementing and maintaining quality control and quality assurance systems to ensure that trials are conducted and data are generated, documented, and reported in compliance with the protocol, accepted standards of Good Clinical Practice, and all applicable federal, state, and local laws, rules and regulations relating to the conduct of the clinical study.

The investigator also agrees to conduct the study in an efficient and diligent manner and in conformance with this protocol; generally accepted standard of Good Clinical Practice; and all applicable federal, state, and local laws, rules, and regulations relating to the conduct of the clinical study.

The investigator must allow study-related monitoring, audits, and inspection by the EC, sponsor (or designee), government regulatory agencies, and, if applicable, University compliance and quality assurance groups of all trial-related documents and procedures.

The investigator shall prepare and maintain accurate study documentation in compliance with Good Clinical Practice standards and applicable federal, state, and local laws, rules, and regulations.

10 DATA ANALYSIS METHODS

10.1 Determination of Sample Size

No formal sample size calculation was done. Based on experience from previous similar studies, the target number of participants to be enrolled is appropriate for the assessment of safety and tolerability.

10.2 Safety Variables

Safety evaluations will include collection of AE, physical examination, vital sign, electrocardiogram, and clinical laboratory data. Laboratory data will include evaluation of:

- Hematology: hemoglobin, hematocrit, erythrocyte count, mean cell volume, neutrophils, lymphocytes, monocytes, eosinophils, basophils, platelets, reticulocyte count.
- Metabolic panel: Serum concentrations of sodium, potassium, chloride, total bilirubin, alkaline phosphatase, alanine transaminase (ALT), aspartate transaminase (AST), blood urea nitrogen (BUN), creatinine, uric acid, phosphorous, calcium, plasma glucose, total protein, albumin, cholesterol, creatinine kinase.
- Coagulation: prothrombin time (PT), activated partial thromboplastin time (aPTT), international normalized ratio (INR).
- Urinalysis: specific gravity, pH, protein, glucose, blood, nitrites, leukocyte esterase. Microscopy will be performed if abnormalities noted for protein, blood or leukocytes, or if clinically indicated.
- Urine human chorionic gonadotropin (hCG) test.

10.3 Pharmacokinetic Variable

Serum anti-SARS-CoV-2 IgY concentration.

10.4 Immunoglobulin E

Immunoglobulin E (IgE) blood samples will be collected from each participant. Samples will be stored and may be used for future allergen specific IgE testing.

10.5 Statistical and Analytical Plans

10.5.1 General Considerations

The analysis of safety variables will include all participants who receive study drug.

All variables will be summarized by descriptive statistics for each treatment group. The statistics for continuous variables will include mean, median, standard deviation, and number

of observations. Categorical variables will be tabulated using frequencies and percentages. Where confidence intervals are presented, they will be two-sided 95% confidence intervals.

10.5.2 Handling of Missing Data

Missing data will not be imputed for safety analyses.

10.5.3 Participant Disposition

Study participant disposition will be summarized by treatment group. Participants who discontinued study drug prematurely or withdrew from the study will be summarized and listed, with reason for early termination/withdrawal.

10.5.4 Participant Characteristics

Demographic and other baseline characteristics will be summarized by treatment group.

10.5.5 Treatment Compliance

Treatment compliance will be evaluated. This will include the date the study drug was dispensed and the final amount of liquid returned.

10.5.6 Safety Analyses

Treatment-emergent AEs are defined as AEs occurring after the first dose of study drug until Day 8 in Part 1 and Day 21 in Part 2. Duration of treatment will be summarized by treatment group.

The incidence of all reported AEs and treatment-related AEs will be tabulated by treatment group. Adverse events will be classified by system organ class and preferred term using the Medical Dictionary for Regulatory Activities (MedDRA).

Adverse events will be listed and summarized by treatment group, MedDRA preferred term, severity, seriousness, and relationship to study drug. In the event of multiple occurrences of the same AE with the same preferred term in one participant, the AE will be counted once as the worst occurrence. The incidence of AEs will be tabulated by system organ class and treatment group. AEs leading to premature discontinuation of study drug or withdrawal from the study will be summarized and listed in the same manner.

Summary statistics for actual values and for change from baseline will be summarized for laboratory results by treatment group and scheduled visit. Participants with laboratory values outside of the normal reference range at any post baseline assessment will be identified.

Data to be listed by subject and summarized by treatment will include AEs, vital signs, ECG parameters, and clinical laboratory evaluations. All values outside the clinical reference ranges will be flagged on the data listings. Other data to be listed by subject will include physical examination findings and concomitant medications.

10.5.7 Pharmacokinetic Analysis

Summary statistics for actual values and for change from baseline will be summarized by treatment group and scheduled visit.

10.5.8 Interim Analyses

No interim analyses are planned for this study.

11 ADMINISTRATIVE, ETHICAL, AND REGULATORY CONSIDERATIONS

The investigator is responsible for presenting the risks and benefits of study participation to the participant in simple terms using the informed consent document. The investigator will ensure that written informed consent is obtained from each participant by obtaining the appropriate signatures and dates on the informed consent document before the performance of protocol evaluations or procedures.

11.1 Ethical Review

The investigator will obtain documentation of the EC approval of the protocol and the informed consent document before the study may begin at the investigative site(s). The name and address of the reviewing EC are provided in the investigator file.

The sponsor will supply the following to the investigative site's EC:

- Protocol and amendments.
- Informed consent document and updates.
- Investigational New Drug Application.
- Relevant curricula vitae, if required.
- Required safety and SAE reports.
- Any additional submissions required by the site's EC.

The investigator must provide the following documentation to the sponsor or its designee:

- The EC periodic (e.g., quarterly, annual) reapproval of the protocol.
- The EC approvals of any amendments to the protocol or revisions to the informed consent document.
- The EC receipt of safety and SAE reports, as appropriate.

11.2 Regulatory Considerations

This study will be conducted in accordance with the protocol and ethical principles stated in the 2013 version of the Declaration of Helsinki or the applicable guidelines on Good Clinical Practice, and all applicable federal, state, and local laws, rules, and regulations.

All data recorded in the CRF for participants participating in this study will be transcribed from medical records. After reading the protocol, the investigator will sign the protocol signature page and return it to the sponsor or designee.

11.2.1 Investigator Information

The contact information and qualifications of the principal investigator and sub-investigators, and name and address of the research facilities are included in the investigator file.

11.2.2 Protocol Amendments and Study Termination

The sponsor will initiate changes to the protocol as necessary (except for changes to eliminate an immediate hazard to a study participant) and seek approval by the EC before implementing. The investigator is responsible for enrolling participants who have met protocol eligibility criteria. Protocol violations must be reported to the local EC in accordance with EC policies.

The sponsor may terminate the study at any time. The EC must be advised in writing of study completion or early termination.

11.2.3 Study Documentation, Privacy, and Records Retention

Government agency regulations and directives require that all study documentation pertaining to the conduct of a clinical trial must be retained by the investigator for a minimum of 5 years (or longer if required by the local EC).

To protect the safety of participants in the study and to ensure accurate, complete, and reliable data, the investigator will keep records of laboratory tests, clinical notes, and participant medical records in the participant files as original source documents for the study. If requested, the investigator will provide the applicable regulatory agencies and applicable EC with direct access to original source documents.

Records containing participant medical information must be handled in accordance with the requirements of the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule and consistent with the terms of the participant authorization contained in the informed consent document for the study. Care should be taken to ensure that such records are not shared with any person or for any purpose not contemplated by the informed consent document. Furthermore, CRFs and other documents should be completed in strict accordance with the instructions provided by the sponsor, including the instructions regarding the coding of participant identities.

11.3 Study Finances

This study is financed through Linear Clinical Research Ltd and SPARK at Stanford.

11.4 Publications

Neither the complete nor any part of the results of the study carried out under this protocol, nor any of the information provided by the sponsor for the purposes of performing the study, will be published or passed on to any third party without the consent of the study sponsor. Any investigator involved with this study is obligated to provide the sponsor with complete test results and all data derived from the study.

12 REFERENCES

Akita EM, Nakai S (1993) Production and purification of Fab' fragments from chicken egg yolk immunoglobulin Y (IgY). *J Immunol Methods* 162(2):155-164.

Arons MM, Hatfield KM, Reddy SC, et al. (2020) Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility. *N Engl J Med* 382(22):2081-2090.

Bostanci Ceran B, Ozates S (2020) Ocular manifestations of coronavirus disease 2019. *Graefes Arch Clin Exp Ophthalmol*. Jun 6:1-5. doi: 10.1007/s00417-020-04777-7. (Online ahead of print).

Cahill TJ, Cravatt B, Goldman LR, et al. (2020) Scientists to Stop COVID-19. Accessed May 1, 2020.

https://s.wsj.net/public/resources/documents/Scientists_to_Stop_COVID19_2020_04_23_FINAL.pdf

Casadevall A, Pirofski LA (2020) The convalescent sera option for containing COVID-19. *J Clin Invest* 130(4):1545-1548.

Chan JF, Yuan S, Kok KH, et al. (2020) A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster *Lancet*. 395(10223): 514-523.

Constantin C, Neagu M, Supeanu TD, Chiurciu V, Spandidos A (2020) IgY - turning the page toward passive immunization in COVID-19 infection (Review). *Exp Ther Med* 20(1):151-158.

Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. (2020) Effectiveness of convalescent plasma therapy in severe COVID-19 patients. *Proc Natl Acad Sci USA* 117(17):9490-9496.

Fu CY, Huang H, Wang XM, Liu YG, Wang ZG, Cui SJ, et al. (2006) Preparation and evaluation of anti-SARS coronavirus IgY from yolks of immunized SPF chickens. *J Virol Methods* 133(1): 112-115.

Giraudi V, Riganti C, Torales MR, Sédola H, Gaddi E (1997) Upper respiratory infections in children: Response to endonasal administration of IGA. *Int J Pediatr Otorhinolaryngol* 39(2): 103-110.

Gisondi P, Piaserico S, Bordin C, Alaibac M, Girolomoni G, Naldi L (2020) Cutaneous manifestations of SARS-CoV-2 infection: a clinical update. *J Eur Acad Dermatol Venereol* Jun 25. doi: 10.1111/jdv.16774. (Online ahead of print).

Guo-Zhu H, Xi-Ling Z, Zhu W, Li-Hua W, Dan H, Xiao-Mu W, et al. (2015) Therapeutic potential of combined anti-IL-1 β IgY and anti-TNF- α IgY in guinea pigs with allergic rhinitis induced by ovalbumin. *Int Immunopharmacol* 25(1):155-161.

Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H (2004) Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. *J Pathol* 203(2): 631-637.

He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. (2020) Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nat Med* 26(5):672-675.

Heikkinen TA, Ruohola A, Ruuskanen O, Waris M, Uhari M, Hammarström L (1998) Intranasally administered immunoglobulin for the prevention of rhinitis in children. *Pediatr Infect Dis J* 17(5): 367-372.

Hemmingsson P, Hammarström L (1993) Nasal administration of immunoglobulin as effective prophylaxis against infections in elite cross-country skiers. *Scand J Infect Dis* 25(6):783-785.

Horie K, Horie N, Abdou AM, Yang J-O, Yun S-S, Chun H-N, et al. (2004) Suppressive effect of functional drinking yogurt containing specific egg yolk immunoglobulin on *Helicobacter pylori* in humans. *J Dairy Sci* 87(12): 4073-4079.

Ikemori Y, Ohta M, Umeda K, Icatlo FC Jr, Kuroki M, Yokoyama H, et al. (1997) Passive protection of neonatal calves against bovine coronavirus-induced diarrhea by administration of egg yolk or colostrum antibody powder. *Vet Microbiol* 58(2-4):105-111.

Jia HP, Look DC, Hickey M, Shi L, Pewe J, Netland M, et al. (2006) Infection of human airway epithelia by SARS coronavirus is associated with ACE2 expression and localization. *Adv Exp Med Biol* 581: 479-484.

Keller MA, Stiehm ER (2000) Passive immunity in prevention and treatment of infectious diseases. *Clin Microbiol Rev* 13(4):602-614.

Kimball A, Hatfield KM, Arons M, James A, Taylor J, Spicer K, et al; and Public Health – Seattle & King County; CDC COVID-19 Investigation Team (2020) Asymptomatic and Presymptomatic SARS-CoV-2 Infections in Residents of a Long-Term Care Skilled Nursing Facility - King County, Washington, March 2020. *MMWR Morb Mortal Wkly Rep* 69(13):377-381.

Kollberg H, Carlander D, Olesen H, Wejåker PE, Johannesson M, Larsson A (2003) Oral administration of specific yolk antibodies (IgY) may prevent *Pseudomonas aeruginosa* infections in patients with cystic fibrosis: a phase I feasibility study. *Pediatr Pulmonol* 35(6):433-40.

Kovacs-Nolan J, Mine Y (2012) Egg yolk antibodies for passive immunity. *Ann Rev Food Sci Technol* 3: 163-182.

Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. (2020) Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. *N Engl J Med* 382(13):1199-1207.

Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, et al. (2020) Antibody responses to SARS-CoV-2 in patients with COVID-19. *Nat Med* 26(6): 845-848.

Mercante G, Ferreli F, De Virgilio A, et al. (2020) Prevalence of Taste and Smell Dysfunction in Coronavirus Disease 2019. *JAMA Otolaryngol Head Neck Surg* Jun 18. doi: 10.1001/jamaoto.2020.1155. (Online ahead of print)

Mizumoto K, Chowell G (2020) Transmission potential of the novel coronavirus (COVID-19) onboard the diamond Princess Cruises Ship, 2020. *Infect Dis Model* 5:264-270.

Nilsson E, Larsson A, Olesen HV, Wejåker PE, Kollberg H (2008) Good effect of IgY against *Pseudomonas aeruginosa* infections in cystic fibrosis patients. *Pediatr Pulmonol* 43(9):892-899.

Nguyen SV, Nguyen MTH, Tran BC, Ho MTQ, Umeda K, Rahman S (2018) Evaluation of lozenges containing egg yolk antibody against *porphyromonas gingivalis* gingipains as an adjunct to conventional non-surgical therapy in periodontitis patients: A randomized controlled clinical trial. *J Periodont* 89(11): 1334-1339.

Nguyen HH, Tumpey TM, Park HJ, Byun YH, Tran LD, Nguyen VD, et al. (2010) Prophylactic and therapeutic efficacy of avian antibodies against influenza virus H5N1 and H1N1 in mice. *PLoS One* 5(4):e10152.

Ong SWX, Tan YK, Chia PY, Lee T, Ng O, Su M, et al. (2020) Air, Surface Environmental, and Personal Protective Equipment Contamination by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) From a Symptomatic Patient. *JAMA* 323(16):1610-1612.

Otterbeck A, Hanslin K, Lantz EL, Larsson A, Stålberg J, Lipcsey M (2019) Inhalation of specific anti-Pseudomonas aeruginosa IgY antibodies transiently decreases P. aeruginosa colonization of the airway in mechanically ventilated piglets. *Intensive Care Med Exp* 7(1):21. Erratum in: *Intensive Care Med Exp*. 2019. 7(1):24.

Rahman S, Higo-Moriguchi K, Htun KW, Taniguchi K, Icatlo FC Jr, Tsuji T, et al. (2012) Randomized placebo-controlled clinical trial of immunoglobulin Y as adjunct to standard supportive therapy for rotavirus-associated diarrhea among pediatric patients. *Vaccine* 30(31):4661-4669.

Rahman S, Van Nguyen S, Icatlo FC Jr., Umeda K, Kodama Y (2013) Oral passive IgY-based immunotherapeutics: A novel solution for prevention and treatment of alimentary tract diseases. *Hum Vaccin Immunother* 9(5): 1039-1048.

Ranjbar M, Behrouz B, Norouzi F, Gargari S (2019) Anti-PcrV IgY Antibodies Protect Against Pseudomonas Aeruginosa Infection in Both Acute Pneumonia and Burn Wound Models. *Mol Immunol* 116:98-105.

Salazar E, Perez KK, Ashraf M, Chen J, Castillo B, Christensen PA, et al. (2020) Treatment of COVID-19 Patients with Convalescent Plasma. *Am J Pathol* 190:1680-1690.

Sarker SA, Casswall TH, Juneja LR, Hoq E, Hossain I, Fuchs GJ, et al. (2001) Randomized, placebo-controlled, clinical trial of hyperimmunized chicken egg yolk immunoglobulin in children with rotavirus. *J Pediatr Gastroenterol Nutr* 32(1):19-25.

Schuster A, Bend J, Høiby N, Verde PE, Rottmann A, Larsson A (2019) Clinical study to evaluate an anti-pseudomonas aeruginosa IgY gargling solution (EUDRACT 2011-000801-39). *J Cyst Fibros* 18, Suppl 1, S23 (abstract WS12-5).

Sethuraman N, Jeremiah SS, Ryo A (2020) Interpreting Diagnostic Tests for SARS-CoV-2. *JAMA*. May 6. doi: 10.1001/jama.2020.8259 (Epub ahead of print).

Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. (2020) Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. *JAMA* 323(16):1582-1589.

Somasundaram R, Choraria A, Antonysamy M (2020) An Approach Towards Development of Monoclonal IgY Antibodies Against SARS CoV-2 Spike Protein (S) Using Phage Display Method: A Review. *Int Immunopharmacol* June 3. 85:106654 [Online ahead of print].

Sungnak W, Huang N, Bécavin C, Berg M, Queen R, Litvinukova M, et al. and HCA Lung Biological Network (2020) SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. *Nat Med* 26 (5): 681-687.

Takeuchi S, Motohashi J, Kimori H, Nakagawa Y, Tsurumoto A (2016) Effects of oral moisturising gel containing egg yolk antibodies against *Candida albicans* in older people. *Gerodontology* 33(1): 128-134.

Vega C, Bok M, Chacana P, Saif L, Fernandez F, Parreno V (2011) Egg yolk IgY: protection against rotavirus induced diarrhea and modulatory effect on the systemic and mucosal antibody responses in newborn calves. *Vet Immunol Immunopathol* 142(3-4): 156-169.

Wallach MG, Webby RJ, Islam F, Walkden-Brown S, Emmoth E, Feinstein R. (2011) Cross-protection of chicken immunoglobulin Y antibodies against H5N1 and H1N1 viruses passively administered in mice. *Clin Vaccine Immunol* 18(7): 1083-1090.

Warr GW, Magor KE, Higgins DA (1995) IgY: Clues to the origins of modern antibodies. *Immunol Today* 16(8): 392-398.

Wei-Xu H, Wen-Yun Z, Xi-Ling Z, Zhu W, Li-Hua W, Xiao-Mu W, et al. (2016) Anti-interleukin-1 beta/tumor necrosis factor-alpha IgY antibodies reduce pathological allergic responses in guinea pigs with allergic rhinitis. *Mediators Inflamm* 2016:3128182.

Weltzin R, Monath TP (1999) Intranasal antibody prophylaxis for protection against viral disease. *Clin Microbiol Rev* 12(3): 383-393.

Wölfel R, Corman VM, Guggemos W, et al (2020). Virological assessment of hospitalized patients with COVID-2019. *Nature* 581(7809):465-469.

World Health Organization (2020) Coronavirus Disease (COVID-19) Pandemic. Accessed August 3, 2020. <https://www.who.int/emergencies/diseases/novel-coronavirus-2019>.

Yang YE, Wen J, Zhao S, Zhang K, Zhou Y (2014) Prophylaxis and therapy of pandemic H1N1 virus infection using egg yolk antibody. *J Virol Methods* 206: 19-26.

Yokoyama K, Sugano N, Shimada T, Shofiqur RA, Ibrahim el-SM, Isoda R, et al. (2007) Effects of egg yolk antibody against Porphyromonas gingivalis gingipains in periodontitis patients. *J Oral Sci* 49(3): 201-206.

Zhang X, Calvert RA, Sutton BJ, Doré KA (2017) IgY: A key isotype in antibody evolution. *Biol Rev Camb Philos Soc* 92(4): 2144-2156.

Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. (2020). A pneumonia outbreak associated with a new coronavirus of bat origin. *Nature* 579(7798):270-273.

Appendix A: Sponsor Protocol Approval

Protocol Title: A Phase 1 Study in Healthy Participants to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single-Ascending and Multiple Doses of an Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Chicken Egg Antibody (IgY)

Protocol Number: CVR001

This study will be conducted in compliance with the clinical study protocol (and amendments), International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, Good Clinical Practice and applicable regulatory requirements

This study protocol has been approved by the following persons:

Signed: _____ Date: _____

Daria Mochly-Rosen, PhD
Founder and Co-Director
SPARK at Stanford

Investigator Protocol Signature Page

Protocol Title: A Phase 1 Study in Healthy Participants to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single-Ascending and Multiple Doses of an Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Chicken Egg Antibody (IgY)

Protocol Number: CVR001

By signing this protocol, the investigator agrees to conduct the study in accordance with the protocol, generally accepted standards of Good Clinical Practice, and all applicable federal, state, and local laws, rules, and regulations relating to the conduct of the clinical study. In addition, the investigator agrees to provide the sponsor with accurate financial information to allow the sponsor to submit complete and accurate certification and disclosure statements as required by federal regulations.

By signing this protocol, the investigator agrees to be responsible for implementing and maintaining quality control and quality assurance systems with written procedures to ensure that the trials are conducted and data are generated, documented, and reported in compliance with the protocol, accepted standards of Good Clinical Practice, and all applicable federal, state, and local laws, rules, and regulations relating to the conduct of the study.

Investigator's Signature

Print Name

Date

Site Address and Telephone